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Abstract
Psoriasis is a common chronic inflammatory skin disease which can also affect the
joints. Its pathogenesis is still to be fully elucidated and involves a wide range of
inflammatory mediators, tissue and immune cells. At present, there is no treatment
available to cure psoriasis. Although biologics have considerably improved the
treatment of the most severe cases there is still a pressing clinical need to improve
therapy for specific disease subtypes (e.g. pustular psoriasis) and the vast majority of
patients suffering from psoriasis classified as mild to moderate. In particular,
efficient and well tolerated topical approaches are lacking.
This work has focused 1) on advancing our understanding of IL-36 cytokines which
are recognised for their significance in pustular psoriasis, 2) on identifying
endogenous disease limiting mediators such as IL-18 binding protein and how they
could be manipulated in a therapeutic approach and 3) on IL-17 neutralising RNA
aptamers as tools for topical therapy.
Main results include the identification of biologic activity of processed and non-
processed IL-36 members. N-terminal cleavage is required to increase activity of all
IL-36 members. The protease responsible for IL-36RA processing was elucidated.
Neutrophil proteases as well as kallikrein 7 can cleave pro-inflammatory IL-36
members. However, a second processing step seems necessary for full activation and
the potentially responsible aminopeptidase remains to be identified. Secondly, it was
found that human primary fibroblasts produce significant levels of IL-18BP, which
controls pro-inflammatory function of IL-18. Endogenous IL-18BP can be induced
by IL-27 which, when given in combination with hydrocortisone does not induce
pro-inflammatory responses. Thirdly, an IL-17 specific aptamer was verified to
block IL-17A activity in fibroblast and fibroblast Th17 co-cultures but not in
keratinocyte cultures. Significant uptake of the RNA aptamer by keratinocytes was
identified as potentially responsible for the lack of neutralising capacity.
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1Chapter 1 - Introduction
21.1 Introduction
Psoriasis is a chronic inflammatory disease which predominantly affects the skin but can
also involve the joints, leading to psoriatic arthritis. Recently co-morbidities such as
cardiovascular disease and psychological disorders have been linked to the disease.
Psoriasis is one of the most common chronic inflammatory skin diseases affecting
around 2-3% of the population [1]. It is often ineffectively treated and considering the
psychological burden and impact on the patient’s quality of life it is important that the
immunological basis of all disease subtype manifestations is more thoroughly
understood. This will then provide a more personalised, stratified approach to treatment.
It is well recognised that there are many cell types and inflammatory mediators involved
in psoriasis, including tumour necrosis factor α (TNFα), interleukin (IL)-1 and IL-17 
[2]. The disease initiation is not well understood but a genetic component with an
environmental trigger such as mechanical damage to the involved tissue (sometimes
termed the Koebner phenomenon), may be involved. However, infiltrating immune cells
reaching the skin as the result of chemokine gradients and other molecules released from
skin resident cells play a critical role in disease development and chronicity [3].
The chronicity of psoriasis means that the inflammation is difficult to treat and the co-
morbidities associated with this, such as psoriatic arthritis cause significant joint damage
[4]. Therefore, it seems important that the psoriatic inflammation is treated as quickly as
possible to prevent debilitating joint damage and other co-morbidities. At present the
treatment for moderate-severe psoriasis insufficiently controlled by topical treatment
relies on systemic immunosuppressant therapy (e.g. ciclosporin A, methotrexate) that
may produce toxicities and the risk of infections. For patients that fail these
conventional agents anti-cytokine biological therapies can be used. It is crucial that
further understanding of the pathogenesis of the disease is achieved in order to develop
novel therapeutics to induce sustained drug free remission or to define novel topical
therapy strategies which are generally less likely to produce significant side effects.
There is good evidence that chronic inflammation in psoriasis is related to a disturbed
balance between inflammatory cascade agonists and endogenous antagonists. This has
3been demonstrated in the identification of a loss-of-function mutation in the IL-36
receptor antagonist which causes generalised pustular psoriasis (GPP), a life-threatening
subtype of psoriasis [5]. The balance of these pro-inflammatory versus anti-
inflammatory mediators may be a key to understanding disease pathogenesis and
correcting this balance may be an achievable and effective therapeutic target. This has
already been utilised with regard to IL-1 which can be neutralised by Anakinra®, which
is a recombinant IL-1 receptor antagonist. Anakinra® is a highly effective treatment in a
number of auto-inflammatory psoriasiform disease phenotypes such as the deficiency of
IL-1 receptor antagonist (DIRA) syndrome [6, 7]. Understanding the complex immune
dysfunction in psoriasis is crucial to provide patients with more effective therapy with
fewer side effects.
1.2 Anatomy of the skin
The skin is divided into two distinct layers, the epidermis and the dermis separated by a
basement membrane. Both layers contain a complex variety of cell types (see Figure 1-
1). The epidermis is divided again into 4 layers, most inferiorly lies the stratum basale
then moving outwards is the stratum spinosum, stratum granulosum and the stratum
corneum. The outermost layer of the skin, stratum corneum consists of terminally
differentiated keratinocytes (corneocytes) which form a crucial part of the physical
barrier of the skin. Keratinocytes undergoing differentiation make up the majority of the
epidermis. Differentiation-associated proteins are expressed by keratinocytes
differentially throughout these layers. Keratins make up a large proportion of the
intermediate filament cytoskeleton in epithelial cells and differentiation state of the
keratinocytes can be ascertained by expression of certain keratins [8]. Apart from
keratinocytes the epidermal layers also contain cells related to the hair follicle (including
an epidermal stem cell compartment), Langerhans cells, pigment producing melanocytes
and merkel cells which are sensory in nature. The physical barrier formed by the
corneocytes and the acidic, hydrolipidic nature of the skin provide functional protection
from invading pathogens. However, changes in keratinocyte differentiation or
composition of the hydrolipidic layer undermine the barrier and play a substantial role in
the pathogenesis of many skin diseases.
4The dermal layer is composed of 2 layers, most inferiorly the stratum reticulare and
superiorly the stratum papillare. The dermis is anatomically more complex, as well as
resident immune cells there are fibroblasts and nerve related cells surrounded by a
structural framework of collagen fibres. The dermis also has an extensive blood supply
and lymphatic drainage which are crucial for migration of immune cells into the skin
compartment [9]. Some immune cells are resident in both the dermis and epidermis.
However, many more will migrate into the epidermis and dermis in an inflammatory
state when tissue resident cells produce chemokines, such as C-X-C motif chemokine 10
(CXCL10) and IL-8. The infiltrating immune cells are also depicted in Figure 1-1.
5Figure 1-1. Diagrammatic representation of the layers of the skin.
The diagram clearly shows the 4 distinct layers of keratinocytes within the epidermis. The red layer at the
base of the epidermis is the basement membrane. Resident immune cells are also depicted in the
epidermis. Specialist cells are shown in the dermis however it is also rich in extracellular matrix and
contains collagen, elastic fibres and reticular fibres [10]
1.3 Skin inflammation
The skin has a crucial function as a barrier, protecting the body from environmental
challenges such as ultraviolet light, mechanical or chemical stress. Forming one of the
largest organs in the body the skin is not just a traditional barrier but has roles as a
sensory-receptive organ, a biochemical barrier to maintain hydration and also for
synthesis of vitamins and hormones. The skin also plays an active role in mounting an
6immune response against invading pathogens with barrier function disruption being
associated with an increased risk of infection. The skin immune system is in a continued
state of readiness to fend off microbial and other potentially detrimental agents so a
dysregulated immune response may predispose to chronic, possibly auto-reactive,
inflammation [10].
1.3.1 Initiation of skin inflammation
The skin immune function was first described in 1983 by Streilein who devised the term
skin-associated lymphoid tissue (SALT) [11] which was later referred to as ‘The skin
immune system (SIS)’ [12]. Streilein recognised that the skin had more than just a
physical barrier function but was also important for local inflammatory response to
trauma or pathogens and for the trafficking of immune cells from circulating blood and
lymph to the skin. One of the important functions of the skin immune system in is
wound healing. Moments after damage to the skin a well-orchestrated immune response
occurs, this is the first step on the pathway to healing of the skin barrier.
The initiation of inflammation in the skin is importantly controlled by release of
cytokines from skin resident cells and both resident and infiltrating immune cells. The
specific cytokine profile indicates different physiological outcomes such as wound
repair or immune activation, these different processes will involve different cell types.
Keratinocytes are the cells that provide the ‘first line of defence’ against any invading
pathogens. In a similar manner to other epithelial cells in mucosal linings keratinocytes
can ‘distinguish’ between harmless resident organisms and harmful pathogens. The skin
microbiome is extensive (1012 resident bacteria/m2) and in normal conditions does not
present a threat [13]. Keratinocytes express receptors named pattern recognition
receptors (PRRs) that recognise evolutionary conserved microbial components proposed
by Janeway as pathogen-associated molecular patterns (PAMPs) such as flagellin,
nucleic acids and lipopolysaccharide (LPS) [14]. The most abundantly studied PRRs in
the skin are toll like receptors (TLRs) with keratinocytes expressing a substantial
number of these [15]. TLR 1, 2, 4, 5 and 6 recognise components of microbial cell wall
and membranes unique to pathogens and are present on the cell surface. Whereas, TLR
3, 7, 8 and 9 recognise single and double stranded RNA from RNA viruses and DNA.
7TLR 3, 7 and 9 are present in endosomes [16]. TLR activation leads to activation of
nuclear factor-kappa B (NF-κB), mitogen-activated protein kinases (MAPK) and 
interferon regulatory factor (IRF) [17]. All of which are involved in the amplification of
the immune response by increasing pro-inflammatory cytokines.
Keratinocytes also react to danger associated molecular patterns (DAMPs), which are
non-infectious molecules that can initiate an immune response. This term was coined by
Matzinger and revolutionised the way we explain recognition of danger by the immune
system [18]. DAMPs involve molecules such as irritants, toxins, ultraviolet (UV) light
and also cellular proteins or constituents that alert surrounding cells to danger following
cell necrosis or mechanical damage to cells i.e. scratching or physical trauma (which is
thought to be related to psoriatic lesion onset). It was more recently described that the
nucleotide-binding domain, leucine-rich repeat-containing (NOD) like receptors (NLR)
gene family can recognise both DAMPs and PAMPs and are highly expressed in the
skin. Activation of these receptors which consequently up-regulates pro-inflammatory
molecules is crucial in pathogen clearance and wound healing. LL-37 produced by
keratinocytes in combination with RNA or DNA following cell damage can activate
TLR7/8 on DCs which consequently causes release of cytokines such as IL-23. This is
important for polarisation of IL-17 producing T cells and aberrant activation of
pathways such as these lead to chronic inflammation such as psoriasis [19].
Pro-inflammatory cytokine release often occurs through activation of the inflammasome
following TLR activation [20]. The inflammasome (described in more detail later in
1.4.1) is a large multi-protein oligomer that is present in the cytoplasm of most cells.
Upon activation of the inflammasome, caspase-1 is activated from its pro-form. Active
caspase-1 cleaves pro-inflammatory inactive cytokines such as IL-1β and IL-18 into 
their active forms [21]. These pro-cytokines are stored inside the cell and released upon
activation of e.g. keratinocytes [22, 23]. The release of these IL-1 family cytokines, not
only plays a role in amplifying the immune response it also has effects on the
keratinocytes themselves inducing proliferation or differentiation therefore altering the
barrier function of the skin. This is relevant in diseases, such as atopic dermatitis, which
is linked to impaired barrier function [24]. The pro-inflammatory cytokines released
8following inflammasome activation are controlled by binding proteins and receptor
antagonists, such as IL-18 binding protein and IL-36 receptor antagonist. On the other
hand, up-regulation of inflammatory cytokines such as IL-1, interferon (IFN)γ and IL-17 
plays a vital role in removing invading pathogens by up-regulating antimicrobial
peptides (AMPs), such as LL-37 and defensins [25]. These molecules are cationic and
kill bacteria by creating holes in the anionic membranes of the bacteria or by removing
iron required for bacterial growth [26]. AMPs such as LL-37 also have chemotactic
roles, causing infiltration of immune cells into the skin.
There is evidence that points to the idea that activation of keratinocytes initiate
inflammation before infiltration of any immune cells [27]. Although we understand that
the skin resident cells play a crucial role in inflammation it is also known that without
immune cell infiltration inflammation cannot occur to its full extent (See Figure 1-2).
The skin contains several populations of dendritic cells (DCs) the best known of which
is Langerhans cells. These are resident in the epidermis so are one of the first subsets of
immune cells to come in to contact with any pathogen or insult to the skin. This subset
of cells is a specialist DC that after migrating to draining lymph nodes effectively
presents antigens to naïve T cells in order to cause clonal expansion of specific T helper
cell subsets [28]. In health the DCs are likely to be more tolerogenic, however in
pathogenic circumstances DCs may lose their tolerance and induce inflammation [29].
Depending on the type of antigen and the co-stimulatory signals presented by the
Langerhans cells, or dermal dendritic cells, gives rise to proliferation of a specific subset
of T helper cells. Following inflammation where a specific set of T helper cells have
been involved, some remain in the skin on resolution of inflammation. These are then
known as tissue-resident memory T cells and provide a faster immune response if
infected with the same pathogen again. Twice as many of these memory cells have been
suggested to be present in healthy skin compared to peripheral blood and 98% of these
are cutaneous lymphocyte associated-antigen (CLA) + [30].
It is known that within minutes of damage to the skin neutrophils are present, recruited
in to the skin by release of IL-8 from skin resident cells [31]. These cells play an
invaluable role in immediate response to invading pathogens by release of, among
9others, antimicrobial molecules, proteases and neutrophil extracellular traps (NETs) [32,
33]. Contrary to early research into the role of neutrophils as purely early inflammatory
response cells it is now understood that neutrophils have a diverse role in both innate
and adaptive immunity. Neutrophils express a wide range of receptors such as TLRs
[34], C-type lectin receptor Dectin-1 [35], retinoic acid-inducible gene (RIG)-1 and
melanoma differentiation-associated protein (MDA) 5 [36]. Therefore under specific
circumstances when they migrate into the skin they can respond to damage or pathogens
by release of a diverse range of cytokines [37].
Macrophages and DCs resident in the dermis are also crucial cells both for antigen
presentation and phagocytosis of pathogens and apoptotic cells. Monocytes are rapidly
recruited from the blood in response to keratinocytes chemokines such as monocyte
chemoattractant protein (MCP)-1 [38]. Both macrophages and neutrophils release
proteases and reactive oxygen species therefore providing potent antimicrobial
properties and further inflammatory cascade amplification [39].
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Figure 1-2. Diagrammatic representation of initiation of skin inflammation.
When skin is damaged or irritated both skin resident cells and infiltrating immune cells mount a well-
orchestrated response to maintain skin homeostasis. Keratinocytes sense damage or pathogenic invaders
and respond by secretion of chemokines and cytokines that attract infiltrating immune cells and activate
fibroblasts. Fibroblasts in turn will produce further cytokines. Langerhans cells and dermal dendritic cells
play a crucial role in antigen presentation of ‘new’ pathogens to naïve T cells which consequently
produces clonal expansion and skin homing T cells of the relevant subset. Macrophages and neutrophils
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also play a critical role in skin inflammation being recruited by chemokines produced predominantly by
keratinocytes [40].
The initiation of inflammation requires a concerted effort from all cell types involved to
deliver a well-orchestrated response to clear any pathogens or damage that may be
compromising the skin barrier (as depicted in Figure1-2).
1.3.2 Maintenance and resolution of skin inflammation
In health a tightly controlled immune response orchestrates inflammation until the
pathogen or damage has been cleared or repaired with subsequent resolution of
inflammation and restoration of normal skin homeostasis. However, a recent publication
has suggested that there is in fact a post-resolution phase which bridges the gap between
innate and adaptive immunity [41]. A state of ‘adaptive homeostasis’ in the tissue allows
for an appropriate response of repeat stimuli, of note this has been established in a
murine model [41]. The regulation of inflammation is controlled by a number of
mediators including cytokines, such as receptor antagonists and binding proteins as well
as transcription factors, many of these are involved in prevention of spontaneous
inflammation without microbial provocation or autoimmunity [42]. These molecules
form a coordinated response that not only prevents spontaneous inflammation but also
controls and aids resolution of acute inflammation [43].
Once the acute inflammatory ‘trigger’ has been resolved, leukocytes must be cleared
from the skin in order to maintain normal skin homeostasis. This process is not a passive
process as previously thought [44] but a metabolically active biochemical process.
Neutrophils also play a role in the resolution of inflammation. At the final stages of
acute inflammation when neutrophils undergo apoptosis a switch from production of
lipid mediators (such as eicosanoids) to specialised proresolving mediators (SPMs)
occurs [45]. The specialised SPMs include resolvins and lipoxins which prevent further
leukocyte infiltration and encourage clearance of debris and apoptotic cells by
macrophages in a non-phlogistic manner [46]. Soluble proresolving mediators reduce
leukocyte infiltration by down-regulation of integrins such as CD11b which prevents
diapedesis [47]. It has recently become evident that neutrophil production of lipid
mediators is dependent on the environment they are in and the cells they interact with.
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Other cell types in the skin such as fibroblasts can also produce SPMs on contact with
neutrophils, as well as macrophages in a specific cytokine micro milieu [48]. A novel
function of these SPMs has also been shown to regulate microRNAs that are involved in
resolution of inflammation [49]. Neutrophils are not only responsible for release of
SPMs but the increase of these mediators up-regulates receptors such as C-C chemokine
receptor type 5 (CCR5) by apoptotic neutrophils. These receptors act as decoy receptors
for chemokines that would otherwise attract further infiltration of leukocytes [50].
In a proresolving environment cytokines released by macrophages also act on
neutrophils to actively release IL-1 receptor antagonist (IL-1RA) which will reduce the
inflammatory actions of IL-1 [51]. Lipoxins also act upon epithelial cells to reduce IL-8
release in response to TNFα [52]. Of note, lipoxins also block CD3-specific antibody 
binding restricting NF-κB signalling in T cells, therefore reducing release of pro-
inflammatory cytokines [53]. SPMs also regulate macrophages. It is generally regarded
that M1 differentiated macrophages are more pro-inflammatory whereas M2 exert more
anti-inflammatory functions. The differentiation fate of macrophages is determined by
micro milieu of cells and cytokines [54, 55]. SPMs have been shown to cause
differentiation of macrophages into an M2 lineage, favouring a more anti-inflammatory
role [47, 56]. Macrophages are also crucial to resolution of inflammation, being the most
prevalent phagocytic cells, and on ingestion of dead and dying cells they release anti-
inflammatory molecules such as transforming growth factor (TGF)-β and IL-10 [57, 58]. 
However, this anti-inflammatory signature cytokine release only occurs on phagocytosis
of apoptotic cells and not necrotic cells.
As with initiation of inflammation in the skin, the resident cells are also important in
controlling inflammation. As discussed further in chapter 3 we have shown that on
following IL-27 stimulation skin fibroblasts and keratinocytes will initially respond by
releasing CXCL10, which initiates infiltration of IFNγ producing lymphocytes. In vitro,
after 24 hours pro-inflammatory mediators will no longer be released and a switch to
anti-inflammatory molecules such as binding proteins (BP) and receptor antagonists
(RA) is seen [59]. Up-regulation of RA can be detected along with its pro-inflammatory
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agonist and this seems to be an important control mechanism to prevent an uncontrolled
inflammation [60].
To maintain homeostasis the skin has many, not yet fully elucidated mechanisms by
which to control inflammation and resolve it in a timely manner. If these mechanisms
fail, chronic inflammation may occur.
1.3.3 Chronic inflammation
Chronic inflammation can occur for various reasons including the persistence of an
inflammatory trigger, genetically determined autoinflammation and lack of
inflammatory resolution. An example of chronic inflammation caused by persistence of
an inflammatory trigger is the presence of non-degradable particles of asbestos or silica
which consistently activate the inflammasome therefore causing aberrant release of pro-
inflammatory cytokines, such as IL-1β and IL-18 [61]. This is particular relevant in 
chronic inflammation of the lung epithelium on inhalation of particulates which often
leads to neoplastic disease [62] or in chronic joint inflammation seen in gout [63].
Chronic inflammation seen in atopic dermatitis (AD) involves breakdown of the barrier,
super infection and of course allergen exposure. Therefore, a persistent inflammatory
trigger is present. However, AD also has a strong genetic component and the most
widely replicated risk factor is a loss-of-function mutation in the gene encoding
filaggrin, which is involved in epidermal barrier maintenance [64, 65]. Chronic
inflammation in AD may be related to barrier function breakdown with persistent
antigen access and risk of lesional skin super infection [66].
Another cause underlying the development of chronic inflammation is the presence of
an abnormal, overactive inflammatory response related to a genetically determined
autoinflammation. In Crohn’s disease a subset of patients have a NOD2 mutation which
results in an aberrant response to inflammatory stimuli due to increased inflammasome
activity [67]. Neonatal-onset multisystem inflammatory disease (NOMID) is an example
of a disease where aberrant IL-1 release results in systemic inflammation including
significant skin pathologies [68]. This genetic disease is due to a gain-of-function
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mutation in the inflammasome complex which activates caspase-1 and consequently
activates IL-1β, leading to excessive IL-1β release.  
Chronic inflammation can also be related to lack of inflammatory resolution and
infiltrating immune cells remaining in the tissue, chronic inflammation has been
regarded as lymphocyte, macrophage and DC mediated until more recently [69].
Neutrophils, for example, have been shown to play a role in the resolution of
inflammation, however if excessive or prolonged neutrophil infiltration into the skin
occurs then this can lead to release of enzymatic granule contents during incomplete
phagocytosis [31]. This consequently leads to tissue damage which is prolonged beyond
clearance of the pathogen and may lead to a pattern of chronic inflammation [31].
Excessive or prolonged neutrophil infiltration is seen in chronic inflammatory skin
diseases such as psoriasis (discussed in detail in 1.3). However, more recently it has
been proposed that fibroblasts play an important role in transition from acute to chronic
inflammation. The cytokine micro milieu produced by skin resident cells defines the
inflammatory infiltrate, therefore if there is aberrant production of pro-inflammatory
mediators by fibroblasts this prevents resolution of inflammation [70].
1.4 Psoriasis and psoriatic arthritis
Psoriasis is a common inflammatory skin disease. It has, however, recently become
evident that psoriasis can no longer be considered as solely a skin disease but potentially
a systemic disease that can affect the joints and the cardiovascular system [71]. Psoriatic
disease of the skin is present in around 2-3% of the European and North American
population and affects more than 25 million people in Europe and North America [72].
Psoriasis can be divided into 3 main subtypes: vulgaris (which simply means common
psoriasis), guttate and pustular. Psoriasis vulgaris is most extensively researched due to
the fact that it affects approximately 85-90% of psoriasis sufferers [73]. It is
characterised by ‘scaly’ plaques that involve an increased capillary network in the upper
dermis, and inflammatory infiltrate including mononuclear cells, T cells and neutrophils
into both the dermal and epidermal compartment. The epidermis is greatly enlarged
(acanthosis) with keratinocytes moving through the epidermis every 4-5 days, a tenfold
acceleration compared to healthy skin. Parakeratosis (maintenance of nuclei into the
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cornified layer) and loss of stratum granulosum is present, with aberrant expression of
keratins in the epidermis namely cytokeratin 16 [19].
1.4.1 Clinical characterisation of psoriasis
Clinical severity of psoriasis is determined by using the psoriasis activity and severity
score (PASI) which assesses; erythema (redness), induration (thickness), and
desquamation (scale) of the plaques in different body sections, with 72 as the maximal
score [19].
Figure 1-3. Clinical characteristics of the psoriatic subtypes.
Clinical photos showing a typical phenotype for each psoriatic subtype. a – Erythrodermic psoriasis. b –
Psoriasis vulgaris. c – Guttate psoriasis. d - Acrodermatitis continua of Hallopeau (a pustular psoriasis
subtype). e – Psoriatic arthritis. f – Palmoplanter pustular psoriasis (a pustular psoriasis subtype). Photos
kindly provided by Dr Miriam Wittmann.
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1.4.1.1 Psoriasis vulgaris
Psoriasis vulgaris is characterised by demarcated dry, red plaques with silvery white
loosely adherent scales. A typical symptom is the Auspitz phenomenon where mild
disruption to the superficial layer of the lesion results in pin point bleeding. These
plaques characteristically form on the extensor region of the elbows and knees and
lumbosacral region and also commonly effect the scalp [3]. Moderate to severe psoriasis
effects 3-10% of psoriasis vulgaris patients and is termed as such if more than 10% of
the body is covered [19]. Moderate psoriasis effects 25% and mild psoriasis effects 65%
of patients. The development of psoriasis vulgaris is complex and is likely to be
different for different subgroups of patients. The Koebner phenomenon, which is
defined by mechanical stress causing development of a lesion, suggests that lesions
often occur after mechanical trauma to the skin.
1.4.1.2 Guttate psoriasis
Guttate psoriasis in contrast to psoriasis vulgaris is characterised by erythematous
forming small droplet (‘gutta’) shaped plaques about 1cm in diameter. Guttate psoriasis
often presents with an acute onset of the disease so all plaques are at the same
developmental stage. It is common in children and adolescents following a
Streptococcal infection or upper respiratory tract infection [74]. Unlike psoriasis
vulgaris the disease is often localised to the trunk. Guttate psoriasis is most often self-
limiting and will spontaneously resolve, however following an outbreak of guttate
psoriasis the risk of developing chronic psoriasis vulgaris is increased [75].
1.4.1.3 Pustular psoriasis
Pustular psoriasis can either be localised or generalised. Lesions are characteristically
tender sterile pustules which have underlying erythematous. Histologically diffuse
neutrophil infiltration is detectable in the dermis and epidermis [76]. Localised pustular
psoriasis can present as palmoplanter pustular psoriasis (PPP) or acrodermatitis continua
of Hallopeau (ACH). PPP is characterised by sterile pustules and hyperkeratosis of the
palmar and plantar surfaces and it is commonly associated with psoriatic nail
involvement [77]. ACH affects predominately the fingers and toes, however the pustules
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can become confluent and spread to the dorsal aspects of the hands and feet. Generalised
pustular psoriasis (GPP) is a rare subtype of psoriasis, however it is a severe form and
affected patients may need intensive care treatment. A subset of GPP has recently been
associated with a loss-of-function mutation in the IL-36 receptor antagonist (IL-36RA)
gene [5]. Treatment can be difficult but success has been described using conventional
drugs such as Acitretin or methotrexate but also biologics involving both TNF and IL-1
inhibitors [78].
1.4.1.4 Erythrodermic psoriasis
This sub type of psoriasis is characterised by widespread erythrema involving most of
the body surface, with some nail involvement. It is often due to poorly managed
psoriasis vulgaris or sudden halt of systemic medication. It can also be related to a drug
reaction, such as lithium, or systemic inflammation [79]. As for GPP, this subtype can
be life threatening if left untreated.
1.4.1.5 Psoriatic arthritis (PsA)
PsA is thought to affect 20-30% of people suffering from psoriasis vulgaris [80-82]. PsA
was originally described by Wright as having 5 clinical characteristics; distal
predominant pattern, oligoarticular asymmetrical, polyarticular rheumatoid arthritis-like,
spondylitis, and arthritis mutilans [82]. It has now been identified that PsA is often
associated with enthesitis [83], for which diagnosis has progressed with use of MRI
imaging [84]. It has been suggested that 20% of PsA patients will develop an aggressive
debilitating disease as seen in rheumatoid arthritis if not treated early and effectively
[85]. As a general rule patients with PsA have a more severe skin disease and are at a
higher risk of developing other co-morbidities associated with severe psoriasis [86].
1.4.2 Pathogenesis of psoriasis
It is widely accepted that psoriasis pathogenesis involves a complex interplay between
genetic and environmental factors. It has been described that genetic factors predispose
to an overreaction to environmental stimuli such as mechanical stress [10]. Plaque
initiation is thought to involve pDCs and myeloid DCs which respond to release of
DAMPs and self DNA by damaged keratinocytes [19]. This view is supported by a
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murine model where imiquimod (a TLR7 agonist) initiates a psoriasis-like plaque [87],
however this does fail to fully represent human psoriasis. Psoriasis is characterised by a
distinctive micro milieu of cytokines that interact in a network manner (see Figure 1-4).
It has been shown that in a co-culture of keratinocytes and activated CD4+ T cells large
amounts of IL-17 can be detected [88]. This response was firstly dependent on IL-1β 
and secondly on IL-23 [88]. It is known that IL-1β and IL-17 can induce each other 
which indicates a possible role for these cytokines in a positive loop mechanism within
psoriatic skin. IL-17 is predominantly produced by Th17 cells [89] and these cells are
regulated and polarised by IL-23, IL-1 and IL-6 [90] in humans. In psoriatic plaques it
has been described that the CCR6+ Th17 cells are attracted into the skin by a
chemokine, C-C motif ligand (CCL)20, which can be released from keratinocytes in
response to TNFα [91]. On binding of IL-17 to its receptor further induction of pro-
inflammatory cytokines, such as TNFα, IL-8 and IL-36 (see 1.4.3), occur which leads to 
neutrophil attraction [90]. These increased levels of neutrophils can be linked to
psoriasis due to the accumulation of neutrophils in the form of Munro’s micro-abscesses
[92], suggesting that IL-8 is important in the pathogenesis of psoriasis. IL-22 is also
released from activated Th17/Th22 cells and is recognised to cause the phenotypic
epidermal symptoms by primarily acting on keratinocytes [93]. As well as Th17 cells
Th1 cells are also present in lesional psoriatic skin and the inflammatory environment
contains Th1 related cytokines such as IFNγ [94]. IL-12 release from DCs is crucial for 
Th1 polarisation [19]. IL-12 and IL-23 are heterodimeric cytokines and share the p40
subunit, due to the known role of these cytokines in psoriatic pathogenesis this p40
subunit has been targeted for antibody therapy (Ustekinumab) [95]. Ustekinumab
prevent binding to of these cytokines to their receptors therefore preventing polarisation
of Th1 and Th17 cells and it has also been shown to inhibit activity of neutrophils and
monocytes [95]. This therapy shows good clinical outcome however more therapeutics
targeting small molecules within this pathway are also being developed such as those
targeting tyrosine kinase 2 and JAK1 which prevents IL-23 signalling [96].
Members of the IL-1 family have also been implicated in the pathogenesis of psoriasis.
IL-36γ has been shown to be increased in psoriatic plaques and is thought to increase 
expression of AMPs [97]. It has also been shown to be up-regulated at the RNA level in
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psoriatic keratinocytes compared to healthy keratinocytes upon stimulation with IL-17
[60] which points to an intrinsic difference in IL-36γ regulation in psoriasis. AMPs such 
as human beta defensin (HBD) 2 and 3, are known to be up-regulated in psoriatic skin
and are thought to be responsible for the low infection rate of psoriatic plaques. An
increase in copy number for HBD2 has also been described contributing to the genetic
background of the disease [98]. The mentioned mediators often have synergistic effects,
this has been shown for TNFα and IL-17 [2]. The combination of IL-1α with EGFR 
ligands such as TGFα induces much higher up-regulation of AMPs, such as HBD-2 and 
S100A7, than any of the mediators alone [97].
The innate immune system may play a more substantial role in psoriasis pathogenesis
than first thought [99]. Of interest, the recently identified type 3 innate lymphoid cells
(ILCs) have been identified as a significant source of IL-17 and IL-22 [100]. There have
been 3 subsets of ILCs identified in humans and these are grouped in relation to their
dependence on specific transcription factors and the cytokines released. The ILC subset
which produces IL-17 and IL-22 [101] is NKp44 + and has been shown to be enriched
in peripheral blood and skin from psoriasis patients [102, 103]. Following treatment
with biologics such as anti-TNFα this enrichment reduces back down to baseline [104]. 
This further implicates the role of not only the adaptive immune system but also innate
cells in the complex pathogenesis of psoriasis.
20
Figure 1-4. Diagrammatic representation of psoriatic inflammation.
The immunological basis for initiation of psoriatic plaques is not fully understood and the many
information are derived from murine models. However, it is thought that in human disease DCs are
important in the initiation of disease following keratinocyte damage. Infiltrating immune cells and the
cytokines released by resident and infiltrating immune cells drive chronicity of the disease.
The pathogenesis of psoriasis is very complex. However, with further understanding of
both the pathogenesis and the genetic background for different subtypes of disease
treatment will be more effective following a more ‘personalised’ medicine approach.
1.4.3 Associated co-morbidities in psoriasis
There has been a long-standing appreciation for the fact that there were co-morbidities
present in connection with psoriasis. Nail dystrophy, psoriatic arthritis and depression
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are well known co-morbidities [3]. Recent studies have shown that psoriasis has a severe
psychological burden on patients [105] which may explain the links to depression and
other psychological co-morbidities such as smoking and alcoholism [86]. More recently
cardiovascular co-morbidities such as atherosclerosis [106] as well as obesity, diabetes
and metabolic syndrome have all been associated with psoriasis with a prevalence
ranging from 7-50% [80, 107, 108]. Taken together this reinforces the concept that
psoriasis is an extremely complex disease of the immune system not only in the skin but
also systemically which indicates need for multidisciplinary management and targeted
therapy of these patients.
1.4.4 Genetic implications in psoriasis
The notion that genetic changes play a role in the disease is supported by 70%
concordance rate in monozygotic twins and 20% in dizygotic twins [109]. There are
multiple genetic variants that contribute to a psoriatic phenotype. Psoriasis susceptibility
region 1 (PSORS1) is the strongest susceptibility locus located in the major
histocompatibility complex and human leukocyte antigen (HLA)-Cw6 is the suggested
primary allele. Patients who are heterogeneous for this mutation are more susceptible to
develop early onset psoriasis vulgaris or guttate psoriasis [110].
The increase in genome wide association studies (GWAS) has led to 36 single
nucleotide polymorphisms (SNPs) being identified in the European population [99].
Most of these SNPs are related to immune function or skin barrier function (see Table 1-
1). However, 2 mutations identified can cause disease independently, IL-36RN and
CARD14. The loss-of-function mutation of IL-36RA identified in 2011 [5, 111] leads to
un-controlled activity of the IL-36 cytokines which cause downstream activation of NF-
κB leading to a multitude of inflammatory mediator release (discussed in more detail in 
1.4.3.2). The CARD14 mutation is a gain-of-function mutation. CARD14 is involved in
activation of NF-κB and this mutation causes an increase in activity therefore again 
causing an increase in inflammatory mediators [112, 113]. These poignant mutations
give us insight into psoriatic disease pathogenesis due to the lack of regulation of
inflammatory mediators leading to this inflammatory disease.
22
Known
susceptibility loci
Notable genes Amino-acid
substitution
Function
rs9988642 IL23R p.Arg381Gln (P) IL-23 signalling
rs27432 ERAP1 p.Gln730Glu Encodes for endoplasmic reticulum
aminopeptidase 1 – important in
immune function due to cleavage of
receptors and inflammatory
cytokines [114].
rs1295685 IL13 p.Arg144Gln Th2 cytokine
rs33980500 TRAF3IP2 p.Asp19Asn (S,P) A TNF associated receptor factor
that encodes Act1. Mediates NF-κB 
signalling [115].
rs2066819 STAT2 p.Met594Ile Transcription factor involved in
type 1 IFN signalling [116].
rs12445568 PRSS53 p.Pro406Ala Encodes polyserases, serine
proteases [117].
rs11652075 CARD14 p.Arg820Trp (S) Encodes a family of caspase
recruitment domain-containing
scaffold proteins (CARD) and
membrane associated guanylate
kinase-like domain-containing
protein (CARMA), mediates
recruitment and activation of NF-
κB [118]. 
rs34536443 TYK2 p.Pro110Ala (S,P) Encodes tyrosine kinase 2 and a
member of the Janus kinase family
and involved in downstream
signalling of many pro-
inflammatory cytokines [119].
rs12720356 TYK2 p.Ile684Ser (S,P)
rs4821124 YDJC p.Ala263Thr Function not well described,
however may play a role in
cleavage of cellobiose-phosphate
[120].
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Table 1-1. Potential causal SNPs following meta-analysis of Immunochip and GWAS data to
identify psoriasis susceptibility loci.
A summary table to show SNPs that have potential causal effects in development of psoriasis in relation
to a recent publication analysing 3 GWAS studies and 2 independent studies genotyped using an
Immunochip. The notable genes, the predicted amino-acid change and the function are also shown. High-
confidence damaging effect (amino-acid change), amino-acid substitution, predicted by SIFT (S) or
Polyphen (P). This meta-analysis was performed using 3 genome wide association studies (GWAS)
identified 15 new susceptibility loci and confirmed other SNPs that had been previously associated to
psoriasis [98].
Table 1-1 shows potentially causal SNPs for the disease and gives us an insight into the
importance of the innate immunity in psoriasis, it is worth noting that this is not all the
SNPs identified but those identified as potentially causal in a recent publication [99].
However it is well regarded that psoriasis is not simply a genetic disease but other
factors are involved for this disease to develop.
1.5 The IL-1 family
The IL-1 family of cytokines play an important role in immune regulation and can
control inflammation at both the receptor and nuclear level. These cytokines act on
nearly all cells and therefore all organs of the body and are the classical endogenous
pyrogens (fever inducing), which consequently leads to their role as pathogenic
mediators in many diseases [121]. IL-1 was identified when researchers were looking
for the cause of fever; it was observed in the 1940’s by Beeston and Menkin that
supernatant from rabbit neutrophils induced fever and the cause of this was shown to be
small proteins [122]. We now know these as IL-1α and IL-1β and these were identified 
in the 1970’s. These members along with IL-1 receptor antagonist (RA) and IL-18 were
identified following purification from cells, whereas other members were identified
using in silico methods from gene banks.
Some IL-1 family cytokines have potent pro-inflammatory effects which are tightly
regulated on the pre- and post-translational level which includes soluble receptors and
receptor antagonists. IL-1 family cytokines impact on all aspects of the immune
response, including polarisation and regulation of Th1, Th2 and Th17 lymphocytes as
well as mast cells, neutrophils and tissue resident cells. The pro-inflammatory IL-1
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cytokines are crucial to protect cells from infection by activation of systemic and local
responses. However if this tight regulation is disturbed at any level it can be detrimental,
as seen in septic shock [123].
There are 11 members of the IL-1 family and they were originally given the
nomenclature IL-1F1-11, however with elucidation of their functional properties, most
have been given individual IL designations [124] (See Table 1-2). All of these members
are located in a cluster on chromosome 2 suggesting they arose from a common
ancestral gene [125].
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Original
Name
Alternative
Name
Property Receptor N-terminal
cleavage
required for
activity
IL-1F1 IL-1α Agonist
Nuclear transcription
factor
IL-1RI,
IL-1RAcP
IL-1R11
No
IL-1F2 IL-1β Agonist IL-1RI,
IL-1RAcP
IL-1R11
Yes
IL-1F3 IL-1Ra Receptor antagonist IL-1RI No
IL-1F4 IL-18/IFN-γ 
inducing factor
Agonist IL-18Rα,  
IL-18Rβ
Yes
IL-1F5 IL-36Ra Receptor antagonist IL-1Rrp2/IL-36R Yes
IL-1F6 IL-36α Agonist IL-1Rrp2/IL-36R,
IL-1RAcP
Yes
IL-1F7 IL-37 Anti-inflammatory IL-18Rα ?
IL-1F8 IL-36β Agonist IL-1Rrp2/IL-36R,
IL-1RAcP
Yes
IL-1F9 IL-36γ Agonist IL-1Rrp2/IL-36R,
IL-1RAcP
Yes
IL-1F10 IL-38 Possible antagonist [126] IL-1Rrp2/IL-36R? ?
IL-1F11 IL-33 Agonist
Transcriptional repressor
ST2,
IL-1RAcP
No
Table 1-2. The IL-1 family nomenclature and associated receptors.
This includes newly designated names that relate to the functions of the cytokines [127] [128] [129] [122].
The IL-1 family can be categorised into functional sub groups based on the length of the
precursor and taking into account the members that have antagonistic properties on the
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others. One functional group includes IL-1α, IL-1β and the antagonist IL-1RA, another 
group includes IL-18 and its antagonist IL-18 binding protein (described in further detail
in 1.4.4). The third group includes IL-36α, IL-36β, IL-36γ and the antagonist IL-36RA. 
Apart from IL-1RA all of the IL-1 family members do not contain a signal peptide and
are primarily intracellular precursors. This means that release of these cytokines from
the cell has to be via a non-conventional pathway or following cell death. All IL-1
members have a conserved IL-1 domain that consists predominantly of beta strands
[118]. The receptor antagonists and binding proteins that block the activity of the pro-
inflammatory members of the IL-1 family represent potential therapeutic molecules for
diseases where dysregulation of IL-1 production occurs, such as in auto-inflammatory
disorders [119]. Unlike other cytokines, IL-1 members can control inflammation at both
the protein level and transcriptional level, both IL-1α and IL-33 have been described to 
relocate to the nucleus and act as transcription factors [122].
1.5.1 Activity and processing of the IL-1 family members
A common feature of some members of the IL-1 family is that cleavage at the N-
terminus is required in order to increase binding affinity to the receptor resulting in
increased activity (see Table 1-2).
The activation of pro-IL-1β and pro-IL-18 is dependent on cleavage by caspase-1 [129]. 
Caspase-1 is activated by the inflammasome, which is a macromolecular protein
complex present in the cytoplasm of most cells. The classical inflammasome is made up
of a cytosolic PRR which is often the NLR, the adapter molecule apoptosis-associated
speck-like protein containing a caspase activation and recruitment domain (CARD)
(ASC) domain, and caspase-1 [130]. These cytosolic PRRs that make up the
inflammasome can either be in the NLR family of receptors or pyrin and HIN domain
containing receptors [131]. There are three proposed mechanisms for activation of the
inflammasome. One is that extracellular adenosine 5'-triphosphate (ATP) stimulates the
purogenic P2X7 ATP-gated ion channel triggering a K+ efflux which is thought to cause
formation of pores by pannexin-1 delivering the specific ligand to the inflammasome
[132]. A second proposed mechanism is that DAMPs are engulfed by phagocytes which
can result in lysosomal damage and release of lysosomal enzymes, such as cathepsin B,
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which activate NOD like receptor protein 3 (NLRP3) [133]. The third mechanism is
that NLRP3 inflammasome ligands cause production of reactive oxygen species (ROS)
which will then activate the NLRP3 inflammasome [61]. The activation mechanism of
the inflammasome may differ depending on cell type as it has been shown that UV
initiates an increase in intracellular Ca2+ which activates the NLRP3 inflammasome in
keratinocytes [134].
At present four inflammasome complexes have been described that will assemble in the
presence of different stimuli which are given in brackets; NLRP1 (Anthrax lethal toxin),
NLRP3 (Cell stress), NLRC4 (Flagellin), AIM2 (double stranded DNA). The best
studied is the NLRP3 inflammasome which is known to be activated by various stimuli
including bacteria, bacterial RNA and danger associated molecular patterns (DAMPs)
[135]. It is well regarded that the processing of caspase-1 dependent IL-1 members is a
two-step process. Signal 1 is required to prime the cells and increase transcription of
pro-IL-18 or pro-IL-1β and NLRP3 expression via NF-κB, this is often due to microbial 
products such as LPS via TLR activation [136, 137]. The second signal is required to
initiate assembly of the inflammasome therefore leading to active caspase-1 and
consequently active IL-18 or IL-1β, this is often a stimulus such as ATP or a crystal 
(e.g. urate) [138, 139].
It is thought that caspase-1 may also play a role in release of mature IL-1β, either in a 
secretory lysosomal manner or by microvesicles, where the complex of mature IL-1β 
and caspase-1 causes formation of the microvesicles [140, 141]. It is thought that ATP
stimulation then results in release of the microvesicle contents [142]. This microvesicle
release has been proposed as a ‘protected’ form of release. IL-1β has a short half-life in 
plasma so when it is protected by a microvesicle it suggests it is destined for an area
away from the local inflammation [143]. IL-1β release has also been proposed to be via 
exosomes, which are small vesicles secreted from late endosomes. This is release
believed to be caspase-1 independent but dependent on NLRP3 activation [144]. Lastly,
both mature and proforms of IL-1 molecules will be released into the extracellular space
in the context of necrotic cell death. The NLRP3 inflammasome has been shown to be
present in human skin [145] as well as synovial fibroblasts [146], this suggests pro-IL-
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18 and pro-IL-1β can be activated in the areas affected by psoriatic inflammation. 
In contrast to IL-1β, which requires cleavage in order to be active IL-1α is active in its 
full length form. It is most widely accepted that IL-1α is an intracellular DAMP only 
released following necrotic cell death [147, 148]. Animal models have suggested that
both IL-1α and IL-1β are important in clearance of fungal infection [149] and the 
inflammatory response to nanoparticles [150]. This is of interest due to the fact that
these two models show both members to be important but both will activate the NLRP3
inflammasome. Recent studies have shown more clearly that activity or release of IL-1α 
may involve assembly of the inflammasome [151, 152]. Two papers in the late 1980’s
[153, 154] did suggest that IL-1α was cleaved by calpain to increase activity, and more 
recently granzyme B has been proposed [155]. Calpain has shown to be active only
during loss of plasma membrane integrity so this could be a trigger for necrotic release
of IL-1α [156]. However, the biological consequences of calpain cleavage are still 
unclear and no mechanisms of action have been confirmed. In contrast to IL-1β, IL-1α is 
present not only in the cytosol but also the nucleus. The proform of IL-1α contains a 
nuclear localisation sequence (NLS) which allows for binding of IL-1α to DNA, this 
pro-IL-1α shuttles rapidly between the cytosol and nucleus [121]. Release of pro-IL-1α 
has been shown to only occur during cell necrosis because during normal apoptosis IL-
1α remains tightly bound to chromatin [157]. Pro-IL-1α will remain in the cytosol when 
a signal such as hypoxia marks the cell for necrotic death [158]. However, it has also
been shown that even during necrotic cell death IL-1α remains in the nucleus in order to 
dampen down sterile inflammation [159]. The specific role of IL-1α in inflammation is 
still not clear, especially in human cells. This is due to the lack of information regarding
the release and activation of IL-1α. However, more recently caspase-1 has been 
implicated in this. It is well regarded that IL-1α is active in its full length form, however 
if IL-1α is cleaved by caspase-1 it may be released from the cell and this mature form 
may also be active, in a similar manner to the proposed mechanisms for release of IL-1β 
[160]. It has also been shown that caspase-1 may play a role in the secretion of various
leaderless proteins, IL-1α in its proform has been shown to be released in a caspase-1 
dependent manner [161]. Further studies will elucidate the specific role of IL-1α and its 
role as an extracellular cytokine as well as a nuclear transcription factor.
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IL-33 has some similar properties to its family member IL-1α due to its possible 
indications as a transcription factor. However it is predominantly involved in type 2
immune responses due to its ability to activate mast cells and its capability to polarise
type 2 innate lymphocytes. It is a driver for allergic inflammatory disease such as
asthma [162], however it has also been implicated in non Th2 driven diseases such as
cardiovascular disease [163] and arthritis [164]. It has more recently been shown to
increase antimicrobial activities of the skin in Staphylococcus aureus infection [165]
and induce neutrophilic infiltration [166]. IL-33 is expressed by many stromal and
haematopoietic cell types and acts on leukocytes, in particular macrophages, mast cells
and keratinocytes [167], stromal and endothelial cells [121]. Similarly to IL-1α IL-33 is 
not cleaved into activation by caspase-1 and is active in its proform. More recently it has
been suggested that IL-33 is inactivated by caspase-1 [168]. As described with other IL-
1 members such as IL-1β, IL-33 has been shown to be cleaved into more active mature 
forms by extracellular proteases such as cathepsin G and elastase [169]. Interestingly the
IL-33 receptor, ST2 has been implicated as a plasma biomarker in the prediction of
treatment resistant graft-versus-host disease which has significant skin implications,
with increased levels indicating therapy resistance [170].
IL-37 and IL-38 are newly recognised members of the IL-1 family. IL-37 has five splice
variants, IL-37b being the most complete. An outstanding feature of IL-37 is its
structural similarity to IL-18 [171]. IL-37 has an instability sequence so the mRNA has
a limited half-life [172]. Many cell types can express IL-37, however it is highly
regulated at the transcriptional level due to the instability of its mRNA, so it requires a
signal such as TLR activation in order to induce expression [173]. It has been suggested
that caspase-1 is also involved in cleavage of IL-37 into its active form and allows for
more efficient nuclear translocation [174, 175]. Similar to IL-33 and IL-1α, IL-37 can be 
found in the nucleus where it is thought to have suppressive functions on cytokine
transcription [175]. This has been confirmed in keratinocyte cultures both with and
without a psoriatic inflammatory induced phenotype [176]. It has now emerged that IL-
37 like other IL-1 members may be a dual function cytokine with functions both at the
intracellular and extracellular level. It has been shown that IL-37 can suppress immune
response by reducing pro-inflammatory cytokine release. This is thought to be reduction
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of DC activation on the cellular level and by interaction with kinases in inflammatory
signalling pathways on the molecular level [177]. Release of full length and mature IL-
37 has been detected in transfected human cells following activation with LPS
indicating a role for caspase-1 dependent and independent release [178]. Murine models
have suggested that IL-37 over-expression provides protection against inflammation
[179], which has indicated IL-37 as an inhibitor of adaptive immunity. Due to the
seemingly outstanding roles of IL-37 in calming inflammation, there is no doubt further
work is required to assess this cytokine as a possible therapeutic.
IL-38 is the least well defined member of the IL-1 family and was identified in silico.
Using immunohistochemistry IL-38 expression has been identified in the skin [121]. It
shares homology with IL-1RA and IL-36RA suggesting that it may have a receptor
antagonist role. As well as its homology to the receptor antagonists IL-38 also has been
shown to bind to IL-1R1, however the binding affinity is a lot lower than IL-1RA or IL-
1β. This has also been shown for the IL-36R, however the binding affinity is again a lot 
lower than IL-36RA or other IL-36 members [126]. At present these binding affinity
studies have only been shown with the full length form of the protein and in order to
increase binding affinity to the IL-36R N-terminal cleavage may be required as with
other IL-36 members (see 1.4.3 for further discussion). GWAS studies have linked IL-
38 polymorphisms to various inflammatory diseases such as ankylosing spondylitis
[180] and PsA [181], which may point to a role for IL-38 in the pathogenesis of these
diseases.
1.5.2 The IL-1 receptors and negative regulators
IL-1Rs belong to a phylogenetically conserved superfamily of proteins, which also
includes the TLR family that are involved in innate immunity and inflammation. The
majority of the IL-1 receptors are comprised of two Ig domains and a cytoplasmic
signalling domain. The conserved domain in this family is the cytoplasmic Toll/IL-1R
(TIR) domain [182], this is involved in the activation of protein kinases such as p38, c-
jun N terminal kinases (JNK), extracellular signal-related kinases (ERKs) and mitogen-
MAPKs. Downstream signalling of the cytosolic TIR domain also allows for
translocation of NF-κB into the nucleus [183]. Within this cytoplasmic TIR domain 
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there are different functional motifs, some more important than others for downstream
signalling [184]. The IL-1 receptor family contains receptors and accessory proteins
(AcP) as well as inhibitory receptors, such as SIGIRR (See Figure 1-5). The AcP
component of the IL-1 receptor is recruited on ligand binding (not RA binding), and this
is common to all IL-1 members apart from IL-18 which has its own AcP. When the
accessory protein is recruited this allows downstream signalling to occur [124, 185,
186]. IL-1R1 is widely expressed in tissues and signals through the NF-κB pathway. 
ST2 is expressed in a constitutive and inducible manner in many cell types including
stromal and haematopoietic cells. Signalling is MyD88-dependent and negative
regulation is via the soluble ST2 and soluble IL-1AcP, which forms a complex and
competes for IL-33 binding with the membrane bound signalling receptor complex
[121]. The receptors and accessory proteins and the ligands of the IL-1 family are
depicted in Figure 1-5.
Figure 1-5. A diagrammatic representation of the IL-1 receptor family.
This diagram identifies known IL-1 receptors and there known ligands as well as the proposed
downstream signalling pathways [121].
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The negative regulators within the IL-1 family are also crucially important. These
consist of the receptor antagonists, IL-1RA and IL-36RA (discussed further in 1.4.3),
which compete with IL-1α, IL-1β and IL-36α, IL-36β, IL-36γ (respectively) to bind to 
IL-1R1 and IL-36R (respectively). IL-1RA binds to IL-1R1 with greater affinity
compared to its agonists, however the IL-1RAcP is not recruited thereby preventing
downstream signalling. In addition to the soluble extracellular IL-1RA there are also
intracellular forms which are thought to be a reserve of IL-1RA which is released upon
cell death in order to dampen down the inflammatory response [121]. The IL-1 family
also has two decoy receptors, IL-1R2 and IL-18 binding protein (discussed in 1.4.4.2). A
negative regulatory receptor SIGIRR also exists as well other orphan receptors that are
thought to play a role in IL-1 signalling namely TIGIRR and IL-1RAPL2, however their
ligands and actions are still to be elucidated [187].
IL-1R2 was first described in 1999 [188] as a typical decoy receptor and more recently a
decoy receptor has been identified for IL-18 as well [189]. IL-1R2 lacks a signalling
domain (TIR) due to its small cytoplasmic domain, therefore on IL-1 binding no
downstream signalling occurs, therefore not only is it acting as a decoy receptor but also
as a ‘scavenger’ for excess IL-1. This decoy receptor is more than just a sequestering
tool for IL-1 it is an active regulator because it binds IL-1RA 100 times less than the
agonists and in a complex with IL-1RAcP it binds pro-IL-1β preventing cleavage into its 
active form [190]. However, caspase-1 will dissociate IL-1R2 from IL-1α therefore 
restoring the biological activity of IL-1α [191]. IL-1R2 is expressed on a relatively 
limited variety of cell types compared to IL-1R1, of note expression of IL-1R2 is high
on fibroblasts. Its expression is enhanced by anti-inflammatory signals such as IL-4 and
IL-13 [192]. It has been described that IL-1R2 can also be cleaved and released in a
soluble form by a disintegrin and metalloprotease 17 (ADAM17) [193], thereby acting
almost as a binding protein. It is thought that IL-1R2 may be a mechanism by which
steroids such as prednisone may be effective, patients treated orally with this showed
increased levels of IL-1R2 on monocytes and levels of IL-1R2 related to response to the
drug [194].
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SIGIRR, also known as TIR8, is unique in the IL-1R family due to its ability to inhibit
not only cytokine signals but also TLR signalling [195]. It is comprised of a single
extracellular Ig domain and a cytoplasmic TIR domain, which has two amino acid
substitutions compared to the other IL-1Rs. These structural differences in SIGIRR
suggest a potential differential signalling pathway [121]. SIGIRR is expressed in a
variety of tissues including the lung, liver, kidney, lymph tissues and digestive tract
[196], however due to the extensive expression of IL-1 this negative regulation may be
limited to these tissues that express SIGIRR. The negative regulatory role of this
receptor is due to its ability to inhibit NF-κB and JNK activation upon agonist binding to 
IL-1R or TLRs by interfering with the recruitment of TIR-containing adapter molecules
[195]. In murine models deficient in SIGIRR it has been shown that following infection
with Candida albicans or Aspergillus fumigatus mice are more prone to lung infection
and have increased mortality and fungal burden. These symptoms following fungal
infection are attributed to increased IL-1 and Th17 cytokine release [197]. The ligand
that binds to SIGIRR is a contentious issue as it is thought that the small extracellular Ig
domain prevents a ligand binding [198]. However, it has been shown that in glial cells
interaction of IL-36RA with SIGIRR attenuates the inflammatory role of IL-36 [199].
The importance of SIGIRR is demonstrated due to the fact that a deficiency is associated
with an increased risk of chronic inflammation, such as psoriasis, in murine models
[200]. This murine model indicates that SIGIRR dampens down IL-1 mediated Th17
differentiation and therefore reducing release of IL-17A [200]. SIGIRR has also been
proposed to play a role in Th2 mediated immunity, it has been shown that SIGIRR can
form a complex with ST2 upon IL-33 binding to inhibit downstream signalling [201]. It
is thought that the intracellular TIR domains of TIGIRR/IL-1RAPL are similar to that of
SIGIRR and do not induce NF-κB activation [202], suggesting they may play a similar 
negative regulatory role in inflammation.
1.5.3 IL-36, a subgroup of the IL-1 family
The IL-36 family has four members IL-36α, IL-36β, IL-36γ and IL-36RA which all bind 
to IL-36R (formerly known as IL-1Rrp2), and the accessory protein IL-1RAcP apart
from IL-36RA (see Figure 1-5) [203, 204]. IL-1RAcP is the signalling element of the
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receptor which when recruited by the IL-36R activates the NF-κB and MAPK pathways. 
This signalling element of the receptor is not recruited when the IL-36RA binds to the
IL-36R, despite its increased binding affinity, therefore no downstream signalling occurs
[185]. IL-36RA (which binds to IL-36R) acts in the same way as IL-1RA (which binds
to IL-1RI).
N-terminal truncation increases the biological activity of all members of the IL-36
family by 1000-10000 fold compared to the full length proteins. Each member of the
family requires a different truncation of the N-terminus to increase activity [128]. IL-
36RA requires only removal of the methionine to drastically increase its activity.
Whereas IL-36α (K6), IL-36β (R5) and IL-36γ (S18) require cleavage 9 amino acids 
away from the IL-1 domain conserved region (A-X-Asp – A = aliphatic amino acid, X =
any amino acid, Asp – Aspartic acid) at the N-terminus (N-terminal amino acid and the
amino acid number from N-terminus are given in brackets) [128]. However, unlike other
IL-1 family members caspase-1 is not likely to be the protease responsible for this
cleavage due to its very specific consensus sequence for cleavage, this consensus
sequence is not present around the IL-36 cleavage site [205]. This has been confirmed in
vitro where LPS/ATP stimulated macrophages with confirmed caspase-1 activity could
not cleave IL-36α [206].  
1.5.3.1 Expression and role of IL-36 cytokines
The expression patterns of these molecules are slightly different when looking at the
four family members. IL-36RA is constitutively expressed in keratinocytes whereas the
agonists often require induction. IL-36β mRNA levels have been detected in human 
synovial tissue [207] and IL-36α shown to be increased in chronic kidney disease [208]. 
IL-36γ has recently been shown to be released from keratinocytes expressing human 
papillomavirus (HPV) 11 interestingly at lower levels than normal keratinocytes [209].
In the same study on HPV11 human monocyte derived immature Langerhans cells were
shown to respond to IL-36γ by release of further pro-inflammatory cytokines [209]. IL-
36γ has also been implicated in lung pathology and is known to be expressed by lung 
epithelial cells in mice where it can induce neutrophil infiltration independently of IL-1α 
and IL-1β [210]. Interestingly this study showed that induction of inflammation was 
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present when the full length form of IL-36α was administered, however the truncated 
form or possible in vivo cleavage/activation was not analysed in this study. All of the IL-
36 cytokines are expressed in the skin and most of the work on IL-36 is focused around
psoriasis. In keratinocytes IL-36 expression is induced by TNFα, IL-17 and IL-1α [60, 
97, 211, 212]. Human lung fibroblasts produce IL-8 and CCL20 in response to IL-36γ 
[213]. IL-36β and IL-36γ have also been implicated in monocyte derived DCs (MDDCs) 
maturation with IL-36β inducing release of IL-18 and IL-12p70 along with increased 
expression of CD40 and CD80 resulting in Th1 cell activation [214]. IL-36γ has also 
been implicated in human Th1 cell lineage and subsequent Th1 type immunoactivation
by activation of T-box expressed in T cells (T-bet) [215]. T-bet is a transcription factor
involved in Th1 lineage polarisation and activation and consequent release of IFNγ 
[216, 217]. This same study also showed that IL-36γ from both myeloid cells and 
keratinocytes may promote a Th1 driven inflammation and also enhance levels of
chemokines such as CCL20, which plays a role in Th17 infiltration. This has also been
confirmed in murine models where IL-36 members have been shown to be expressed by
innate immune cells and lymphocytes. This consequently leads to increased release of
pro-inflammatory cytokines and chemokines. This role of IL-36 leads to Th1 and Th17
cell proliferation and polarisation and DC activation [218]. Interestingly it was also
noted that active forms of IL-36γ induce further release of IL-36γ from primary human 
keratinocytes [215]. This was also shown for IL-36β [212] and suggests that the IL-36 
cytokines show a similar pattern to that of IL-1, where an autocrine effect has been
indicated [219]. This work along with others indicates a pivotal role for IL-36γ in innate 
and adaptive immunity. Due to the fact that in humans IL-36 expression seems largely
limited to epithelial cells, IL-36 activity blockade could be of interest for therapy in
inflammatory skin diseases such as psoriasis.
Release of IL-36 from the cell is at present not well understood. TLR activation has
been shown to induce transcription of IL-36γ in primary human keratinocytes, however 
the TLR3 agonist polyinosinic:polycytidylic acid (Poly I:C) was the only stimulus that
allowed visualisation of IL-36γ outside the cell [211]. However, this was consequently 
shown to be due to induce caspase-3/7 and pyroptosis, programmed cell death, which
was indicated to be a caspase-1 dependent mechanism. Interestingly it was also shown
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that IL-36γ transcription is caspase-1 dependent, suggesting expression is switched on 
before the cell goes into a state of pyroptosis [211]. Release of IL-36α in bone marrow 
derived macrophages has been shown to only occur following a stimulus coupled
mechanism i.e. two stimuli such as LPS and ATP, in a similar manner to IL-1β. It was 
assumed that IL-36α did not undergo proteolytic cleavage during release due to its 
appeared similar motility on an sodium dodecyl sulphate (SDS) page gel in the
supernatant and lysate [206]. However, we now know that the mature form of IL-36α 
only requires cleavage of 5 amino acids from the N terminus and the difference would
not be detectable on an SDS page gel.
It has to be highlighted that current knowledge on IL-36 regulation is mainly based on
mRNA and the lack of protein expression data or in vivo detection of IL-36 members
suggests there is still a plethora of knowledge still to be gained regarding these elusive
IL-1 members.
1.5.3.2 The relevance of IL-36 in psoriasis
Psoriatic inflammation is complex involving many factors of the skin cytokine network.
IL-36 appears to be another important mediator as highlighted by the severe clinical
phenotype seen in patients with unleashed IL-36 activity (loss-of-function mutation in
the RA).
The recent interest in the role of IL-36 in psoriasis is due to 1) findings related to the
loss-of-function mutations [5, 111] and 2) data showing that IL-36 is highly up-
regulated in psoriatic skin [60, 97, 220]. It was shown that IL-36 expression could be
induced in human primary keratinocytes by treatment with IL-17 and this induction was
much more prominent in keratinocytes derived from psoriatic patients [60]. A multitude
of genome studies and microarrays have shown that IL-36γ frequently appears as one of 
the top 30 up-regulated genes when comparing non-lesional and lesional psoriatic skin
[221]. Most recently IL-36γ has appeared in the top 20 when comparing psoriatic skin to 
skin from cutaneous lupus erythematosus [222]. These findings were strengthened when
it was shown that mice over-expressing IL-36α developed a psoriasis-like skin 
phenotype including epidermal thickening and immune cell infiltration, this phenotype
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was worsened by a deficiency in IL-36RA [220]. This supports the view that the balance
between IL-36 agonists and antagonists plays a crucial role in psoriatic inflammation.
Of interest, mice over expressing IL-36α also showed over-expression of the psoriasis 
relevant mediators IL-17A, IL-23 and TNFα. Inhibition of IL-36R prevented psoriatic 
like changes in the skin [223]. In murine models of imiquimod induced psoriasiform
dermatitis increased IL-36 expression in DCs was noted. Mice deficient in IL-36R are
protected from developing the imiquimod induced psoriasiform dermatitis, and
accordingly mice deficient in IL-36RA had exacerbated disease [224].
IL-36 members can induce AMPs, such as HBD, expression. AMPs are highly up-
regulated in psoriasis and the IL-36 may play a role as an important amplifier [97].
Along with the induction of AMPs IL-36 has also been shown to not only be up-
regulated in response to Th17 cytokines but also induce Th17 cytokine release in
psoriatic skin lesions [212]. A study has also suggested a link between IL-36 and
rheumatoid arthritis and PsA, IL-36α was shown to be up-regulated in the synovium 
which consequently induced IL-8 and IL-6 release from the synovial fibroblasts [207,
225]. IL-36β mRNA has also been detected in synovial fibroblasts [207].  
The link between IL-36 and psoriasis has been further strengthened by the discovery of
a loss-of-function mutation in IL-36RA which consequently causes unleashed activity of
the IL-36 agonists. This mutation causes a rare, potentially life threatening form of
psoriasis termed generalised pustular psoriasis (GPP). This disease phenotype related to
the IL-36RA mutation has been given the name deficiency of IL-36 receptor antagonist
(DITRA) as a comparison to the IL-1 related disease, deficiency of IL-1 receptor
antagonist (DIRA) [5, 111, 226]. DITRA has now been identified in a variety of
populations, however the mutation is only present in a subset of GPP patients. Mutations
in IL-36RA have now also been identified in patients suffering from severe adverse drug
reactions which manifests as acute generalised exanthematous pustulosus (AGEP) [227].
This is suggestive of a role for IL-36 in a pustular phenotype of disease indicative of
neutrophil inflammation and innate immunity activation.
In light of recent publications IL-36 is evidently an important mediator in psoriasis and
PsA along with other pro-inflammatory cytokines such as IL-17, IL-22, TNFα and IL-8.  
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1.5.4 Interleukin-18
As previously mentioned IL-18 is a member of the IL-1 family. It was first described as
‘IFNγ inducing factor’ in 1989 because following intraperitoneal injection of endotoxin 
into mice IL-18 was identified in the serum. It was then first cloned in 1995 [228]. IL-18
as with other IL-1 family members contains no signal peptide, so is therefore secreted
from the cell via an unconventional pathway. IL-1β and IL-18 are similar in the fact that 
they are produced in a pro-form and are then cleaved into activity. However, pro-IL-18
is constitutively expressed in a wide range of cells, the best described being in blood
monocytes that express pro-IL-18 but not pro-IL-1β [229]. The expression pattern of IL-
18 is indeed similar to IL-1α and IL-33, all of which are present in keratinocytes and a 
large proportion of epithelial cells. However, pro-IL-18 is structurally similar to IL-37
suggesting a close association between the two [230].
1.5.4.1 Processing and function of IL-18
Cleavage of pro-IL-18 is very similar to that of IL-1β in that assembly of the NLRP3 
inflammasome is required in order to cleave pro-caspase-1 into its active form which
then consequently cleaves pro-IL-18 into its active form. As mentioned previously
assembly of the NLRP3 inflammasome requires a two-step stimulation and this often
occurs following cellular stress. In humans LPS appears to be a strong stimulus for IL-
18 production which is detectable in the peripheral blood from sepsis patients [231].
This confirms that idea that stimulation with a TLR agonist followed by a cellular stress
signal is required in order to see release of mature IL-18 [232]. Activation of the NLRP3
inflammasome in keratinocytes has also been shown to occur by Dermatophagoides
pteronyssinus (house dust mite) in a cysteine protease dependent manner, suggesting
that such allergens can be triggers for skin inflammation [233]. Following activation of
IL-18 by caspase-1 IL-18 is secreted, however up to 80% of the pro-IL-18 remains
unprocessed and intracellular. The importance of caspase-1 in activation of IL-18 has
been shown using caspase-1 deficient mice where very little circulating IFNγ is 
detectable following endotoxin challenge [234]. Conversely, in caspase-1-deficient
murine macrophages stimulated with Fas ligand biologically active IL-18 was detected
[235]. In a similar manner to IL-1α and IL-33 pro-IL-18 is also released following cell 
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death, which could be Fas signalling mediated. However it is yet to be elucidated
whether pro-IL-18 is then cleaved in the extracellular space by neutrophilic proteases
[236]. Mature active IL-18 binds to IL-18Rα with low affinity unless in the presence of 
the accessory receptor, IL-18Rβ. On binding of mature IL-18 to the IL-18Rα and IL-
18Rβ a complex is formed which allows for downstream signalling via the TIR domain 
and subsequently activates NF-κB [237]. The IL-18Rα is widely expressed on cells 
whereas the expression of IL-18Rβ is more limited and found predominantly on T cells, 
ILC1 and DCs. This limits the cell types that respond to IL-18, however cytokines such
as IL-2 can induce expression of IL-18Rβ [238]. IL-18 is also present as a membrane 
protein on around 30-40% of macrophages stimulated with macrophage colony
stimulating factor (MCSF) [239].
The main cellular source for IL-18 is activated macrophages and monocytes [240].
However, keratinocytes have also been shown to produce bioactive IL-18 in the
inflammatory state [241]. In the presence of IL-12 or IL-15 IL-18 is a potent inducer of
IFNγ and Th1 polarisation [242], the co-stimulation is required in order to up-regulate 
IL-18Rβ, as mentioned previously. IL-18 as a polariser along the Th1 and ILC1 pathway 
[243] plays a role in particular in chronic inflammatory conditions including chronic
atopic eczema, lupus erythematosus and psoriasis [244] [245].
Interestingly IL-18 can also enhance a Th2 response [246] in the appropriate
microenvironment. It can enhance IL-13 production and when combined with IL-2 it
activates T cells and NK cells [247]. Keratinocytes also respond to IL-18, following a
dual signal in order to up-regulate the receptor, by production of CXCL10 which is a
chemokine that attracts C-X-C chemokine receptor (CXCR)3 IFNγ producing T cells 
(Th1 subset) [245].
1.5.4.2 IL-18 binding protein (IL-18BP)
IL-18 is tightly regulated at the transcriptional level, the protein level by controlling
cleavage as well as at the receptor level, where IL-18BP prevents binding of IL-18. IL-
18BP was first identified when screening potential soluble receptors for IL-18 [248]. It
has now been shown that it is constitutively expressed and binds with high affinity to
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IL-18, [249] preventing binding to its receptor. In fact IL-18BP binds IL-18 at a much
higher affinity than it binds to IL-18Rα. There have been four isoforms of IL-18BP 
described in humans a, b, c and d. IL-18BPa and IL-18BPc neutralise IL-18 to >95% at
a molar excess of 2. However, IL-18BPb and IL-18BPd lack complete Ig domains on
the C-terminus so have therefore lost any neutralising capacity [250]. IL-18BP is not
categorised as a traditional soluble receptor because it does not contain the extracellular
ligand binding domain of the IL-18R. IL-37b has also been suggested to bind to IL-
18BP following which a complex is formed with IL-18Rβ preventing the formation of a 
functional receptor complex and therefore inhibiting downstream signalling. Of note,
IL-37b binds the IL-18Rα and prevents recruitment of the IL-18Rβ [171]. 
In healthy human serum IL-18BP is present at a 20 molar excess compared to IL-18
[251]. IL-18 and IL-18BP are often up-regulated together especially in the context of
inflammatory conditions. IL-18BP has been shown to be robustly induced by IFNγ in a 
diverse number of non-leukocyte cell types [252, 253]. This is in line with the concept
that on induction of pro-inflammatory molecules, the antagonist is also up-regulated to
control inflammation. In disorders such as familial hemophagocytosis IFNγ is unable to 
up-regulate IL-18BP therefore the activity of IL-18 is uncontrolled [254]. It is thought
that the imbalance between IL-18 and IL-18BP may play a role in the pathogenesis of
IFNγ or IL-18 mediated diseases. In systemic lupus erythematosus IL-18 and IL-18BP 
are hugely increased over healthy controls, however IL-18BP is not sufficiently up-
regulated to neutralise IL-18 effectively [255]. This insufficient up-regulation in IL-
18BP in the plasma has also been shown for patients suffering from chronic liver disease
[256]. Over-expression of IL-18BP in murine models has also been shown to suppress
antigen presentation cells (APC)-derived Th17 polarising cytokines, suggesting that if
IL-18BP was used as a possible therapeutic it may have effects on not only Th1 derived
cytokines but Th17 derived cytokines [257]. IL-18BP has been trialled (Phase I) as a
subcutaneous therapeutic in patients suffering from RA and psoriasis vulgaris, the drug
was well tolerated and it was shown that the drug displayed dose dependent
pharmacokinetics [258].
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1.5.4.2.1 Utilisation of IL-18BP by viruses
Some viruses have developed a strategy to avoid immune surveillance by either up-
regulating host IL-18BP or producing their own homologue. This allows the virus to
prevent IL-18 mediated immune responses. Poxviruses produce a homologue of IL-
18BP which shares 20-40% amino acid sequence with the human IL-18BP [259].
Interestingly, this is thought to have been acquired from the host and then modified by
natural selection. Molluscum contagiosum virus has an IL-18BP homologue that
contains a long C-terminal tail which has been shown to provide increased binding
properties [260]. Furthermore, specific human papillomavirus (HPV) proteins have been
shown to up-regulate the endogenous form of IL-18BP in the host which may support
viral immune evasion [261].
1.6 Interleukin-27
IL-27 is a heterodimeric cytokine and member of the IL-12 family which was first
described as a cytokine thought to act on T cells [262]. Since the discovery of IL-27
many studies have tried to fully elucidate its functional roles within the immune system
and both pro-inflammatory and anti-inflammatory roles have been highlighted. However
many roles of this cytokine still remain enigmatic [263]. IL-27 is comprised of two
subunits, p28 and Epstein-Barr virus-induced 3 (EBI3) (see Figure 1-6). The IL-27
subunits also have other binding partners which consequently form different cytokines,
such as IL-12 and IL-35. Due to the weak binding of the subunits it is thought they may
act independently as natural antagonists of the heterodimeric IL-27 [264]. IL-27 is
produced by APCs early in the immune response and increases sensitivity of target cells
to IL-12 [265].
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Figure 1-6. Diagrammatic representation of the IL-12 family of cytokines and receptors.
This demonstrates the significant homology of IL-27 with other IL-12 family members. EBI3 is shared
with IL-35 and p28 is shared with cytokine like factor-1 (CLF-1) and may also signal on its own. The IL-
27 receptor complex also has homology with the other IL-12 family receptors, sharing glycoprotein 130
(gp130) with the IL-35 receptor and 2 receptor subunits with CLF-1 [266]. Of note, the IL-6R also
contains a gp130 subunit [267].
1.6.1 IL-27 receptor and signalling
The IL-27 receptor is a heterodimeric receptor comprised of WSX-1/IL-27RA and
gp130 (see Figure 1-6). WSX-1/IL-27RA contains a cytoplasmic domain which contains
box 1 binding motifs for janus kinase (JAK)1/2 which contributes to the downstream
signalling of the WSX-1/gp130 complex [268]. Downstream signalling of IL-27 leads to
activation of both STAT1 and 3 pathways [269]. A STAT3-responsive molecule,
suppressor of cytokine signalling (SOCS) 3, has been shown to inhibit STAT3
signalling by binding directly to the gp130 receptor chain preventing JAK
phosphorylation [270]. SOCS3 also cross-regulates STAT1 activation. Interestingly
keratinocytes fail to up-regulate SOCS3 efficiently when compared to autologous
macrophages and as a consequence fail to regulate/stop the production of pro-
inflammatory cytokines such as CXCL10 in the context of repeated stimulation with IL-
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27 [271]. The two receptor subunits of IL-27 are differentially expressed in tissues as
with many heterodimeric receptors. Gp130 is expressed relatively widely whereas
WSX-1 is expressed predominately on immune cells such as B and T cells [272]. A
soluble WSX-1/IL-27RA has also been identified released from a range of cell lines and
primary cells, metalloproteases have been implicated in production of this soluble
receptor [273].
1.6.2 Pro-inflammatory roles of IL-27
IL-27 was initially described to provide a rapid clonal differentiation and expansion of
Th1 cells, consequently causing production of IFNγ [262, 274]. Antigen-stimulated 
WSX-1-deficient cells have significantly reduced IFNγ levels, suggesting a role of IL-27 
in increasing responsiveness of T cells to IL-12 leading to increased Th1 polarisation
[262]. WSX-1 deficient mice with proteoglycan-induced arthritis had delayed onset of
disease and reduced severity, this was associated with fewer Th1 and Th17 cells [275].
However, the role of IL-27 in arthritis is not entirely clear as local addition of IL-27 into
the joints of mice with collagen induced arthritis show disease amelioration [276].
With regard to human pathologies, in the serum of psoriatic patients IL-27 is
significantly higher compared to healthy controls. IL-27-secreting cells were identified
in the dermal layer of psoriatic lesions and these cells were not present in healthy
controls or atopic dermatitis lesions, suggesting that IL-27 may be involved in the
development of psoriatic lesions [277]. However, further studies have also shown that
IL-27 is expressed in chronic eczematous skin lesions. IL-27 can prime keratinocytes to
be more responsive to pro-inflammatory signals [278]. Increased serum levels of IL-27
have also been identified in patients suffering from ankylosing spondylitis which was
indicated to correlate with disease severity [279]. Monocytes, mast cells [272, 280],
primary human keratinocytes, fibroblasts and human antigen presenting cells all react to
IL-27 [59, 278]. In inflammatory dendritic epidermal cells (IDECs) and keratinocytes,
IL-27 acts as a priming signal for IL-23 and CXCL10 production respectively. This
effect is specific to IL-27 and was not shown for any other IL-12 family members [281].
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1.6.3 Anti-inflammatory roles of IL-27
As previously discussed it has been suggested that IL-27 plays a pro-inflammatory role
in initiation or early stages of inflammation, however in the later stages of inflammation
a more anti-inflammatory role has been proposed. This suggests that IL-27 may be an
important mediator in the prevention of chronicity of inflammation. The suggestion that
IL-27 played a role in Th1 differentiation was shattered, at least in murine models, when
it was shown that WSX-1 knockout mice only had a reduction in IFNγ briefly following 
infection with Leishmania major, subsequently which normal IFNγ levels were detected 
[282]. However, these mice did develop organ damage thought to be due to exacerbated
action of T cells, possibly indicating a role for IL-27 as an anti-inflammatory mediator.
Mice deficient in WSX-1 infected with Toxoplasma gondii are still capable of mounting
a sufficient inflammatory response but the inflammation is not resolved and
consequently developed a lethal T cell mediated inflammation [283]. The ability of IL-
27 to dampen down wide ranging inflammation opened up questions as to the
mechanisms involved. It has been shown that IL-27 can antagonise the activity of IL-2
and has also been shown to reduce the expression of both Gata3 and RORγt, which may 
explain its role in dampening down T cell mediated inflammation [284]. Another anti-
inflammatory role of recombinant IL-27 has been shown by its ability to reduce ROS
released from activated macrophages and neutrophils [285].
A number of the regulatory roles of IL-27 have been attributed to the up-regulation of
IL-10. It is thought that IL-27 acts on all T helper subtypes to enhance IL-10 production
[286-288]. This was initially shown in 2007 using murine models and has now been
attributed to human IL-27 as well in the context of visceral Leishmaniasis [289]. During
respiratory viral infections, such as influenza CD8+ T cells respond to IL-27 with
increased expression of IL-10. However memory CD8+ T cells in the same viral
infection lose the gp130 receptor which consequently deems them unable to respond to
IL-27 on repeat infection [290] [291]. Interestingly, patients suffering from multiple
sclerosis (MS) are often treated with IFNβ and it has been shown that this causes 
increases in IL-10 and a decrease in IL-23 and IL-1β. It is thought that response to IFNβ 
therapy in MS is mediated by IL-27 because responders to therapy show significantly
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more IL-27 release from PBMCs compared to non-responders. This is supported by
murine models of experimental autoimmune encephalomyelitis where treating with
IFNβ increased IL-27 and attenuated signs of disease [292]. In vitro experiments have
shown that stimulation of fibroblast-like synoviocytes derived from rheumatoid arthritis
patients with IL-27 showed a significant reduction in release of pro-inflammatory
mediators such as IL-6 and CCL20 [293]. Of note, many of the studies looking at the
anti-inflammatory or regulatory roles of IL-27 are in mice therefore the role of IL-27 in
humans remains to be fully accounted for. However, a recent publication in human
PBMCs have indicated a complex mechanism between IL-27 and IL-17A, where the
inflammatory state may determine responses and the actions between the two are by no
means unidirectional. This implies a possible anti-inflammatory role in surrounding
resting cells to prevent over-activation but also boosting inflammatory responses by
their reciprocal actions [294]. This current finding is of interest in IL-17A mediated
diseases such as psoriasis.
1.7 Proteolytic cleavage of inflammatory mediators in the skin
It is well known that both IL-1β and IL-18 require cleavage in order to gain biological 
activity as described previously. However, proteolytic cleavage is not just limited to that
of the IL-1 family members but extends to other cytokines such as IL-6, IL-2 and TNFα 
and chemokines as well as cytokine receptors. This proteolytic cleavage may be
intracellular such as via the inflammasome, or by a protease present in the extracellular
space. Proteolytic cleavage discussed in this section will be inflammasome independent
as cleavage dependant on the inflammasome has been discussed in 1.4.1.
1.7.1 Proteases in the skin
On the basis of the catalytic domain proteases are grouped as follows; aspartate,
cysteine, glutamate, metallo-, serine and threonine with the prime aim to break peptide
bonds. The prominent proteases present in the skin compartment are metallo-, serine,
cysteine and aspartic proteases [295]. Of note, aminopeptidases are also likely to be
present in the skin due to their widespread expression. Aminopeptidases are often
membrane bound and will remove a single amino acid from the N-terminus. The most
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well studied of these is aminopeptidase N (AMN) or CD13 which is Zn2+ dependent
ectopeptidase [296]. Within the skin compartment serine proteases appear to play a role
in barrier homeostasis. Proteases will also be present in the skin as fungal or bacterial
derivatives as well as proteases produced by infiltrating immune cells such as
polymorphonuclear (PMN) cells. Proteases themselves require cleavage to gain activity
often by removal of an N-terminal amino acid which then initiates a downstream
cascade of activation and is important to prevent constant activation of inflammatory
mediators [295]. The balance of proteases and protease inhibitors is crucial in
maintaining healthy skin homeostasis and there are also many protease inhibitors
expressed in the skin that have wide ranging inhibition often to a specific catalytic
domain protease. This is evident in the rare genetic disorder, Netherton syndrome which
leads to widespread break down of the epidermal barrier. It is caused by mutations in the
serine protease inhibitor Kazal-type 5 (SPINK5) gene [297]. There are now an
increasing number of disease states especially within the skin that are being attributed to
the imbalance of protease and protease inhibitor.
1.7.1.1 Metalloproteinases in the skin
Metalloproteinases are proteases whose catalytic activity is dependent on the presence
of a metal ion. Matrix metalloproteinases (MMPs) are Zn2+ dependent and are important
in remodelling of tissue by cleavage of collagens. MMPs expressed in mammals
primarily cleave specific collagens as well as some growth factors. Aberrant expression
of MMPs has been attributed to many disease states where tissue degradation is present
such as arthritis and psoriasis [298]. ADAMs are a family of metalloproteinases of
which ADAM10 and ADAM17 are expressed in the skin. This family of proteases are
important in the cleavage of receptors from the plasma membrane to produce soluble
receptors [299] which are crucial in the control of inflammation. Loss of function of
ADAM17 causes chronic inflammation [295].
1.7.1.2 Cysteine and aspartic proteases in the skin
Cysteine proteases can be classed into two categories in mammals based on the
structural organisation of the active site, one group being related to papains and one
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which includes the caspases and legumains [300]. It is thought that these cysteine and
aspartic proteases in the skin are essential for desquamation and thereby are important in
the maintenance of the skin barrier.
Cysteine-dependent aspartate-directed proteases (caspases) are a family of 14
endoproteases that rely on a catalytic cysteine residue in the caspase active site and only
cleave after aspartic amino acids in the substrate [301]. Caspases are widely expressed
and as discussed previously caspase-1 plays a crucial role in intracellular cleavage of IL-
18 and IL-1β. An important epidermal enzyme is caspase-14 which is required for the 
breakdown of filaggrin into natural moisturising factors in order to maintain barrier
homeostasis [302] [303]. Like other caspases it is produced in a pro-form and thought to
be cleaved into activation by a serine protease with elastase-like properties in the
cornified layer of the epidermis [304]. Another cysteine protease expressed in the skin is
cathepsin C which is a lysosomal protease in the papain family. Mutations in the
cathepsin C gene are responsible for two genetic disorders, Papillon-Lefevre [305] and
Haim-Munk [306], both of which have clinical phenotypes that indicate a role for
cathepsin C in the organisation of the epidermis and barrier function. However,
cathepsin C deficient mice do not display the phenotype of the human disease but do
have deficiencies in processing and activation of granzyme A and B which are essential
for T cell mediated killing [307].
Cathepsin D is an aspartic protease and is the most abundant protease in the
endolysosomes. It is active at the pH of healthy skin, around 5.5. Cathepsin D is thought
to be crucial in the final stages of desquamation [308] and therefore deficiency of
cathepsin D results in down-regulation of the proteins such as involucrin. Clinically this
produces symptoms such as dry skin with hyperkeratosis [309].
1.7.1.3 Serine proteases in the skin
Serine proteases are large family of proteases that use a catalytic triad in the substrate
binding pocket (Ser, His, Asp). It is thought that as with the cysteine and aspartic
proteases, the serine proteases produced by keratinocytes are important in terminal
differentiation and desquamation of keratinocytes therefore maintaining barrier
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homeostasis. Serine proteases can be divided in to three distinct groups; trypsin-like
enzymes (cleaves C-terminally at Arg or Lys), chymotrypic enzymes (cleaves after
aromatic or bulky hydrophobic amino acids) and elastase-like enzymes (cleaves after
small or medium non-polar amino acids) [300].
Matriptase and prostasin are important serine proteases produced by keratinocytes in the
interphase between the stratum granulosum and stratum corneum. These proteases are
transmembrane anchored proteases that crucially cleave profilaggrin in to its active form
[310]. This is an extremely important protein in barrier homeostasis and mutations in the
filaggrin gene have been linked to atopic dermatitis and asthma, possibly due to the
disturbed barrier allowing penetration of allergens as well as infectious agents [311].
Matriptase is thought to be activated by exposure to acidic pH in the skin and this in turn
may activate prostasin [312]. However, activation of these proteases is tightly controlled
due to the complex mechanism by which activation occurs, therefore a small window is
present where they are both active and have the ability to cleave the substrate [313]. The
importance of these proteases is not just limited to activation of filaggrin but it has also
been proposed that matriptase may activate the largest family of serine proteases in the
skin, kallikrein-related proteases [314], suggestive of a role for these proteases in
mediation of inflammatory skin diseases.
Kallikrein-related proteases (KLKs) are tryptic or chymotryptic serine proteases. These
proteases are produced by keratinocytes in the stratum granulosum where they are
released from lamellar bodies [300]. At present eight members have been described in
healthy skin, the most important described as KLK5, KLK7, KLK8 and KLK14 in skin
homeostasis. KLK 5 and KLK7 have been isolated in an active form in the stratum
corneum and KLK14 has been predominantly identified in the sweat glands [315]. The
specific functions of the KLKs in the skin remains to be fully elucidated, however with
the use of murine models and in vitro studies some light has been shed on their possible
roles in the skin. Kallikreins have been shown to cleave corneodesmosomes, which as
with other proteases produced by keratinocytes suggests crucial involvement in
desquamation and barrier homeostasis [316]. There has also been suggested roles in
regulating antimicrobial activity in the skin [317] which may contribute to the
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pathogenesis of rosacea [318]. KLK5 and KLK14 have been shown to cleave and
consequently activate protease-activated receptor 2 (PAR-2) [319]. These receptors are
involved in maintenance of the barrier, however they also play a role in inflammation,
pruritis and scar formation [315]. KLK7 over-expression in murine models displays an
itchy, hyperproliferative, inflamed phenotype with reduced barrier integrity [320]. This
suggests that KLK7 may be involved in the pathogenesis of skin diseases that develop
this phenotype such as atopic dermatitis. The only kallikrein knockout mouse that has
been published is KLK8. This murine model has apparently normal skin apart from
when inflammation is induced using UV light and resolution of inflammation is delayed
[321]. Due to the unique environment of the skin and the necessity for control of
desquamation, the activity of KLKs are pH and water dependent [322].
Apart from the serine proteases produced by keratinocytes, those produced by
infiltrating cells also contribute to inflammatory pathologies. The serine proteases
produced by these cells may play an important role in the pathogenesis of inflammatory
disorders. The serine proteases produced by neutrophils are present in the azurophils
and are thought to be responsible for intracellular degradation of microorganisms [323].
These proteases also have action in the extracellular space and it is thought that
avoidance of the numerous circulating serine proteases inhibitors may be via the serine
proteases remaining on the cell membrane but maintaining activity [324].
Three structurally similar serine proteases are present in neutrophils; cathepsin G (CG),
proteinase 3 (PR3) and neutrophil elastase (E). Murine models deficient in these specific
proteases has indicated an important role in bacterial clearance [325]. It is also worth
noting that a fourth serine protease is also present in neutrophil granules, neutrophil
serine protease 4 (NSP4). This protease shares <40% structural homology with the other
neutrophil serine proteases and is unique in that it has a preference for cleavage with an
Arg at the P1 position [326]. However, mice deficient in NSP4 show no changes in
phenotype that seems of clinical relevance [327]. Neutrophil serine proteases require
processing for enzymatic activity, in a murine model cathepsin C, which is a lysosomal
cysteine protease, has been identified for processing and activation of PMN proteases
[328]. C-terminal cleavage is also required for normal trafficking within the cell [329].
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1.7.2 Inactivation of inflammatory mediators by proteolytic cleavage
As previously described proteases are prevalent in the skin and provide important
extracellular proteolytic activities especially at the sites of inflammation. TNFα was the 
first pro-inflammatory cytokine to be identified as rapidly inactivated following
incubation with activated PMNs [330] and also recombinant E and CG. The cleavage of
TNFα into at least two fragments results in loss of cytotoxic activity [331]. This has also 
been shown for the inflammatory cytokine IL-6 at the sites of inflammation.
Recombinant PMN serine proteases cleave IL-6 at different sites; however, all lead to
inactivation. IL-6 is known to activate neutrophils so cleavage may be a way to provide
negative regulation [332, 333]. IL-2, the potent T cell activator has also been shown to
be susceptible to cleavage by E and these cleaved products actually have a negative
regulatory role in preventing the pro-adhesive properties of IL-2 thereby preventing
further immune cell infiltration [334]. Chemokines including CXCL12 and CCL3 have
also been shown to be cleaved by serine proteases released by neutrophils and
recombinant E, CG and PR3 resulting in loss of chemotactic activity [335, 336].
Another important modulatory role of proteases within the skin is the shedding of
cytokine receptors. Membrane bound metalloproteases as well as PMN serine proteases
have been implicated in this role. PMN serine proteases cleave the IL-2 receptor, TNF
and IL-6 receptor (IL-6R) close to the plasma membrane and form soluble receptors
[337]. However, ADAM17 is the predominate sheddase that cleaves both TNF receptor
(TNFR) I and TNFRII as well the IL-6R and IL-15R. ADAM10 also cleaves IL-6R, and
both ADAM10 and ADAM17 are involved in cleavage of adhesion molecules to alters
cellular adhesion and consequently cellular infiltration [338, 339]. This not only
provides soluble receptors to act as decoys but is also important in regulation of cell
adhesion controlling cellular infiltration into inflamed areas.
1.7.3 Activation of inflammatory mediators by proteolytic cleavage
Pro-inflammatory cytokines often require cleavage before activation occurs. Proteases
released from immune cells only present in inflammation are common mechanisms by
which pro-inflammatory cytokines are activated. However, other proteases present in the
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skin may also play a crucial role in the cleavage of cytokines into bioactive forms. As
previously discussed IL-1β is cleaved in to activity by caspase-1 within the cell. 
However if pro-IL-1β is present in the extracellular space due to cell necrosis alternative 
cleavage of IL-1β can occur to enable activity. This has been confirmed by turpentine-
induced inflammation in murine models; those deficient in IL-1β were protected from 
inflammation whereas those deficient in caspase-1 were not [340, 341]. Serine proteases
released from neutrophils can cleave IL-1β into its active form, specifically PR3 [342]. 
This is not the same cleavage site as caspase-1 but between the valine-arginine adjacent
to this caspase-1 site [337]. However, MMPs have also been shown to cleave pro-IL-1β 
such as stromelysin 1 and gelatinases A and B [343]. There has also been some
suggestion that PR3 released from neutrophils can cleave pro-IL-18, however it has not
been confirmed as to whether this cleavage produces the bioactive product [236] [344].
Chemokines are crucial in the inflammatory response and enable infiltration of immune
cells to the site of inflammation. Chemokines however often require cleavage. CXCL8
or IL-8 is a potent chemokine that attracts neutrophils. IL-8 is cleaved to increase its
chemotactic functions by PR3 [345]. This is a protease produced predominantly by
neutrophils suggesting that on infiltration of neutrophils release of proteases encourages
further infiltration. There are various isoforms of IL-8, clustering into 3 main categories
one of which has no chemotactic ability while the other 2 have significant biological
activity. This needs to be taken into account when assessing levels of IL-8 and the
balance between active and inactive forms following cleavage [346]. CG cleaves
CXCL5 into activation to increase its neutrophil chemotactic ability [347]. The
chemotactic ability of CCL15 (MIP3δ) to attract monocytes can be increased 1000 times 
following N-terminal cleavage by CG [348].
TNF is produced as a pro-form that is membrane bound and is proteolytically released
from the membrane. A metalloprotease was identified that cleaves TNF into its active
from and this was named TNF-converting enzyme (TACE) [349], which is now known
as ADAM17. This has been confirmed by using murine models which express an
inactive form of ADAM17. T cells from these mice have significantly reduced TNF
levels. [350]. As well as ADAM17 it has also been shown that PR3 can cleave TNF
52
into its active form [351]. Interestingly the two other prominent serine proteases
released from neutrophils, E and CG, have been shown to inactivate mature TNF [352].
The cleavage sites of PR3 and ADAM17 in order to activate TNF are not identical. PR3
cleaves between a valine-arginine in the immediate vicinity to the site of ADAM17
[337].
1.8 RNA aptamers
RNA aptamers are single stranded oligonucleotides selected in vitro to bind a target with
high specificity and affinity. Single stranded RNA is conformationally very flexible and
can adopt a range of 3-dimensional (3-D) structures, some of which will bind to the
target. Of note, ssDNA aptamers can also be generated and are being developed in
parallel with RNA aptamers. RNA aptamers can function in a similar way to antibodies
and small molecule inhibitors that are currently used in therapy. However, in
comparison to antibodies they provide a non-immunogenic alternative and have
advantages due to their small size and also their ability to target epitopes that antibodies
cannot. The structural flexibility of aptamers also means that RNA aptamers can often
bind epitopes that are hidden from antibody targeting. Due to these unique features of
RNA aptamers they present as interesting potential therapeutics [353]. RNA aptamers
are also being developed to act as delivery systems that can be loaded with toxins,
enzymes and chemotherapy agents to target specific cells [354]. Fusion of siRNA and
shRNA with RNA aptamers has been shown to effectively deliver these interfering
RNAs to specific cells [355].
1.8.1 Production of RNA aptamers
RNA aptamers are traditionally generated through the use of systemic evolution of
ligands by exponential enrichment (SELEX). This can either be performed in vitro or
using whole cells, such as cancer cells which may provide an array of cellular targets for
establishing healthy cell from cancerous cell (Cell-SELEX) [356]. In vitro SELEX is
performed using a library of RNA molecules which is then incubated with the receptor
or ligand of interest. This is heated and cooled to encourage formation of stable
structures, followed by washing to remove unbound molecules. The RNA structures that
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bound to the target are eluted and incubated with a control sample, this provides
negative selection. The molecules that bound in the positive round and did not bind in
the negative round are then isolated, reverse transcribed and then amplified using
polymerase chain reaction (PCR) and then the process is repeated until the pool of RNA
molecules are specific for the required target. This pool is then cloned and sequenced to
obtain the individual sequences (see Figure 1-7). Due to the in vitro nature of this
process it can be altered depending on the properties required for the end product, such
as different temperatures and different forms of negative selection, which can be
repeated more than once [357]. Cell-SELEX is performed in a similar manner, for
example using live cancer cells for the positive selection round and healthy cells for the
negative selection. The library of single stranded oligonucleotide segments incubated
with the cells can be fluorescently labelled, allowing the whole process to be monitored
using flow cytometry [356].
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Figure 1-7. Summary of the SELEX process.
Steps 1 – 4 are performed before the cycle is repeated until a few RNA molecules are bound with high
specificity and affinity. These are then cloned and sequenced and then chemical modification can be
performed on the specific RNA molecules [358].
This method is undoubtedly faster than producing monoclonal antibodies and more
specific due to the multiple rounds of selection and screening. However, RNA
molecules are inherently unstable, so without chemical modification these molecules
would be of no use as a therapeutic or research tool [359]. Chemical modification such
modifying the 2’OH position of the ribose of pyrimidines to incorporate a fluorine
reduces RNase degradation and maintains hair-pin loops and single stranded structures
that are thought to be important for the binding of the aptamer to its target. Other
common modifications used are the addition of O-methyl or amino group to the 2’
position of the ribose [360]. However, fluorine is the most common modification due to
its small size compared to the other chemical modifications available. These chemical
modifications have been shown to allow stability of aptamers for 2 hours in human
serum [361]. These chemical modifications also increase thermodynamic stability
therefore maintaining structure of the RNA molecule. Aptamers can also be easily
labelled with fluorophores in order to track the aptamers, this has been utilised in an
experimental setting however it can also be used in diagnostics to identify diseased cells
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[357]. Aptamers can also be used as a diagnostic due to the binding affinity of RNA
aptamers, detecting cancerous cells at extremely low levels [357].
1.8.2 Potential clinical use of RNA aptamers
The use of aptamers as therapeutics is relatively novel and aptamers have shown
promising results so far. A number of aptamers are in pre-clinical trials and at least nine
aptamers are in various stages of clinical testing [362]. Apart from the above mentioned,
another advantage of aptamers over antibodies is their small size which allows increased
transport and tissue penetration. However aptamers are not likely to be utilised as a
systemic therapy so antibodies will be advantageous when systemic therapy is required
[353]. Small molecule inhibitors which are increasing in popularity especially for
treatment of inflammatory diseases are a similar size to aptamers and therefore the
systemic clearance will be comparable. However, aptamers have the advantage of being
potentially more specific avoiding off target side effects [363]. The majority of aptamers
that have been produced as a potential therapeutics bind a target to modulate
downstream signalling, they are most commonly used as neutralisers rather than
stimulators. This typically occurs by the binding of the target and preventing structural
changes that are required for downstream signalling [364] or prevent binding to the
receptor [365]. However, a few aptamers have been produced as agonists, namely
aptamers against the extracellular domain of the EGFR [366] and isoleucyl tRNA
synthetase [367].
RNA aptamers have been produced most commonly as a cancer therapeutic. Aptamers
produced using Cell-SELEX can provide a tool to distinguish between healthy and
cancerous cells [368]. This is essential for cancer therapy due to the need to reduce
healthy tissue death and side effects. RNA aptamers have been produced to target
various aspects of the disease including adhesion molecules such as E-selectin which
prevents metastases [369]. Modulation of the immune system has also been targeted
including cytotoxic T-cell antigen 4 (CTLA-4) [370]. An aptamer has been produced
against CXCL12, which is involved in aiding tumour metastases and angiogenesis
[371]. Immunological targeting by aptamers has also been demonstrated as an
alternative to antibody neutralising therapy, prevention of pro-inflammatory cytokines
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binding to the receptor is an invaluable tool to control dysregulated immune responses.
Pro-inflammatory cytokines such as IL-17A have been targeted for aptamer therapy
which is prominent in many inflammatory diseases such as psoriasis [365].
1.8.3 Potential mechanisms of internalisation of oligonucleotides
In order for RNA aptamers to function inside the cell, targeting signalling pathways or
nuclear proteins directly, aptamers need to cross the cell membrane. This would either
have to be achieved using chemical introduction into the cells or by utilising
physiological mechanisms. If an aptamer was to be used therapeutically then it would be
preferable to utilise cellular mechanisms without the need for chemical treatment of the
cells which could damage the cell membrane and may cause unwanted immune
responses. A DNA aptamer, AS1411, has been described as an effective anti-neoplastic
aptamer which targets nucleolin, which is often over-expressed in cancer cells and
binding of the aptamer consequently interferes with DNA replication and leads to cell
death [372]. In contrast to initial studies it has now been shown that this DNA aptamer
is in fact internalised by healthy cells and cancer cells rather than cancer cells alone.
However in cancer cells the aptamer is thought to be taken up by macropinocytosis and
in healthy cells it is thought that the uptake is via an alternative mechanisms which may
lead to lysosomal degradation [373]. Interestingly the AS1411 uptake mechanism
appears to play a role in the efficacy of the aptamer, with the aptamer only having an
effect in cancer cells [373]. Macropinosomes have been shown to be leaky, therefore
possibly allowing delivery of the aptamer in to the cell.
Another mechanism that has been suggested for aptamer uptake is via specific receptors.
The uptake of AS1411 was shown in a fibroblastic cell line, however plasmid DNA
uptake has also been identified in human primary keratinocytes. This uptake was shown
to be receptor-dependent and indicated a possible role for DNA-binding proteins. It was
shown that ezrin and moesin, which are DNA-binding membrane-cytoskeleton proteins,
are involved in the uptake and trafficking of DNA however, the specific transmembrane
DNA receptor is yet to elucidated [374]. Receptor mediated uptake has also been shown
utilising the IL-6R, the RNA aptamer specific to this receptor could carry cargo (toxins
or siRNA) 10x its molecular weight and deliver this into the cell [375]. Therefore
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possible mechanisms by which aptamer uptake in to cells occurs has been shown to be
via both macropinocytosis [373] and receptor-dependent [374, 375]. These mechanisms
deliver the oligonucleotide molecules into the cells in a form by which they still
maintain neutralising effects. However, mechanisms have also been suggested by which
uptake occurs and the oligonucleotides internalised are targeted for degradation and are
therefore not functional [373].
More extensive research has been performed in the delivery of siRNA into cells and
various mechanisms are utilised to increase efficacy. It is thought that siRNA is
internalised predominantly via endocytotic mechanisms, and delivery mechanisms can
be improved by association with other molecules such as aptamers or antibodies that
target a specific ligand to initiate receptor-dependent endocytosis [376]. An important
feature of delivering siRNA into the cell via endocytosis is the endosomal escape to
avoid degradation and enter the cytosol to enable their silencing effects [377]. This is
often overcome by promoting fusion with the endosomal membrane or causing
disruption of the membrane and this would be important in the formulation of siRNA to
ensure escape of endosomal degradation [377]. However, as with the aptamers
macropinocytosis has also been described as an effective delivery mechanism for siRNA
[378].
1.8.4 The challenges of using RNA aptamers for therapeutics
Following the development of the aptamer technology it took 15 years for an RNA
aptamer to be available on the market as a therapeutic. Currently there is only one food
and drug administration (FDA) approved therapeutic aptamer on the market, Macugen®
(Pegaptanib) which is in use for treatment of age-related macular degeneration as well a
diabetic retinal disease [379]. There are many challenges that present when establishing
oligonucleotide therapy. Aptamers have been administered intravenously,
subcutaneously and intravitreally. However nuclease degradation, renal clearance and
rapid biodistribition need to be overcome [380]. Nuclease degradation is overcome by
the chemical modifications made to oligonucleotides either before or after SELEX.
Following SELEX further modifications can be made including capping of
oligonucleotide termini protecting from exonuclease activity. Protection from nucleases
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can also be achieved by the use of Spiegelmers. This is the replacement of the D-ribose
with an L-ribose which yields unnatural L-nucleotides [381, 382]. Renal clearance of
aptamers has been overcome by the addition of high molecular weight polyethylene
glycol (PEG). This is a commonly used strategy for therapeutics and has been shown to
slow renal clearance and increase half-life therefore increasing bioavailability [383].
Toxicity of aptamer therapy has not been extensively studied however in trials
Macugen® and AS1411 have shown minimal toxicity [380]. The immune response to
oligonucleotides has been studied in relation to the activation of TLRs, which are known
to respond to both RNA and DNA and produce an IFN type immune response. However
this response is primarily following sensing of extensive regions of double stranded
RNA or DNA [384]. This would have to be a consideration when assessing an aptamer
for therapeutic use.
1.9 Interleukin-17
In 2005 it was demonstrated that with regard to Th cells, there were more than the three
lineages, Th1, Th2 and T reg. This new lineage was described to produce IL-17 and
consequently this new subset of Th cells was named Th17 [89, 385]. IL-17A was first
cloned and described in 1993 and was previously known as CTLA8 [386]. IL-17A and
IL-17F are the best characterised of the IL-17 family and are the only members known
to be produced by Th17 cells. However, genomic sequencing has also identified IL-17B,
IL-17C, IL-17D and IL-17E (also known as IL-25) [387]. All of these are covalent
homodimers although a heterodimer of IL-17A and IL-17F has also been described
[388] (see Figure 1-8). There are diverse cellular sources and expression of the IL-17
family members which all are thought to have pro-inflammatory roles [389].
1.9.1 IL-17 receptors and signalling pathways
The IL-17 receptor family comprises of five distinct subunits, IL-17RA-IL-17RE (see
Figure 1-8). All of these subunits contain a single transmembrane protein domain, with a
conserved extracellular fibronectin III-like domain and a cytoplasmic SEF/IL-17R
(SEFIR) domain. It is still to be fully elucidated how these receptor subunits form a
functional receptor [387].
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Figure 1-8. Diagrammatic representation of the IL-17 receptor subunits and the pairings formed to
produce functional receptors.
IL-17RA-IL-17RC has three known ligands whereas IL-17RB-IL-17RA and IL-17RE have only one
know ligand. IL-17RD-IL-17RA and IL-17RD have no known ligands. Downstream signalling pathways
have been established for IL-17RA, IL-17RD-IL-17RA, IL17RB and IL-17RD.
IL-17RA is the largest IL-17R complex [390] and was initially identified as the receptor
for IL-17A. It has now been shown to bind IL-17F and the heterodimer of IL-17A and
IL-17F. Initial studies with human IL-17 suggested that binding of IL-17A to IL-17RA
was not sufficient to elicit a response [391], it was not until much later that it was
described that IL-17RC was required to have a fully functional receptor complex [392].
However, it is not fully understood what number of each of these subunits is present in
this receptor complex and many theories have been proposed as to how these subunits
form the functional receptor [387]. At present it is thought that a trimeric receptor is
likely, as shown in figure 1-8. IL-17RA expression is widespread including epithelial
cells, fibroblasts and macrophages [390] and also can be induced in T cells by IL-21 and
down-regulated by phosphoinositide-3-kinase (PI3K) [393, 394]. Unlike other cytokine
receptors the IL-17R is required at high levels to elicit a response and it has been
suggested that IL-17RA may act in a regulatory role by internalising IL-17A upon
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binding and removing it from the inflammatory environment [394]. The other IL-17
receptor subunits are poorly described and the pairing shown in figure 1-8 is the
proposed mechanism by which these subunits form their functional receptors [395].
The downstream signalling from the IL-17 receptors is complex and many pathways
have been reported to be activated, such as the JAK pathway which was implicated
following inhibition of JAK which consequently reduced IL-17A expression [396].
However, these results using small molecule inhibitors should be interpreted with
caution due to the possible non-specific effects and possible transcription factor
activation due to cytokines up-regulated down stream of IL-17 [397]. Due to the highly
pro-inflammatory role of IL-17A it was originally proposed that the downstream
signalling of its receptor may well compare to the IL-1R and the TLRs. Downstream of
the IL-17RA activation of p65 and p50 has been shown which suggests that the
canonical NF-κB pathway may play a role in the inflammatory signature of IL-17A 
[398]. Act1 has been shown to be recruited to the IL-17RA intracellular domain, which
is a known adapter molecule for NF-κB activation [399]. MAPKs are also activated 
downstream of IL-17RA, the most strongly activated of these are ERKs [400]. Unlike
IL-17RA, IL-17RB contains a TNFR-associated factor 6 (TRAF6) binding motif in its
cytoplasmic component of the receptor, this is a well-known mechanism by which NF-
κB is activated [401]. The downstream signalling of IL-17RD is still to be fully 
elucidated although activation of MAPKs have been proposed due to the evolutionary
origins of IL-17RD and its role in non-primate development [402].
1.9.2 Functional roles of IL-17
As previously mentioned IL-17A and IL-17F are thought to be predominantly leukocyte
derived cytokines, T cells and innate lymphocytes such as ILCs have been described to
produce IL-17 [403, 404]. IL-17 producing cells express the transcription factor
associated with IL-17 production, RORγt. Most studies have also shown that IL-6 and 
IL-1β is required for Th17 development [405]. However IL-21, IL-23 and TGFβ 
signalling has also been implicated [406-408]. The role of IL-23 in the development of
the Th17 subset in an inflammatory context has now been extensively researched [409,
410]. A well-known biological role of IL-17 is the induction of pro-inflammatory
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cytokines, chemokines and MMPs from tissue resident cells leading to tissue
remodelling and, among others, recruitment of neutrophils to site of inflammation [411].
IL-17 and the often co-expressed IL-22 play a prominent role in induction of AMPs and
mice deficient in IL-17 are highly susceptible to both fungal and bacterial infections.
This has also been confirmed in humans with genetic mutations leading to reduced Th17
numbers, or upon treatment with IL-17 neutralising antibodies [412]. Dominant-
negative mutations in STAT3 lead to a hyper-IgE syndrome which prevents generation
of Th17 cells and consequently these patients suffer from mucocutaneous candidiasis
and pulmonary infections, predominantly due to Staphyloccus aureus [413]. STAT3 is
essential for Th17 development downstream of IL-6 [414]. These observations indicate
a crucial role for IL-17 in the defence against invading pathogens. Together with the
environmental stimuli, levels of IL-21, IL-23 and TGFβ control the magnitude of the IL-
17 mediated response by stimulating surrounding cells to produce chemokines such as
IL-8 to further recruit inflammatory cells such as neutrophils [405]. IL-17 has been
shown to promote contact-dependent cytotoxicity by IFNγ-induced up-regulation of 
intracellular adhesion molecule (ICAM)-1 on keratinocytes [415]. The role of IL-17 in
Th1 differentiation is controversial with some studies suggesting it plays a role in Th1
generation [416] and some that suggest a negative feedback loop by RORγt on Th1 
differentiation [417]. IL-17 has also been shown to induce other pro-inflammatory
mediators such as the IL-36 family members [212].
1.9.3 The role of IL-17 in disease
As previously discussed IL-17 is highly pro-inflammatory and is an effective mediator
in host defence. However if IL-17 expression is dysregulated this can lead to
uncontrolled and chronic inflammation and tissue damage. The role of IL-17 in
autoimmunity was established when it was shown in murine models that Th17 cells
were crucial in the initial stages of experiment autoimmune encephalitis [418]. IL-17A
and IL-17F are also highly expressed in rheumatoid arthritis [419]. It is thought that in
rheumatoid arthritis IL-17 causes a induction of cytokines (e.g. TNFα and IL-6) and 
chemokines (e.g. IL-8) as well as destructive enzymes such as MMP1 from
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synoviocytes [420]. IL-17 has also been shown to inhibit apoptosis of synoviocytes
causing tissue hyperplasia [421].
IL-17 has extensively been described as playing a pivotal role in the pathogenesis of
psoriasis. After the identification of the Th17 subset of cells, it was shown that these are
highly prevalent in lesional psoriatic skin [3]. Specifically keratinocytes have been
identified as targets for IL-17 and IL-22 activity. In these cells, IL-17 acts
synergistically with TNFα on inflammatory mediators known to be critical in psoriatic 
inflammation [2]. IL-17 and IL-22 play a role in the change of barrier homeostasis
typical for psoriatic plaque [422]. Interestingly, in a relatively small cohort of psoriasis
patients Th17 cells were not shown to be the most prominent producers of IL-17A but
mast cells and neutrophils [423]. It has also been shown that the CD8+ T cells in
psoriatic skin contain significantly more IL-17 producing CD8+ cells compared to
healthy skin [423]. Due to the apparent importance of IL-17 in psoriasis it is an
important target for antibody therapies. Data on the extremely high efficacy of
secukinumab (blocks IL-17A) holds the promise to not only control but clear psoriasis
with this treatment [424]. There is also a monoclonal antibody that blocks the p40
subunit of IL-12 and IL-23 (ustekinumab), two cytokines crucial for Th1 and Th17
differentiation. Ustekinumab has shown good clinical responses in skin psoriasis and
data for PsA seem promising [387].
1.10 Project aims
Although the pathogenesis of psoriasis is extensively studied there are still shortfalls in
our understanding as to the role of all aspects of the disease pathogenesis. There is no
doubt that this is a highly inflammatory disease [425] which is predominantly mediated
by an influx of immune cells [3]. However, the role of the skin resident cells particularly
the largely overlooked fibroblasts have not been well described in the chronic
inflammation seen in psoriasis. The inflammatory response is a highly regulated process
that is tightly controlled in order to prevent tissue damage and chronic inflammatory
states. This control occurs at various levels, including transcriptional, translation and
receptor regulation. At the receptor level the balance of agonists, antagonists and
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binding proteins is crucial. This balance is not well understood, especially in disease
states.
Therapeutic approaches for psoriasis patients varies greatly depending on severity of
disease. The most severe patients are most commonly treated with systemic anti-
inflammatories that are not always effective and frequently show side effects. However,
for these patients recently developed biologics hold the promise for long-term, efficient
control of the disease. Due to the very high costs of biologics this approach is not
available for the majority of patients. There is a great need in particular for the mild to
moderate disease group, to develop more effective and well tolerated topical therapies.
The main aim of this investigation on psoriatic inflammation was:
 To understanding the role of the novel group of IL-1 family cytokines, IL-36 in
psoriasis and the importance of proteolytic cleavage of these proteins.
Additional aims were as follows:
 To identify how endogenous IL-18BP production can be enhanced in the skin
compartment. The focus is on IL-27, which has previously indicated as a
possible inducer of IL-18BP. To investigate the therapeutic value of an IL-17
targeting RNA aptamers in relation to psoriatic skin inflammation.
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Chapter 2 – Materials and methods
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2.1 Materials
Unless otherwise stated all reagents were analytical grade and obtained from Sigma-
Aldrich, UK.
Table 2-1. Primary antibodies used
Antibody Specificity Species and
isotype
Source
162601 Human IL-36β Mouse IgG1 R&D systems
162122 Human IL-36α Mouse IgG2B R&D systems
2A8 Human IL-36γ Mouse IgG1κ Sigma-Aldrich
GTX108466 Human IL-36γ Rabbit IgG  GeneTex 
278706 Human IL-36γ Rat IgG2A R&D systems
190524 Human IL-36RA Mouse IgG2B R&D systems
ab171844 Human IL-1RL2 Rabbit IgG Abcam
GT239 Human GAPDH Mouse IgG2B GeneTex
CD28.2 Human CD28 (LEAF™) Mouse IgG1κ BioLegend
OKT3 Human CD3 (LEAF™) Mouse IgG2Aκ BioLegend
A-5598 Myc tag (HRP) Rabbit IgG Sigma-Aldrich
R6H1 Human CCR6 (PE) Mouse IgG1 eBioscience
SC-23877 Human cytokeratin 10 Mouse IgG1 Santa Cruz
D1.3 Hen egg lysozyme (Isotype
ctrl)
Mouse IgG1 Produced in-house
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Table 2-2. Secondary antibodies used
Antibody Specificity Species Label Source
A-0168 Mouse IgG Goat HRP Sigma-Aldrich
A-9542 Rat IgG Rabbit HRP Sigma-Aldrich
STAR124P Rabbit IgG Goat HRP AbD Serotec
STAR120F Mouse IgG Goat FITC AbD Serotec
2.1.1 Buffers used
Loading dye for SDS-PAGE gels – 62.5 mM Tris pH 6.8, 10% Glycerol, 2% SDS,
0.001% bromophenol blue +/- 5% β2-mercaptoethanol 
Gel electrophoresis running buffer – 25 mM Tris, 90mM glycine, 0.1% SDS
Western blot transfer buffer – 90 mM glycine, 25 mM Tris 20% Methanol
Western blot blocking buffer – Tween-20 0.1% in PBS + 5% milk
PBS Tween (for washing Western blot membranes) – PBS, 0.1% Tween-20
NP-40 lysis buffer – 1% NP-40 (or equivalent), 0.15M NaCl, 10mM EDTA, 10Mm
NaN3, 10mM Tris-HCl pH8
Coomassie stain – 40% Methanol, 10% Acetic Acid, 0.05% Brilliant Blue R-250,
remaining dH2O
Coomassie de-stain - 10% Acetic Acid, 40% Methanol, remaining dH2O
Bacterial lysis buffer – 20mM Tris pH8, 10% Glycerol, 5mM MgSO4
Nickel column buffer – 500mM NaCl, 20mM Tris pH7.4, 10% Glycerol, 20-500mM
Imidazole
Size exclusion column buffer – 20mM Tris pH7.4, 300mM NaCl, 5% Glycerol
TBE: 0.09M Tris, 0.09M Boric acid, 2mM EDTA
6x DNA loading dye – 0.05% Orange G, 30% glycerol
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2YT bacterial media – 3.3% Tryptone soya broth, 1% Yeast extract (Oxoid, Thermo
Scientific)
Complete E-media - E-media contained per litre; 600ml DMEM HEPES (Sigma-
Aldrich, UK), 320ml Hams F-12 (Gibco Invitrogen), 0.10 mg/ml streptomycin and
100U/ml penicillin (Gibco Invitrogen), 5% FCS, 10ug Cholera Toxin (Sigma-Aldrich,
UK), 5mg/ml hydrocortisone (Sigma-Aldrich, UK), 5ng/ml epidermal growth factor
(EGF) (BD Biosciences), 10ml 100x cocktail mix containing; 0.18M Adenine (Sigma-
Aldrich, UK), 5mg/ml Insulin (Gibco), 5mg/ml Transferrin (Sigma-Aldrich, UK), 2x10-
8µg MT3 (Sigma-Aldrich, UK).
2.1.2 Cell lines used
Human Embryonic Kidney 293 T (HEK293T) are adherent derivatives of the human
embryonic kidney 293 cell line that was established by transformation with sheared
adenovirus type 5 DNA [426].
Human Embryonic Kidney 293 TT (HEK293TT) cell lines are adherent derivatives of
293 cells with a sheared adenovirus type 5 DNA and simian virus-40 [427]
Human Embryonic Kidney 293 FT (HEK293FT) cell lines are also adherent derivatives
of 293 cells which stably expresses the SV40 large T antigen from the
pCMVSPORT6TAg.neo plasmid. Expression of the SV40 large T antigen is controlled
by the human cytomegalo-virus (CMV) promoter.
COS-7 are an adherent fibroblast-like cell line established from SV40 T antigen
transformed CV-1 simian cells from African Green Monkey kidney cells [428].
HaCat cells are an adherent spontaneously transformed cell line derived from adult
human keratinocytes [429].
2.2 General methods
Unless otherwise stated all reagents are from Sigma-Aldrich, UK. Unless otherwise
stated cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Lonza,
Slough, UK) supplemented with 5% fetal calf serum (FCS) (PromoCell, Heidelberg,
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Germany), 0.5% L-Glutamine (Sigma-Aldrich, UK) and 0.05 mg/ml streptomycin and
50U/ml penicillin (Sigma-Aldrich, UK) at 37°C, 5% CO2 and 95% humidity.
2.2.1 Obtaining primary cells
All human samples were taken in accordance with the Declaration of Helsinki and
participants gave their written informed consent (REC number: 11/YH/0368 NHS
patients – see Appendix figure 25). Healthy volunteers were also recruited from the
university and written consent was also sought (BIOSCI09-001).
2.2.2 Culture of primary cells and cell lines
Human primary keratinocytes (HPK) were cultured in Keratinocyte Growth Media
(KGM) Kit II (PromoCell, Heidelberg, Germany). Culture medium was changed every
second to third day. On stimulation keratinocytes were placed in Keratinocyte Growth
Media with all supplements apart from epidermal growth factor and hydrocortisone.
When the fibroblasts reached 90% confluency and HPK 60-70% confluency the cells
were passaged. For primary fibroblasts and all adherent cell lines, cells were washed
with sterile phosphate buffered saline (PBS) (Gibco, Life technologies, UK) and then
trypsin (170.000U/L)-EDTA (200mg/ml) (Lonza, Slough, UK) was added and placed in
the incubator for 2 minutes at 37°C, 5% CO2. An equal amount of serum containing
DMEM was added to the trypsinised cells in order to neutralise the enzyme. The cells
were then centrifuged at 230xg and then re-seeded. For HPK, cells were also washed
with sterile PBS and then EDTA (Versen) 1% (Pan Biotech, Germany) was added for 2
minutes at 37°C, 5% CO2. Trypsin was added in the same manner as for the fibroblasts
however neutralisation was achieved with trypsin neutralising solution (Lonza, Slough,
UK). Cell lines were cultured in the same manner as human primary fibroblasts. In order
to freeze cells they were re-suspended in freezing media (PromoCell, Heidelberg,
Germany) and placed in a Mr. Frosty™ (Thermo Scientific) at -80°C for 24 hours
before long-term storage in liquid nitrogen.
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2.2.3 Outgrowth of fibroblasts from healthy and patient derived skin and tendon
biopsies
Biopsies were taken from healthy controls or patients following consent (NHS patient
donors - REC number: 11/YH/0368) and transported in DMEM supplemented with 5%
FCS (PromoCell, Heidelberg, Germany), 0.5% L-Glutamine (Sigma-Aldrich, UK), 0.05
mg/ml streptomycin and 50U/ml penicillin (Sigma-Aldrich, UK) and 0.5% of 250μg/ml 
amphotericin B (Sigma-Aldrich, UK). Skin biopsies were then cut into small sections
using a scalpel. The sections were carefully placed into a six well plate and left to air dry
in the cell culture hood for approximately 15 minutes. The same media that the biopsies
were transported in was then carefully added to the wells ensuring that the tissue stays
adhered to the plate. Biopsies were then cultured at 37°C, 5% CO2 for 1-2 weeks before
cells were sufficiently confluent to passage and consequent culture was in media with
out amphotericin B.
2.2.4Transfection of primary cells and cell lines
Cells were cultured in normal growth media until confluency of 80-90% was reached in
a 6-well plate. On the day of transfection normal media was substituted for reduced
serum Opti-MEM (Gibco, Life Technologies, UK). 1µg of DNA was then diluted in
400µl of Opti-MEM and then 6µl of TurboFect transfection regent (Thermo Scientific,
UK) was added. The solution was vortexed and incubated for 15-20 minutes at room
temperature. This solution was then added dropwise into the 6 well plate containing 4ml
of Opti-MEM in each well. After 8 hours the media was removed and replaced with 2ml
of fresh Opti-MEM.
2.2.5 Peripheral blood collection
In order to isolate neutrophils and peripheral blood mononuclear cells (PBMCs) 30-
60ml of peripheral blood was collected from healthy donors and psoriatic patients in
sterile Vacutainer® lithium heparin (BD Biosciences, Oxford, UK). Ethical approval
was sought from the University of Leeds for healthy donors and national ethical
approval was gained for patient material. Consent of donors was sought and anonymity
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was strictly adhered to. Blood was kept at room temperature after donation and used
immediately.
2.2.6 Isolation of PBMCs from whole blood
PBMCs were isolated from peripheral whole blood using density gradient. Peripheral
blood was diluted 1:1 with sterile PBS (Gibco, Life technologies, UK). An equal amount
of diluted blood was then carefully layered onto Ficoll-Paque plus (GE Healthcare,
Buckinghamshire, UK). This was then centrifuged for 40 minutes at 400xg with no
brake. PBMCs were then removed and diluted 1:1 with sterile PBS. Cells were then
centrifuged at 350xg for 4 minutes and supernatant removed. PBMCs were either used
immediately or cultured in Roswell Park Memorial Institute (RPMI)-1640 supplemented
with 5% FCS (PromoCell, Heidelberg, Germany), 0.5% L-Glutamine (Sigma-Aldrich,
UK) and 0.05 mg/ml streptomycin and 50U/ml penicillin (Sigma-Aldrich, UK).
2.2.7 CD4+ T cell isolation from PBMCs – using MACS® cell separation
PBMCs were centrifuged at 350xg for 4 minutes. The supernatant was removed before
washing with sterile PBS. Using the CD4+ T cell isolation kit II (Miltenyi Biotec,
Surrey, UK) cells were then stained with magnetic labels as per manufacturer’s
instructions. After magnetic labelling the cells were then put through LS columns
(Miltenyi Biotec, Surrey, UK) as per manufacturer’s instructions. The method used
allows for collection of untouched CD4+ cells so there is no magnetic tags which could
potentially interfere with further experiments. After separation, cells were centrifuged at
350xg for 4 minutes and either used immediately or cultured in RPMI-1640
supplemented with 5% FCS (PromoCell, Heidelberg, Germany), 0.5% L-Glutamine
(Sigma-Aldrich, UK) and 0.05 mg/ml streptomycin and 50U/ml penicillin (Sigma-
Aldrich, UK).
2.2.8 Culture of primary CD4+ T cells
Freshly isolated T cells were cultured in RPMI-1640 media (Lonza, Slough, UK)
supplemented with 5% FCS (PromoCell, Heidelberg, Germany), 0.5% L-Glutamine
(Sigma-Aldrich, UK) and 0.05 mg/ml streptomycin and 50U/ml penicillin (Sigma-
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Aldrich, UK). If CD4+ T cells were cultured for longer than 2 days the media was
supplemented with 5ng/ml of IL-2 (Immunotools, Friesoythe, Germany).
2.2.9 Enrichment of CCR6+ T cells from CD4+ T cells
Following magnetic separation of CD4+ population cells were centrifuged at 300xg for
10 minutes and then re-suspended in 40μl of a PBS based buffer, pH 7.2, containing
0.5% bovine serum albumin (BSA) and 2mM EDTA. Cells these were then stained with
10μl of PE labelled CCR6 antibody (eBioscience, Hatfield UK. Clone: R6H1) for 10
minutes at 4°C. In order to remove unbound primary antibody 1-2ml of buffer was then
added before centrifugation at 300xg for 10 minutes. Supernatant was then removed and
80μl of buffer used to re-suspend the cells, 20μl of Anti-PE microbeads (Miltenyi
Biotec, Surrey, UK) was then added and incubated for 15 minutes at 4°C. The cells were
washed again with 1-2ml of buffer and then re-suspended in 500μl of buffer before
magnetic separation was performed with LS columns (Miltenyi Biotec, Surrey, UK) as
per manufacturer’s instructions. Cells were either used immediately or cultured in
RPMI-1640 supplemented with 5% FCS (PromoCell, Heidelberg, Germany), 0.5% L-
Glutamine (Sigma-Aldrich, UK) and 0.05 mg/ml streptomycin and 50U/ml penicillin
(Sigma-Aldrich, UK).
2.2.10 Isolation of PMNs from whole blood
Whole blood was separated by using density gradient in a similar manner to that used
for isolation of PBMCs however instead of using Ficoll, Histopaque 1077 (Sigma-
Aldrich, UK) was layered in equal amounts on top of Histopaque 1119 (Sigma-Aldrich,
UK). The diluted whole blood was then layered on top of this and centrifuged at 400xg
for 30 minutes with no brake. The PMN layer, which is above the red blood cell pellet,
was then removed using a 10ml sereological pipette and cells were washed with PBS. In
order to remove contamination of erythrocytes the pellet was re-suspended in 0.2%
NaCl and the tube was inverted 10x. An equal volume of 1.6% NaCl was then added
and inverted once. Cells were then centrifuged at 350xg for 4 minutes and the cell pellet
was re-suspended with RPMI-1640 supplemented with 5% FCS (PromoCell,
Heidelberg, Germany), 0.5% L-Glutamine (Sigma-Aldrich, UK) and 0.05 mg/ml
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streptomycin and 50U/ml penicillin (Sigma-Aldrich, UK). Cells were stimulated on day
of separation and were not cultured for longer than an hour.
2.2.11 Construction of skin equivalents
Human primary fibroblasts from either healthy controls or psoriatic patients were
cultured as described previously. The first step for skin equivalent construction involves
making a dermal scaffold to support the human primary keratinocytes. For this 1 – 2 x
106 of human primary fibroblasts were used for each collagen scaffold. In order to make
the collagen plug all solutions and plastic ware were kept cold and then following
harvesting and pelleting of fibroblasts (as previously described) the pellet was re-
suspended in 0.3ml of 10xDMEM + 0.3ml of 10x reconstitution buffer (2.2g NaHCO3,
4.77g HEPES, 100ml 0.05M NaOH). Then 2.4ml of Collagen G (Type 1 and 4 –
Biochrom AG, Merck Millipore) was added and 3mls of fibroblast/collagen mix was
added to a 35mm Petri dish. The gels were allowed to solidify at 37°C 5% CO2 for 30
minutes before adding 1.5ml of E-medium (with 5ng/ml EGF). These were then cultured
for 2 days. 1 – 2 x 106 of primary keratinocytes was then seeded on the top of each
collagen scaffold and cells were allowed to grow to confluence, the media was changed
daily (E-medium + EGF). After 2 days skin equivalents were ready for the air/liquid
interface stage. The support grids (Sigma, UK) were placed in 10cm Petri dishes and
then using sterile forceps the skin equivalent was carefully placed on the support grid.
E-medium (no EGF) was then added, ensuring that media did not come over the edge of
the support grid and only sat underneath it touching the underside of the skin equivalent.
Media was changed every other day for 14 days and if stimulation was required this was
added into the culture media 96 hours before fixing rafts with 4% paraformaldehyde.
Skin equivalents were sectioned, mounted onto slides and H&E stained by Propath Ltd
UK (Hereford, UK).
2.2.12 Enzyme-linked immunosorbent assay (ELISA)
Cell-free supernatant was collected, stored at -20 (short term) or -80°C and analysed for
the content of protein using a DuoSet human ELISA kit (RnD Systems, Abingdon, UK
or BioLegend, Hatfield, UK) following the manufacturer’s instructions.
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2.2.13 Flourescence assisted cell sorting (FACS)
In order to stain for surface receptors cells were detached, if adherent, using EDTA
(Versen) 1% (Pan Biotech, Germany) and then washed with PBS. Cells were then
incubated with blocking buffer (5% serum in PBS) for 1 hour on ice before spinning
down and washing twice with PBS. Cells were then incubated with the primary antibody
at the concentration recommended by supplier for 1 hour on ice following which they
were washed twice with PBS. Cells were then incubated with secondary antibody at the
concentration suggested by supplier for 1 hour on ice following which cells were
washed 3 times with PBS. Cells were re-suspended in PBS and kept on ice before
analysis.
2.2.14 Quantitative real-time polymerase chain reaction (qRT-PCR)
qRT-PCR was performed on a RotorGen (Qiagen, Hilden, Germany) using a ΔΔCT-
analysis based on the generation of standard curves for both the housekeeping gene
(U6snRNA – Forward ctcgcttcggcagcaca, Reverse gcaaattcgtgaagcgtt) and the target
gene (QuantiTect Primer Assay, Qiagen unless otherwise stated). For RNA isolation
Quick-RNA MiniPrep (Zymo Research, Cambridge Bioscience, Cambridge, UK) was
used. First strand cDNA synthesis kit (Fermentas / Thermo Fisher Scientific,
Loughborough, UK) was used for reverse transcription. QuantiFast SYBR green PCR
(Qiagen) was used to carry out the RT-PCR following manufacturer’s instructions.
2.2.15 Fixing and staining cells for fluorescence imaging
Following culture of cells on a 13mm glass cover slip in a 24 well plate cells were
washed 3 times with PBS. 4% paraformaldehyde was then added to cells and incubated
at room temperature for 15 minutes. For experiments detecting fluorescent molecules
within the cells, following fixation antibody staining was not required. Cells were
washed with PBS 3 times, the last wash containing 1µg/ml of 4',6-diamidino-2-
phenylindole (DAPI) to stain the nucleus. Before mounting, slides were washed with
dH2O. Coverslips were mounted onto Poly-lysine coated slides using Fluoromount-G™
(eBioscience, Hatfield, UK) and sealed around the edges. Once mounted, slides were
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kept at 4°C before imaging using an inverted LSM510 confocal microscope coupled to a
LSM Image Browser.
2.2.16 Di-AminoBenzidine (DAB) staining of paraffin embedded skin equivalents
Skin equivalents were sectioned and mounted onto microscope slides by Propath UK.
Mounted microscope slides were rehydrated and deparaffinised by submerging in
Xylene (VWR chemicals) for 5 minutes, this was repeated twice. Slides were then
sequentially submerged in 100%, 90% and 70% ethanol for 1 minute before being
submerged for 5 minutes in water. Water was changed after 2 minutes of incubation.
Slides were then submerged in 10mM sodium citrate + 0.05% Tween (pH 6) and boiled
for 10 minutes in order to unmask antigens from paraffin embedding before antibody
staining. Slides were again washed with water 3 times for 5 minutes before incubating
with 3% hydrogen peroxide for 10 minutes. Slides were washed twice in water for 5
minutes each before being washed in PBS for 5 minutes. Slides were then placed in a
humidity chamber and blocking buffer added (10% FCS in PBS) for 1 hour or overnight
at 4°C. Following incubation sections were washed for 5 minutes in PBS, this was
repeated 5 times. Slides were then incubated in humidity chamber with primary
antibody diluted in 1.5% blocking buffer (1.5% FCS in PBS) for an hour at room
temperature. Washing in PBS was performed again 5 times before addition of secondary
antibody diluted in 1.5% blocking buffer (1.5% FCS in PBS) and incubated in humidity
chamber for 1 hour at room temperature. PBS washing was repeated again 5 times. DAB
staining was performed using a Vector Laboratories (Peterborough, UK) substrate kit
following manufacturer’s instructions. A counterstain was performed using
haematoxylin (Sigma-Aldrich) for 20 seconds before washing repeatedly with water.
Sections were then dehydrated by incubation of slides in 95% ethanol twice for 10
seconds. Sections were then incubated in 100% ethanol twice for 10 seconds, then in
xylene twice for 10 seconds. Slides were then air-dried and mounted with coverslips
using DPX mounting media (VWR chemicals). Slides were then imaged using a Leiss
light microscope.
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2.3 Molecular biology
2.3.1 SDS-Polyacrylamide gel electrophoresis (PAGE)
Whole cell extracts were prepared by lysing cells in a NP40 lysis buffer supplemented
with protease inhibitors (Complete EDTA-free protease inhibitors, Roche). Cells were
removed from the tissue culture plate in lysis buffer and left on ice for 15-20 minutes
before being centrifuged to remove cell debris. Supernatant from the lysed cells was
removed and samples were stored at -20°C or used immediately. Samples were mixed
with 4 x loading buffer and boiled for 5 minutes. Following brief centrifugation of the
samples they were loaded onto a 4% polyacrylamide stacking gel (pH6.8) and resolved
on a 12-17% acrylamide gel (pH 8.8) alongside molecular weight markers (New
England Biolabs). 1.5mm gels were cast and run using a Mini PROTEAN III gel system
(Biorad). Gels were run in running buffer at 0.03-0.04 Amps per gel as long as required
for good separation. Gels were either analysed by Coomassie staining followed by de-
stain or were used in Western blots.
2.3.2 Western blotting
Following SDS electrophoresis, resolved polypeptides were transferred to HybondC+
nitrocellulose (Amersham biosciences) or Immobilon-P (Millipore) membranes in
transfer buffer by applying 100V for 1-2 hours. Membranes were then blocked for 1
hour in blocking buffer. Primary antibodies were diluted to the concentration advised by
the manufacturer in blocking buffer and incubated with agitation for 1 hour at room
temperature. Membranes were then washed with PBS 0.1% Tween-20 3 times each for 5
minutes at room temperature with agitation. Secondary horse radish peroxidase (HRP)
antibodies (Sigma-Aldrich, UK) were diluted to a concentration advised by the
manufacturer in blocking buffer and membranes were incubated for 1 hour with
agitation at room temperature. Membranes were then washed as before. The ECL was
used as per manufacturer’s instructions (GE Healthcare) to detect specific antibody
binding to membranes and emitted light was detected on X-ray film (GE Healthcare)
following incubation of varying incubation times from 20 seconds to 5 minutes.
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2.3.3 Agarose gel electrophoresis
Gels were prepared using electrophoresis grade agarose in 1xTBE containing 0.2µg/ml
Ethidium Bromide. DNA samples were mixed with 6x DNA loading dye and run at
100V alongside 1 kb DNA ladders. DNA in agarose was observed and photographed
under short-wave UV light for observation or long-wave UV light when further cloning
was required.
2.3.4 Conventional PCR for cloning
Primers were designed (see Appendix for all primers, figures 3-23) in order to amplify
the sequence for the protein of interest using conventional PCR (KOD hot start DNA
polymerase, Novagen). A sample was then taken from the PCR product and run on a 1%
agarose gel alongside a DNA marker (New England Biolabs) and UV light used to
assess whether a band was present at the correct size. Extra adenine nucleotides were
added on to the end of the product using TAQ polymerase (Promega, USA) in
preparation for insertion into a TA overhang vector (Champion pET SUMO expression
system, Invitrogen, USA). Following addition of nucleotides the product was run on a
1% agarose gel and the band carefully cut out with a scalpel. DNA was extracted from
the gel using QIAquick gel extraction kit (Qiagen) following manufacturer’s
instructions.
2.3.5 Restriction digest
PCR products and vectors were cut with relevant restriction enzymes in optimal buffers
with 1% BSA (New England Biolabs). Reactions were carried out at 37°C for 3 hours.
For the vectors after 2 hours of incubation alkaline phosphatase was added to prevent re-
ligation of the vector. Following digest products were run on a 1% agarose gel and then
bands cut out and purified using QIAquick gel extraction kit (Qiagen) following
manufacturer’s instructions.
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2.3.6 Ligation
The ligation of the insert into the vector was carried out at a molar ratio of 1:3 vector to
insert and 1ng of insert was added. T4 ligase was used following manufacturer’s
instructions (Invitrogen, USA). The reaction was carried out overnight at 16°C.
2.3.7 Transformation
Following ligation the vector was transformed into DH5α cells (Φ80lacZΔM15 
Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, mK+) phoA supE44 λ– thi-1
gyrA96 relA1) in order to allow enough DNA proliferation to sequence. The ligation
reaction was added to the thawed cells for 30 minutes on ice. The cells were then heat
shocked at 42°C for 30 seconds, then placed back on ice for 2 minutes before adding
SOCS medium (Invitrogen, USA) and then placed at 37°C with shaking for 1 hour.
Cells were then plated on 2% agar plates containing relevant antibiotics.
Following overnight incubation at 37°C colonies were picked and a colony PCR
performed using TAQ polymerase (Promega, USA). Positive colonies were then grown
up in 2YT media containing relevant antibiotics overnight at 37°C. DNA was extracted
from the cells using QIAprep Spin Miniprep kit (Qiagen) following manufacturer’s
instructions. Sequencing was then confirmed using Sanger sequencing (GATC- Biotech,
Germany). Sequence profiles were analysed using a BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) programme for comparison with the predicted
sequence (see Appendix for all sequences).
2.3.8 Expression of IL-1 family members in E. coli
Following successful sequencing of the constructs 1ng DNA was then transformed in to
expression strains of E. coli – BL-21 (DE3) (fhuA2 [lon] ompT gal (λ DE3) [dcm] 
∆hsdSλ DE3 = λ sBamHIo ∆EcoRI-B int::(lacI::PlacUV5::T7 gene1) i21 ∆nin) and
BL21-CodonPlus(DE3)-RIPL (E. coli B F– ompT hsdS(rB – mB–) dcm+ Tetr gal
λ(DE3) endA Hte [argU proL Camr] [argU ileY leuW Strep/Specr]) in the same manner 
as with the DH5α cells. (DE3) encodes an Lac inducible T7 polymerase. The BL21-
CodonPlus (DE3)-RIPL cells also contain a plasmid encoding rare tRNA that are needed
for expression of mammalian proteins. Cells were then grown overnight in either
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33µg/ml of kanamycin for BL21 (DE3) or both kanamycin and 33µg/ml
chloramphenicol for the BL21-CodonPlus cells. Larger cultures containing relevant
antibiotics and 5% filtered glucose, to prevent leaky expression were then inoculated
with 1 50th of the overnight culture. Initially cells were grown at 37°C until they reached
an optical density (at 600 nm) of 0.6 and then cells were induced with isopropyl β-D-1-
thiogalactopyranoside (IPTG) at 0.8mM and then grown over night at 16°C, 25°C and
37°C. The optimal temperature for expression was assessed by running the bacterial
lysates before and after induction on an SDS page gel and then stained over night with
Coomassie and de stained the following day. Following optimisation larger volumes of
culture were grown up at the ideal temperature in order to get the required amount of
protein. After overnight growth of cultures they were spun down at 4000g for 5 minutes.
The bacterial pellet was then re-suspended in bacterial lysis buffer. Lysozyme
(0.35mg/ml) and DNase (20µg/ml) were added and the bacteria were sonicated on ice
for 8 cycles of 20 seconds on 30 seconds off. The lysed bacteria were then spun at
30,000g for 30 minutes and the supernatant removed and filtered. The constructs
produced contained a His tag so protein was purified using a nickel-affinity
chromatography. The column was equilibrated with 20mM imidazole nickel column
buffer and then the filtered bacterial supernatant was added containing 20mM imidazole
to prevent non-specific binding to the column. Following addition of bacterial
supernatant the nickel column was washed with 5 column volumes of 20mM imidazole
and then 50mM imidazole. Protein was eluted from the column in 5 column volumes of
100mM imidazole and then 500mM and 1ml fractions collected to run on a SDS page
gel and stain with Coomassie to analyse when the protein comes off the nickel column.
Fractions that contained the protein were then pooled.
2.3.9 Purification of protein using size exclusion column
Pooled fractions from nickel-affinity chromatography purification were concentrated to
5ml and then sterile filtered at 0.45µm. The size exclusion column was prepared by
running 1 column volume of degassed sterile filtered water and then the same for
column buffer. The protein was loaded and fractions were collected when a 280nm peak
was present, excluding any peaks that were present in the void volume or any that were
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suggestive of a protein dimer. Fractions were pooled and concentrated before being run
on an SDS page gel and stained with Coomassie to check that the purity of the protein.
Western blots were also carried out to check the protein expressed and purified was
correct.
2.3.10 Removing SUMO from relevant constructs
Following size exclusion protein purification when it was necessary the SUMO tag was
removed from the constructs. Optimisation of the amount of SUMO protease, His-ULP-
1, was carried out and this differed depending what the preceding amino acid was.
Therefore, between 1:50 and 1:200 ratio protease to protein was used for between 24-48
hours at 4°C. Cleavage was assessed by running on an SDS page and then Coomassie
stained. Due to the SUMO and SUMO protease containing His tags these constructs
could be removed using a nickel column to purify protein away from the SUMO and
SUMO protease. For all constructs that were to be used in cell culture the nickel column
was thoroughly washed with 0.5M NaOH before calibration with 20 mM imidazole
buffer. The sample was then added and the column elute collected which would
represent the pure cut protein. This was then re-run on the size exclusion column to
ensure purity and only monomers of the protein were present. Again, all glassware used
to make buffers and the column itself was thoroughly washed with 0.5M NaOH.
2.3.11 RNA aptamer chemical synthesis
Chemical syntheses of the RNA aptamers used were produced in house by the
University of Leeds. The aptamers were produced with a 5’ monophosphate and a
fluorine modification at the 2’ on pyrimidine bases. The sequenced produced without
flourophores was: 5' GGU CUA GCC GGA GGA GUC AGU AAU CGG UAG ACC 3'.
Addition of a 5’ Cy3 flourophore: 5' cy3-GGU CUA GCC GGA GGA GUC AGU AAU
CGG UAG ACC 3'. Addition of a 5’ Cy3 and 3’ Cy5: 5' cy3-GGU CUA GCC GGA
GGA GUC AGU AAU CGG UAG ACC-cy5 3'.
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Chapter 3 – IL-18 binding protein is up-regulated by
IL-27
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3.1 Introduction
The production and release of pro-inflammatory cytokines by skin resident cells during
an inflammatory response is crucial to aid in eradication of invading pathogens and
maintain skin homeostasis (see 1.2.2 for in depth discussion). However, resolution of
inflammation once the environmental threat has been removed is crucial to avoid
permanent tissue damage (e.g. scarring) or chronic inflammatory conditions (see 1.2.3
for in depth discussion). The skin resident cells possess a control mechanism in that
release of pro-inflammatory mediators is followed by release of anti-inflammatory
mediators to antagonise their activity. These mechanisms are tightly regulated and are
essential for the prevention of chronic inflammation (see 1.2.4 for in depth discussion).
The focus of this chapter is to describe a novel anti-inflammatory mechanism of IL-27
which is its ability to up-regulate IL-18 binding protein (BP) which antagonises IL-18.
IL-27 is a member of the IL-12 family of cytokines that has been shown to have
pleiotropic roles in inflammation and both anti-inflammatory and pro-inflammatory
actions have been identified. Interestingly, IL-27 appears to possess unique features that
are not shared with other IL-12 family members. IL-27 has been shown to up-regulate
the IL-12R which displays high binding affinity with its agonists and is crucial in Th1
polarisation [265]. IL-27 has also been shown to induce IL-23 release from APCs,
which plays a role in Th17 polarisation but also IFNγ release from memory Th1 cells 
[281]. In human macrophages, monocytes and keratinocytes IL-27 has been described to
play an inflammatory role by induction of CXCL10. Due to the property of CXCL10 to
attract CXCR3+, IFNγ producing T cells to the area of inflammation, IL-27 has been 
proposed as an important mediator in inflammatory skin diseases such as eczema and
psoriasis [277, 278]. However, in contrast work carried out in murine models has
suggested a role for IL-27 as an anti-inflammatory mediator in the later stages of
infection. IL-27 knock-out mice have been shown to be more susceptible to
experimental autoimmune encephalitis [430]. Mice over-expressing WSX-1 displayed
reduced lupus erythematosus like symptoms in a disease model [431]. Conversely to
what has been shown in human cells, IL-27 has also been shown to inhibit Th17
differentiation in mice in a STAT1-dependent but IFNγ-independent manner [430]. IL-
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27 has also been shown to stimulate murine cells to produce IL-10, a well-known anti-
inflammatory mediator [432].
IL-18 is a member of the IL-1 family of cytokines and has been described to have a
highly pro-inflammatory function [186, 433, 434]. Within the skin IL-18 is expressed by
resident skin DCs and also keratinocytes. However, expression of IL-18 is not seen by
fibroblasts in the skin compartment [435, 436]. IL-18 supports both Th1 and Th2
differentiation depending on the surrounding cytokine milieu and is important in
regulation of innate and adaptive immunity [433, 437]. Murine models deficient in IL-
18 have a significantly reduced ability to produce IFNγ as well a reduction in NK cell 
activity [438]. In murine asthma models deficiency in IL-18 reduced airway remodelling
and chronic inflammation [439]. IL-18 and its receptor have also been found to be
highly expressed in chronic inflammatory skin lesions, such as psoriatic plaques [440,
441] and cutaneous lupus erythematosus (CLE) [442]. It is thought that IL-18 plays a
role in the chronification of inflammatory diseases and its role in inflammatory fibrosis
has been shown in lung [443], kidney [444] and cardiac pathologies [445]. Skin
epithelial cells isolated from patients with CLE were shown to be more responsive to IL-
18 with regard to production of TNFα compared to healthy controls. TNFα induced 
apoptosis in response to IL-18 was also noted in this study, which is crucially important
in the disease pathogenesis of CLE [446]. Healthy keratinocytes respond to IL-18
stimulation by producing CXCR3 ligands such as CXCL10 [245] and increased surface
expression of MHC I and II [442]. IL-18 has recently been found to activate IFNγ 
producing innate lymphoid cells 1 (ILC1). The recently described ILCs seem to be
closely linked to tissue responses at epithelial surfaces [447].
Due to the evident pro-inflammatory effects of IL-18, it is important as with any pro-
inflammatory cytokine that it is controlled. IL-18 is controlled by its natural antagonist,
IL-18BP [248]. IL-18BP prevents IL-18 binding to its cell surface receptor and exhibits
a high neutralising capacity [249]. The balance between IL-18 and IL-18BP is crucial in
understanding pathologies related to over-expression of IL-18 or IFNγ. However, in 
inflammatory disorders both IL-18 and IL-18BP are up-regulated and current methods
have limitations in quantitative determination of cytokine activity in the tissue (in
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particular as IL-18 exists as a pro- and active form) [444, 448, 449]. At the start of this
project IFNγ was the only known inducer of IL-18BP. However, IFNγ not only induces 
IL-18BP but also the chemokine CXCL10 which attracts further Th1 cells into the area
of inflammation. This has been shown in a variety of non-leukocytic cell types [252]. It
has been identified that in DLD-1 colon carcinoma cells IL-18BP expression is
dependent on STAT1 binding to the GAS element in the IL-18BP promoter [450]. The
importance of IL-18BP can be demonstrated by the fact that viruses such as human
papillomavirus (HPV) and pox viruses either produce a IL-18BP homologue or up-
regulate the endogenous form leading to increased viral virulence [260, 261, 451, 452].
It is of importance to understand potential alterations in the balance between anti-
inflammatory and pro-inflammatory mediators, particularly in the development of
chronic inflammatory skin diseases. Experimental work presented in this chapter aimed
to identify and describe novel mediators that have the ability to up-regulate endogenous
IL-18BP in human skin resident cells.
3.2 IL-18BP expression following IL-27 stimulation
IL-27 was established as an interesting molecule for IL-18BP production when all the
IL-12 family cytokines were used to treat human primary keratinocytes to assess their
functional responses. IL-27 has also been previously described to induce CXCL10
which suggests STAT1 activation occurs downstream of the IL-27 receptor, which
supposedly is also required for IL-18BP expression [278].
Human primary keratinocytes were treated with 50 ng/ml of IL-12 family cytokines
including IL-12, IL-27 and IL-23. IFNγ was used as a positive control at 10ng/ml and 
50ng/ml to assess cell responsiveness (Figure 3-1 a). After 48 hours of treatment cell
free supernatant was removed and IL-18BP levels were detected using ELISA. A
significant difference was detected between the non-stimulated control and IL-27
treatment. No significant expression of IL-18BP was detected with the other two IL-12
family members. IFNγ at a concentration of 50 ng/ml showed approximately a 100 fold 
stronger response compared to IL-27 at the same concentration in human primary
keratinocytes. Human primary keratinocytes were treated with increasing concentrations
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of IL-27 ranging from 5 ng/ml to 100 ng/ml for 48 hours before IL-18BP protein
concentrations were analysed by ELISA (Figure 3-1 b). A significant difference was
shown between the non-stimulated control and treatment with IL-27 at 50 ng/ml and 100
ng/ml. IL-18BP protein release showed no further increase after 100 ng/ml (data not
shown). This experiment was also performed in HaCat cells. IL-27 treatment using
HaCat cells ranged from 1 ng/ml to 100 ng/ml and again significance between non-
stimulated control and IL-27 treatment at 50 ng/ml and 100 ng/ml was detected (Figure
3-1 c). At 10ng/ml HaCat cells also produced significant levels of IL-18BP compared to
non-stimulated control. HaCat cells displayed a similar expression of IL-18BP in
response to IL-27 as primary cells. Interestingly, human primary keratinocytes were the
only skin resident cells to have a basal expression of IL-18BP (Figure 3-1 and Figure 3-
3).
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Figure 3 - 1. IL-27 dose dependently up-regulates IL-18 binding protein (BP) in human
keratinocytes.
Human keratinocytes and HaCat cells were plated at 20,000 cells per well and then stimulated for 48
hours following which supernatants were removed and IL-18BP protein concentration analysed by
ELISA. a - Human primary keratinocytes (HPK) were stimulated with varying concentrations of IFNγ and 
IL-12 family member cytokines. n = 7, independent experiments and different donors. b - Human primary
keratinocytes were stimulated with IL-27 (5 ng/ml-100 ng/ml). n = 3, independent experiments and
different donors. c – Human keratinocyte cell line, HaCat cells were also stimulated with IL-27 (1 ng/ml-
100 ng/ml). n = 3. Mean +/- Standard error of the mean (SEM) is depicted on all graphs. ns = Non-
stimulated. Raw data was analysed using an un-paired student’s t-test (GraphPad Prism 5.03, GraphPad
Software, San Diego, CA). ** = p ≤ 0.01 *** = p ≤ 0.001. Data in this figure was collected in 
collaboration with Division of Immunodermatology and Allergy Research, Department of Dermatology,
Hannover Medical School, Hannover, Germany [59]
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In order to study whether primary human dermal fibroblasts also produced IL-18BP in
response to IL-27 cells were treated with increasing concentrations of IL-27 (1ng/ml to
100 ng/ml). Following 48 hours of treatment IL-18BP concentrations analysed by
ELISA (Figure 3-2 a). Human primary fibroblasts produced unexpectedly high amounts
of IL-18BP and significant differences in IL-18BP levels were seen compared to non-
stimulated control at IL-27 concentrations of 10 ng/ml, 50 ng/ml and 100 ng/ml. As
IFNγ is presently the only known inducer of IL-18BP, cells were also treated with 
equivalent concentrations (50 ng/ml) of IL-27 and IFNγ for 48 hours prior to IL-18BP 
measurement (Figure 3-2 b). In contrast to human primary keratinocytes, IL-27
(50ng/ml) stimulated fibroblasts produced IL-18BP in the same range as after
stimulation with the equivalent concentration of IFNγ at 50 ng/ml.  It is also worth 
noting that human primary fibroblasts produced higher concentrations of IL-18BP
compared to human primary keratinocytes. Human primary fibroblasts are responsive to
extremely low levels of IL-27, around 70% of donors responded to 1 ng/ml of IL-27.
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Figure 3 – 2. IL-27 dose dependently increases levels of IL-18BP in human primary fibroblasts.
Human primary fibroblasts were plated at 20,000 cells per well and then stimulated for 48 hours following
which supernatants were removed and IL-18BP protein concentration was analysed by ELISA. a –
Human primary fibroblasts were stimulated with IL-27 (1 ng/ml-100 ng/ml) for 48 hours. n = 7,
independent experiments and different donors. b – Human primary fibroblasts were stimulated with 50
ng/ml of IL-27 and IFNγ for 48 hours. n = 4, independent experiments and different donors. Mean +/- 
SEM is depicted on all graphs. ns = Non-stimulated. Raw data was analysed using an un-paired student’s
t-test (GraphPad Prism 5.03, GraphPad Software, San Diego, CA). ** = p ≤ 0.01 *** = p ≤ 0.001 [59] 
These experiments indicated that 50 ng/ml of IL-27 was sufficient to induce significant
levels of IL-18BP and this concentration was used for all future experiments.
3.3 Time dependent expression of IL-18BP and CXCL10 in response to
IL-27
As a known inducer of IL-18BP IFNγ was used a comparator in this experimental setup. 
Human primary fibroblasts and human primary keratinocytes were treated with 50 ng/ml
of IL-27 for 5 hours and 16 hours before mRNA was isolated and qRT-PCR was
performed to determine mRNA levels of IL-18BP (Figure 3-3). In primary human
fibroblasts there was a significant increase in mRNA levels at 16 hours compared to
non-stimulated control (Figure 3-3 a). No significant differences were seen in human
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primary keratinocytes, however a slight increase in IL-18BP mRNA levels was present
(Figure 3-3 b). The mRNA levels of IL-18BP were hugely increased (10 fold to 100
fold) in human primary fibroblasts compared to human primary keratinocytes, which is
in line with what has been shown on protein expression levels.
Figure 3 – 3. mRNA levels of IL-18BP are up-regulated in IL-27 stimulated human primary
fibroblasts.
Primary human cells were plated at 20,000 cells per well and then stimulated with 50 ng/ml IL-27 and
mRNA expression of IL-18BP was determined by quantitative PCR (qPCR), the values were normalised
using a housekeeping gene, U6 and then normalised to the ns control to depict fold increase. a - Human
primary fibroblasts were stimulated with 50 ng/ml IL-27 for 5 and 16 hours. n = 2, independent
experiments and different donors. b – Human primary keratinocytes (HPK) were stimulated with 50 ng/ml
of IL-27 for 5 and 16 hours. n = 2, independent experiments and different donors. Mean +/- SEM is
depicted on all graphs. ns = Non-stimulated. Raw data was analysed using an un-paired student’s t-test
(GraphPad Prism 5.03, GraphPad Software, San Diego, CA). * = p ≤ 0.05 [59] 
In order to establish whether protein expression of IL-18BP was also increased over
time human primary fibroblasts and HaCat cells were stimulated with 50 ng/ml of IL-27
for 24, 48, 72 and 96 hours before cell-free supernatants were removed and IL-18BP
protein expression was analysed using ELISA (Figure 3-4). A significant increase of IL-
18BP expression was detected in the human primary fibroblasts after 48, 72 and 96
hours; whereas HaCat cells only showed a statistically significant difference after 72 and
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96 hours. In human primary fibroblasts the production of IL-18BP was maintained until
96 hours and the same time kinetic was also seen in human primary keratinocytes (data
not shown). In vitro experiments are difficult to perform for longer than 96 hours,
however experiments performed at 120 hours suggest that IL-18BP production and
consequent accumulation plateaus at 96 hours.
Figure 3 – 4. IL-18BP is released in a time dependent manner in response to IL-27.
Human primary fibroblasts and HaCat cells were plated at 20,000 cells per well and then stimulated with
50 ng/ml of IL-27 for varying amounts of time before supernatants were collected and IL-18BP protein
concentration assessed by ELISA. a – Human primary fibroblasts were stimulated with 50 ng/ml of IL-27
for varying time points (24, 48, 72, 96). n = 4, independent experiments and different donors. b – HaCat
cells were stimulated with 50 ng/ml of IL-27 for varying time points (24, 48, 72, 96). n = 4. Mean +/-
SEM is depicted on all graphs. Raw data was analysed using an un-paired student’s t-test (GraphPad
Prism 5.03, GraphPad Software, San Diego, CA). * = p ≤ 0.05 ** = p ≤ 0.01 *** = p ≤ 0.001[59] 
It is known that both IFNγ [252] and IL-27 [278] induce CXCL10 therefore levels of 
CXCL10 in response to both IL-27 and IFNγ were studied in human primary fibroblasts 
in order to compare the pro-inflammatory ability of these mediators. Cells were treated
with 50 ng/ml of IL-27 or with 10 ng/ml of IFNγ, which is within the physiological 
range for these cytokines (Figure 3-5). After 24, 48, 72 and 96 hours cell-free
supernatants were removed and analysed by ELISA. Results from these experiments
showed that CXCL10 is released along with IL-18BP at 24 hours however IL-18BP
expression is maintained for longer. This is consistent with observation from other
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mediators where upon stimulation expression of the anti-inflammatory molecule is seen
at a later time point than the pro-inflammatory one. IL-27 induced lower levels of
CXCL10 compared to IFNγ. In the cells treated with IFNγ CXCL10 levels peaked at 24 
hours whereas IL-27 treated cells peaked at a later time point maintaining the expression
for longer, however at a lower level overall. Taken results from Figure 3-2 b into
account these results may suggest that IL-27, compared to IFNγ, promotes the 
production of the anti-inflammatory IL-18BP rather than the pro-inflammatory
CXCL10.
Figure 3 – 5. CXCL10 is differentially expressed compared to IL-18BP in response to IL-27 or
IFNγ. 
Human primary fibroblasts were plated at 20,000 cells per well and then stimulated with 50 ng/ml of
cytokine for varying amounts of time before supernatants were collected and CXCL10 protein
concentration assessed by ELISA. a – Human primary fibroblasts were stimulated with 50ng/ml of IL-27
for varying time points (24, 48, 72, 96). n = 4, independent experiments and different donors. b – Human
primary fibroblasts were stimulated with 10 ng/ml of IFNγ for varying time points (24, 48, 72, 96). n = 4. 
Mean +/- SEM is depicted on all graphs.
3.4 IL-27 activates STAT1 downstream of its receptor
It has previously been shown that STAT1 activation is crucial for IL-18BP expression as
well as expression of CXCL10 [450]. In order to decipher the signalling pathways
involved in the ability of IL-27 to up-regulate IL-18BP experiments were performed in
collaboration Prof. Heiko Muhl at Pharmazentrum Frankfurt/ZAFES. This research
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group had previously performed experiments regarding STAT1 activation and IL-18BP
promoter in IFNγ stimulated DLD-1 colon carcinoma cells [450]. Here, HaCat cells 
were treated with 100 ng/ml of IL-27 or 20 ng/ml of IFNγ for 30 minutes before cell 
lysis. Cell lysates were run on an SDS page gel before western blotting for both STAT1
and phosphorylated STAT1 (Figure 3-6 a). IL-27 initiated STAT1 phosphorylation and
thus activation after 30 minutes however this was to a lesser degree than seen for IFNγ. 
mRNA levels of IL-18BP in HaCat cells were also confirmed using qRT-PCR.
Significant levels of IL-18BP mRNA were detected following treatment with IL-27 as
seen in human primary keratinocytes (Figure 3-6 b); however IFNγ did up-regulate IL-
18BP mRNA to a greater extent. Luciferase reporter assays were performed to analyse
the IL-18BP promoter activity in response to IL-27 (Figure 3-6 c). Wild type promoter
(pGL3-BPwt) indicates induction of IL-18BP which was significantly inhibited when
the proximal GAS site (pGL3-BPmt/prox) was mutated. In contrast, if the distal GAS
site (pGL3-BPmt/dist) was mutated there was no significant difference in mRNA levels
of IL-18BP. A double mutation in both the distal and proximal GAS site (pGL3-
BPmt/prox/dist) resulted in a similar inhibition of the gene promoter compared to a
single mutation in the proximal GAS site. These results indicate a crucial role for the
proximal GAS site in the IL-18BP promoter.
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Figure 3 – 6. IL-27 induces IL-18BP via a STAT1 pathway and the proximal GAS site in the IL-
18BP promoter is crucial for gene activation.
HaCat cells were stimulated with IL-27 and IFNγ and analysis performed in order to elucidate 
downstream signalling for release of IL-18BP. a – HaCat cells were stimulated for 30 min with 100 ng/ml
of IL-27, 20 ng/ml of IFNγ or used as a non-stimulated control. Cells were lysed and the obtained nuclear 
extract analysed by Western blot using antibodies specific for total STAT1 and pSTAT1-Y701. n=3, one
representative experiment shown. b – HaCat cells were stimulated for 24 h with 50 ng/ml of IL-27, 20
ng/ml of IFNγ or used as un-stimulated control and mRNA expression of IL-18BP was determined by 
qRT-PCR. IL-18BP mRNA was normalised to that of GAPDH and is shown as mean fold induction
compared to un-stimulated control. n = 6. c – HaCat cells were transfected with the indicated IL-18BP
promoter constructs. After 24 h, cells were kept as non-stimulated control or stimulated with 100 ng/ml of
IL-27. After another 24 h, cells were harvested and luciferase assays were performed. Data are expressed
as mean fold-luciferase induction (compared to the non-stimulated control transfected with the same
plasmid). n = 4, independent experiments. * = p ≤ 0.05 and ** = p ≤ 0.01 compared to non-stimulated 
control of the respective plasmid; #p,0.05 compared pGL3-BPwt under the influence of IL-27, $$p,0.01
compared to pGL3-BPmt/dist under the influence of IL-27. Experiments carried out in collaboration with
Prof. Heiko Muhl (Pharmazentrum Frankfurt/ZAFES, University Hospital Goethe-University Frankfurt,
Frankfurt am Main, Germany). [59]
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3.5 Understanding the different expression levels of IL-18BP and
CXCL10 at different time points
The results shown in figures 3-4 and 3-5 indicate that CXCL10 and IL-18BP are
released at different kinetics following activation by IL-27 or IFNγ. One possibility for 
prolonged protein expression is increased stability of the IL-18BP mRNA. Therefore in
order to study this fibroblasts were stimulated with 50 ng/ml of IL-27 for 4 hours and
then actinomycin D was added, which stops all transcription. mRNA was isolated at the
point of actinomycin D addition and then 1, 2, 3 and 4 hours after actinomycin D
addition (Figure 3-7 a). Once the mRNA was isolated qRT-PCR was performed for IL-
18BP and IL-8. IL-8 mRNA is known to be relatively unstable, therefore this provided a
good comparator to assess whether IL-18BP mRNA was stabilised following IL-27
treatment. IL-18BP mRNA showed a kinetic very similar to IL-8 mRNA in this
experiment so we concluded that mRNA stability was not a key factor in prolonged IL-
18BP production. Another hypothesis was that IL-27 may cause constant activation of
STAT1 and the consequent maintenance of IL-18BP expression that has been shown in
previous experiments. In order to study this hypothesis human primary fibroblasts were
treated with 50 ng/ml of IL-27. The media was then removed and fresh media added
after washing cells 1, 4, 12, 24 hours after IL-27 treatment. The cells were then cultured
for 48 hours (from the point of initial stimulation) and supernatants removed, IL-18BP
levels were analysed by ELISA. Interestingly, removal of the stimulus from the
supernatant after an hour did not have a marked reducing effect on IL-18BP production,
possibly suggesting that constant receptor activation is not required to have a continued
expression of IL-18BP.
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Figure 3 – 7. IL-18BP RNA does not show increased stability and constant IL-27 receptor activation
is not required for prolonged production of IL-18BP.
Human primary fibroblasts were plated at 20,000 cells per well and then stimulated with 50 ng IL-27. a –
Human primary fibroblasts were stimulated and then 4 hours later treated with actinomycin D (AD), cells
were lysed at 1, 2, 3 and 4 hours following treatment. qPCR was performed using primers for IL-18BP
and IL-8, a known low stability RNA. n = 1 b – Human primary fibroblasts were stimulated with IL-27
and then media removed and cells washed at 1, 12, 24 hours and fresh media added. Following addition of
fresh media cells were cultured for 48 hours from point of initial stimulation for levels of IL-18BP protein
using ELISA. n = 1. NS = Non-stimulated. [59]
If IL-27 was to be used therapeutically as a topical inducer of the anti-inflammatory
protein IL-18BP in IL-18 mediated diseases then the release of CXCL10 would need to
be completely inhibited. This was attempted in vitro by treating human primary
fibroblasts with 50 ng/ml of IL-27 and then adding 10 µg/ml hydrocortisone at the same
time or 1, 4, 8, 12 and 24 hours either before or after IL-27 treatment (Figure 3-8).
Treatment of human primary fibroblasts with 50 ng/ml of IL-27 induced significantly
less CXCL10 compared to IL-18BP. However, addition of hydrocortisone 1 hour before
IL-27 treatment (Figure 3-8 a) or hydrocortisone 1 hour after IL-27 treatment (Figure 3-
8 b) completely inhibited CXCL10 expression while maintaining IL-18BP levels and
this was maintained for up to a 12 hour gap between treatments. It is worth noting that
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addition of IL-27 and hydrocortisone at the same time did not reduce CXCL10
expression.
Figure 3 – 8. CXL10, but not IL-18BP release is prevented by hydrocortisone.
Primary human fibroblasts were plated at 20,000 cells per well and then stimulated with 50 ng/ml of IL-27
in the presence and absence of 10µg/ml of hydrocortisone (HC) and IL-18BP and CXCL10 ELISAs were
carried out to establish the level of protein released. a – Human primary fibroblasts were stimulated with
10µg/ml of HC and then at time points ranging from 1 – 24 hours later 50 ng/ml of IL-27 was added.
After 48 hours IL-18BP and CXCL10 were analysed via ELISA.. n = 3. b – Human primary fibroblasts
stimulated with 50 ng/ml of IL-27 and then at time points ranging from 1 – 24 hours 10 µg/ml of HC was
added. After 48 hours IL-18BP and CXCL10 were analysed via ELISA. n = 3. Mean +/- SEM is depicted
on all graphs. NS = Non-stimulated.
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3.6 Discussion and future work
Skin resident cells play a crucial role in the pathogenesis of many chronic inflammatory
skin diseases such as psoriasis and CLE. These diseases often have uncontrolled levels
of pro-inflammatory cytokines and it is thought that an imbalance between the pro-
inflammatory and the anti-inflammatory mediators may play a role in the development
of chronic disease. In this chapter a novel anti-inflammatory mechanism of human IL-27
has been defined in skin resident cells. As previously described, IL-18 is thought to play
a pathogenic role in many inflammatory skin diseases [453]. IL-18 may well be
important in the maintenance of inflammation due to its ability to induce TNFα and 
initiate IFNγ release from Th1 lymphocytes and ILC1. In addition, its ability to induce 
MMPs may be important in chronic inflammation. As well as its involvement in chronic
inflammation IL-18 has also been described to play a role in allergic contact dermatitis
[454], which is a common, difficult to treat skin manifestation of delayed type
hypersensitivity.
At present, in depth knowledge about the expression levels of IL-18 and its natural
antagonist IL-18BP is lacking in chronic inflammatory skin diseases. It is has been
identified that the amount of free IL-18 and the amount bound to IL-18BP needs to fully
understood in relation to skin disease [455]. For other diseases, levels of IL-18 and IL-
18BP have been determined and up-regulation of both has been shown in chronic liver
disease. However, in advanced cirrhotic liver disease Ludwiczek et al., suggests that
IL-18BP is not sufficiently up-regulated to control IL-18 mediated immune responses
[256]. Heart failure patients have also been described to have increased IL-18 but
decreased IL-18BP, again suggestive of an uncontrolled inflammation due to imbalance
of pro- and anti-inflammatory mediators [456]. In contrast, a recent study has shown
that IL-18 and IL-18BP are both highly up-regulated in the blood of patients with
atherosclerosis [449]. However, some imbalance may be present as blocking of IL-18
has been shown to reduce the size and inflammatory state of the atherosclerotic plaque
[457]. IL-18 has also been implicated in adult-onset Still’s disease and the analysis of
free IL-18 has been used as an important factor in the assessment of disease remission
[458].
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IL-18BP is clearly a crucial mediator that is important for controlling the highly
inflammatory functions of IL-18 and possibly important in the resolution of
inflammation. It is thought that there are basal levels of IL-18BP present in the
circulation and also data in this chapter has highlighted the ability of keratinocytes to
produce basal levels of IL-18BP. It is worth noting that data presented here suggest that
dermal fibroblasts are significant producers of IL-18BP. These cells do no produce IL-
18, which points to a possible role for dermal resident cells as ‘controllers’ of
inflammation. Thus dermal fibroblasts which produced significantly higher levels of IL-
18BP compared to the keratinocytes, seem to play an important role in the complex
network of cell types and mediators that provide the fine tune control of inflammatory
responses.
As described previously IL-27 is a pleiotropic cytokine that has been described to have
both pro-inflammatory and anti-inflammatory roles. It has been shown to prime
keratinocytes, macrophages and IDECs for IL-23, CXCL10 and TNFα production and 
has therefore been described to play a role in many inflammatory diseases [277, 278,
281, 432]. On the contrary other studies have suggested a role for IL-27 as an anti-
inflammatory mediator in the later stages of infection. In one study IL-27 was shown to
down-regulate cytokines involved in Th1, Th2 and Th17 subset development [459]. This
study and others support the notion that IL-27 may have pro-inflammatory functions to
produce a robust inflammatory response, following which at the later stages of infection
IL-27 plays a more regulatory role. The complex mechanism by which IL-27 acts may
be due to its downstream signalling, both STAT1 and STAT3 are known to be activated
during IL-27 receptor activation. Of note, STAT3 does not play a role in the expression
of IL-18BP in colon carcinoma cells [460]. The anti-inflammatory roles of IL-27 have
predominantly been described in murine models however, in this chapter a novel anti-
inflammatory mechanism of IL-27 has been described. This may be crucial in
understanding the role of IL-27 in the pathogenesis of inflammatory diseases.
The anti-inflammatory roles of IL-27 have predominantly been described in murine
models however, data presented in this chapter add a novel anti-inflammatory
mechanism of IL-27 relevant for human tissues. Data presented indicate that the
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proximal GAS site on the IL-18BP promoter is crucial for IL-18BP expression.
However, a previous study has shown that in cardiac myocytes the β2-adrenergic 
receptor triggers a signalling cascade that leads to cAMP response element-binding
(CREB) and CCAAT-enhancer-binding protein (c/EBP) β dependent IL-18BP release 
[461]. This was also shown in another study where c/EBP bound to the proximal GAS
site on the IL-18BP promoter in HepG2 cells [462]. Taken together this suggests that
there may be differential transcription factors involved in IL-18BP expression in
different cell types, the studies shown here are in transfected cell lines and murine cell
which may differ greatly to human primary cells. Therefore this is an important avenue
for further work. However, due to the emerging interest in the IL-18/IL-18BP axis in
cardiomyopathy it would be interesting to further elucidate a role for c/EBP in the
induction of IL-18BP in human cardiac myocytes.
It would be of therapeutic interest to manipulate the IL-18/IL-18BP axis. There has been
one Phase I clinical trial in patients with rheumatoid arthritis and plaque psoriasis where
subcutaneous doses of IL-18BP were well tolerated and levels were maintained in the
serum if injections were repeated every two days [258]. However, efficacy was not fully
determined in that Phase I study and further work is required to establish whether
treatment with IL-18BP would reduce chronic inflammation in different organs. It was
however noted that IL-18BP at intermediate doses did in fact improve some clinical
symptoms, interestingly at high doses this disease altering effect and reduced cell
activation was not seen [258]. This is consistent with murine models of collagen-
induced arthritis where IL-18BP at high doses increased disease severity [463]. It is a
possibility that high levels IL-18BP may be bound by the IL-1 family member, IL-37
depriving IL-18BP of its antagonist properties [464]. In some immune responses it
would not be beneficial to reduce IL-18. For example in viral infection where virus
virulence is increased by the ability of the virus to increase either endogenous IL-18BP
or homologues of this molecule [261]. In this situation the antiviral properties of IL-18
are crucial to reduce viral infection. However, in myocardial infarction and murine
models of heart failure IL-18BP seems to play a protective role against tissue damage
and may therefore in some situations be a viable therapeutic [465]. Due to the issues
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demonstrated using recombinant IL-18BP as a therapeutic, up-regulation of endogenous
IL-18BP may present a promising alternative option as a therapeutic.
Interestingly, data in this chapter has shown that the inflammatory mediator CXCL10
that is also induced following IL-27 stimulation and consequent STAT1 activation can
be inhibited in skin resident cells with the simple addition of commonly used anti-
inflammatory, hydrocortisone. However, this effect was not seen if given at the same
time as IL-27, hydrocortisone only inhibited CXCL10 if given an hour before or after
IL-27. Hydrocortisone and hydrocortisone acetate are often used topically in skin
inflammation. These drugs exert their action by binding to the glucocorticoid receptor in
the cytoplasm and this consequently leads to reduction in pro-inflammatory transcription
factors. This has been shown to involve reduction in NF-ĸB pathway activation but it 
has been suggested that there may be other pathways targeted [466]. Interestingly,
treatment of cells with hydrocortisone had no effect on levels of IL-18BP. This suggests
that the downstream signalling of IL-27 may be more complex than currently reported
and these cytokines may not only be STAT1 dependent, as previously discussed c/EBP
may also play a role [462].
Taken together, the presented data suggest that IL-27 could be used as a therapeutic.
However, having an hour between treatments is not a practical solution and more work
is needed make use of the anti-inflammatory properties of IL-27. IL-27 could be a novel
way to induce endogenous IL-18BP in the skin. This could be achieved by using a
combination of IL-27 and a commonly used immune suppressive topically for the
treatment of inflammatory skin diseases. However, IL-27 would need to be assessed
more thoroughly for its ability to induce any other pro-inflammatory mediators. In
conclusion, the results presented describe a novel anti-inflammatory mechanism for the
pleiotropic cytokine, IL-27. IL-27 has the ability to preferentially up-regulate IL-18BP
and may control IL-18 mediated inflammation. The data show that IL-18BP expression
following treatment with IL-27 is dependent on STAT1 activation and indicates the
importance of the proximal GAS site on the IL-18BP promoter. Following stimulation
of skin resident cells with IL-27 IL-18BP seems to have a delayed production, peaking
at around 48 hours but with a prolonged ability to release protein, up to 120 hours. This
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has been proposed as accumulation of stabilised protein rather than stabilisation at the
transcriptional level as we failed to see high mRNA stability. A previous study has
suggested that IL-18BP accumulates in the supernatant of cultured cells [462]. Constant
receptor activation was not shown to impact IL-18BP protein levels, again suggestive of
an accumulation of protein that is stable for a prolonged period. However, washing the
cells with PBS may not have sufficiently removed the IL-27, therefore more work is
required to analyse activation of downstream transcription factors over a range of time
periods. Data in this chapter also suggests that the pro-inflammatory cytokine CXCL10,
which is also up-regulated to a lesser degree than IL-18BP by IL-27, could be fully
inhibited by the use of well know immune suppressive drugs in combination with IL-27.
However, further work is needed to fully elucidate the downstream signalling pathway
following IL-27 receptor activation before this can be used in pilot studies as a
therapeutic molecule.
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Chapter 4 – Establishing the efficacy of the anti-IL-
17A RNA aptamer, Apt21-2 in skin resident cells
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4.1 Introduction
IL-17A is a pro-inflammatory cytokine that has been implicated in the pathogenesis of
many inflammatory diseases. This cytokine is predominantly produced by Th17
lymphocytes and is a key mediator in chronic tissue inflammation [467]. However, Th17
cells do not exclusively produce IL-17 but also produce IL-21 and IL-22 [468], the latter
of which has also been implicated in psoriasis [469]. IL-17A was initially described as a
player in autoimmunity, being identified in human rheumatoid arthritis as an up-
regulated mediator. More recently, the IL-17 family has been identified as having six
members; IL-17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F. IL-17A and IL-17F
have been most well described and are thought to be involved in IL-17 mediated disease
[387]. Apt21-2 has been shown to be a specific neutraliser of IL-17A. Lack of
crossreactivity is not surprising considering that IL-17F and IL-17A only share 55%
homology [365].
Murine models and use of neutralising antibodies against IL-17 have provided useful
insights into the pathogenic role of IL-17. This has led to the development of
neutralising anti-IL-17 therapeutic antibodies for treatment of both multiple sclerosis
and ankylosing spondylitis [470]. However, IL-17 has also been linked directly to
disease in humans. Th17 cells were identified in the lesional skin of psoriasis which
initially linked IL-17 to a possible role in disease pathogenesis [3]. IL-23, which has
been shown to be crucial in Th17 development, is also up-regulated in psoriasis [471].
The effector cytokines released from Th17 cells such as IL-17A cause the pathogenic
skin changes seen in psoriasis as well as increased inflammatory mediators that further
enhance Th17 activity. This positive feedback loop maintains the psoriatic lesion and
contributes to the chronicity of the disease. These observations along with extensive
publications suggesting a pathogenic link between psoriasis and IL-17 has led to the
development of novel biologics targeting this pathway [472]. Humanised antibodies
targeting IL-17A (secukinumab and ixekizumab) and blocking its pro-inflammatory
action by preventing binding to its receptor have been developed, as well as antibodies
targeting the IL-17 receptor and preventing agonist binding (brodalumab) [424, 473]. At
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present these biologics are showing promising results in clinical trials, affirming the
concept that IL-17 is a critical cytokine in the pathogenesis of psoriasis [474].
These highly pro-inflammatory and pathogenic roles of IL-17A make this molecule an
obvious target for therapeutic intervention. Th17 cells co-express IL-22 which is
described to play a role in psoriatic skin symptoms but it has also been shown to be
protective in colitis [469]. This suggests that the pathogenic role of Th17 cytokines may
be relevant to the tissue context and surrounding cytokine milieu and this needs to be
taken into account when designing therapeutics to target this pathway.
The importance of IL-17 in disease is evident. However, at present humanised
monoclonal antibodies and limited small molecule inhibitors are the only therapies
specifically targeting this pathway. Antibodies have disadvantages in that they can be
immunogenic and anti-drug antibodies can be detected in a substantial number of
patients [475]. This can lead to symptoms ranging from mild skin reactions to
anaphylaxis and often significant reduction of the therapeutic efficacy [475].
Therapeutic antibodies are also costly to produce and they have systemic
immunosuppressive properties. Systemic therapy is however not necessarily required in
a skin limited disease. Treatment of systematic diseases, such as multiple sclerosis and
severe psoriasis, may be suited to an antibody based systemic therapy but these
biologics do not work in all patients. For this reason and the fact that these biologic
therapies are often associated with side effects an effective, topical strategy is required
for treatment of psoriasis and other chronic inflammatory skin diseases [476].
RNA aptamers are single stranded oligonucleotides segments that bind targets
specifically and with great affinity [379] (See 1.7 for more detailed discussion). These
molecules are non-immunogenic due to the lack of a 5’ triphosphate and limited regions
of double stranded RNA which prevents activation of intracellular retinoic acid-
inducible gene 1 (RIG-I) or TLR3 [477, 478]. RNA aptamers are easily produced in
vitro keeping costs down. Multiple rounds of selection allows for highly specific
binding. The small size and structural flexibility of these RNA molecules also allows for
binding to epitopes on the target molecules that would not be detected by antibodies
[380]. The first RNA aptamer was FDA approved in 2004 against VEGF for treatment
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of age-related macular degeneration (Macugen®) [479], many more are currently in
various stages of clinical trials for treatment ranging from cancer to inflammatory
diseases [353]. An anti-human IL-17A RNA aptamer was produced in 2011 by Ishiguro
et al. [365], who showed that this aptamer prevented IL-17A binding to its receptor
consequently preventing downstream signalling. Murine models were used to assess
efficacy of the aptamer and it was shown to inhibit IL-17 action in the Th17 mediated
autoimmune models. This chemically produced RNA aptamer was named Apt21-2 and
will be referred to as this from here on. A RNA aptamer has also been produced that
specifically binds and antagonises the heterodimeric form of IL-17A/IL-17F, however
this aptamer is still at its early stages and requires optimisation to increase its
neutralisation capacity [480]. Of note, this aptamer is not being designed for therapeutic
use but for a tool to overcome the hurdles of specifically identifying this heterodimeric
form of IL-17.
This chapter will aim to assess the efficacy of Apt21-2 in human skin resident cells with
the view to further elucidate the potential of this aptamer as a topical therapy for the
treatment of Th17 mediated skin diseases such as psoriasis. This will focus on both
primary human keratinocytes and dermal fibroblasts and also whether Apt21-2 can
neutralise the effects of endogenous human IL-17A.
4.2 Structure of Apt 21-2
Apt21-2 was produced synthetically in house at the University of Leeds according to the
sequence of the previously published functional anti-IL-17A RNA aptamer [365].
Apt21-2 is 33 nucleotides long and includes pyrimidines modified with the addition of
2’ fluorine to increase stability of the RNA molecule. Apt21-2 has very limited sections
of double-stranded RNA which is advantageous for reducing activation of the
intracellular TLR3 and RIG-I receptors (Figure 4-1). Apt21-2 was also produced with
fluorophores added on either exclusively the 3’ end (Cy3) or both the 3’ (Cy3) and 5’
(Cy5) end (for sequences see 2.2.18). This was to allow monitoring of the aptamer using
fluorescence microscopy and the double-labelled aptamer allowed for visualising
whether the RNA molecule was still intact.
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Figure 4 – 1. IL-17A aptamer - Apt21-2
An mfold (Michael Zuker & Nick Markham, the mfold web server) diagram of the potential structure
Apt21-2 is depicted. It is worth noting that this is only a prediction and Apt21-2 may form a different
structure and oscillate between many. This aptamer was chemically synthesised due to its known ability to
antagonise IL-17A activity. It is 33 nucleotides long and has a small portion of double stranded RNA,
which is advantageous in reducing TLR and RIG-I responses The pyrimidines have been modified by the
addition of fluorine to increase stability of the RNA.
4.3 Efficacy of Apt21-2 in human primary fibroblasts
The previously published study describes the efficacy of Apt21-2 in murine models and
human cells. However in order for this to be a potential therapeutic to treat skin-related
disease the ability of Apt21-2 to neutralise the effects of physiologic IL-17A on skin
resident cells need to be assessed. The focus of this chapter is on skin resident cells due
to the known relevance of IL-17A in the pathogenesis of psoriasis. In order for Apt21-2
to be developed as a topical therapy it needs to be confirmed that it has human IL-17A
neutralising capacity with regard to both human primary keratinocytes (results depicted
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in 4.4) and fibroblasts activation. In order to address these questions human primary
fibroblasts were treated with 10 ng/ml of recombinant IL-17A and then increasing
concentrations of Apt21-2 (5 nM-100 nM). After 24 hours cell-free supernatant was
removed and IL-6 protein concentrations analysed using ELISA. In the previously
published study [365] IL-6 was used as the pro-inflammatory readout and levels were
reduced in the presence of Apt21-2, hence why it has been used in this study. A size-
matched control aptamer was also used in these experiments. This aptamer (47tr) was
synthesised against polymerase from foot-and-mouth disease virus [481].
Human primary fibroblasts treated with increasing doses of Apt21-2 in the presence of
10ng/ml of recombinant IL-17A showed significant reduction of IL-6 release, the
significant reduction in IL-6 correlated with increasing aptamer concentrations (Figure
4-2 a). This data set was normalised to the IL-17A treated cells without Apt21-2 and
compared to this control in the presence of 80 nM of Apt21-2 more than a 50%
reduction in IL-6 was seen. No significant reduction of IL-6 production was seen when
cells were treated with increasing concentrations of 47tr in the presence of IL-17A,
suggestive of the fact that IL-17A cannot be neutralised by a size matched control RNA
aptamer. Recombinant TNFα was also used in combination with increasing 
concentrations of Apt21-2 to assess whether this aptamer was specific to IL-17A (Figure
4-2 b).  Human primary fibroblasts were treated with 10ng/ml of IL-17A and TNFα in 
the presence and absence of increasing concentrations of Apt21-2 (5 nM – 100 nM).
This data set was also normalised to IL-17A or TNFα alone and a reduction in IL-6 
release was evident in the presence of Apt21-2 but not in the presence of the control
aptamer, 47tr. This indicates that Apt21-2 is a specific neutralising RNA aptamer
against IL-17A and does not have an effect on other pro-inflammatory cytokines. These
experiments were carried out in healthy human primary fibroblasts as well as fibroblasts
isolated from psoriatic patients (Figure 4-2 c). Both healthy and psoriatic fibroblasts in
the presence of 10ng/ml of IL-17A and increasing concentrations of Apt21-2 (5 nM –
100 nM) showed reductions in IL-6 levels. This indicated that Apt21-2 also had an
effective neutralising capacity in fibroblasts derived from psoriatic patients.
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Figure 4 – 2. Apt21-2 effectively neutralises recombinant IL-17A in healthy and psoriatic human
primary fibroblast culture.
Human primary fibroblasts were stimulated with 10 ng/ml of IL-17A in the presence or absence of
increasing concentrations of aptamer. After 24 hours IL-6 levels were analysed by ELISA. a – Human
primary fibroblasts were stimulated with 10 ng/ml of IL-17A in the presence or absence of chemically
synthesised control aptamer (47tr) (n = 3) and Apt21-2 (n = 4). IL-6 levels shown represent normalised
values to the control stimulated with IL-17A only. b – Human primary fibroblasts were stimulated with 10
ng/ml of IL-17A or 10ng/ml of TNFα in the presence and absence of Apt21-2. IL-6 levels shown 
represent normalised values to the IL-17A only control. n = 2. c – Human primary fibroblasts isolated
from both healthy control and psoriatic patients were stimulated with 10ng/ml of IL-17A in the presence
and absence of Apt21-2. n = 1. Mean +/- Standard error of the mean (SEM) is depicted on all graphs. NS
= Non-stimulated. Raw data was analysed using a one way ANOVA with Bonferroni post-test (GraphPad
Prism 5.03, GraphPad Software, San Diego, CA). ** = p ≤ 0.01 *** = p ≤ 0.001. [476] 
Human primary fibroblasts were also co-cultured with human CD4+ CCR6+ IL-17
producing T cells to assess the functionality of Apt21-2 on endogenous rather than
recombinant IL-17A (Figure 4-3). In order to do this CD4+ CCR6+ T cells were isolated
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from PBMCs using MACS® separation from both healthy and psoriatic donors.
Following isolation CD4+ CCR6+ T cells were cultured with healthy human primary
fibroblasts in the presence of antiCD3/antiCD28 to activate the T cells and increasing
concentrations of Apt21-2 (5 nM – 100 nM). As shown with the recombinant IL-17A
there was a substantial decrease in IL-6 release following treatment with the aptamer.
Interestingly the CD4+ CCR6+ T cells derived from psoriatic patients required a higher
concentration of Apt21-2 in order to detect neutralisation of IL-6, suggestive of the fact
that more IL-17A was produced by these cells.
Figure 4 – 3. Apt 21-2 effectively neutralises physiologic IL-17A in a T cell – fibroblast co-culture.
Human primary fibroblasts were cultured in the presence or absence of CD4+ CCR6+ (Th17 cells)
isolated from either healthy donors or psoriatic donors. Th17 cells were stimulated with 450 ng/ml and
200 ng/ml of aCD3/aCD28 antibodies respectively. Increasing concentrations (5 nM – 80 nM) of Apt 21-2
was added to the co-culture. After 24 hours IL-6 levels were analysed by ELISA. n = 1. NS = Non-
stimulated. [476]
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4.4 Efficacy of Apt21-2 in human primary keratinocytes
Apt21-2 was confirmed to have neutralising effects in human primary fibroblasts
therefore experiments were also carried out in human primary keratinocytes.
Keratinocytes were treated with 10 ng/ml of recombinant IL-17A in the presence and
absence of increasing concentrations of Apt 21-2 and control aptamer, 47tr (5 nM – 100
nM). After 24 hours of stimulation cell free supernatants were removed and both IL-6
(Figure 4-4 a) and IL-8 protein (Figure 4-4 b) concentrations were analysed by ELISA.
IL-8 was used as an additional pro-inflammatory mediator that is produced by
keratinocytes in response to various inflammatory mediators [482] and in these
experiments the human primary keratinocytes were producing low levels of IL-6.
Unexpectedly no significant neutralisation of IL-8 or IL-6 release was detected in the
human primary keratinocytes, in contrast to the human primary fibroblasts where
neutralisation could be seen with the addition of only 5 nM of Apt21-2. High
concentrations of Apt21-2 (80 nM) were also added to the cells alone to assess for
possible activation of the keratinocytes. However levels were not significantly different
to the non-stimulated control. No difference in the effects of Apt21-2 and the size
matched control, 47tr could be detected.
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Figure 4 – 4. Apt 21-2 does not neutralise IL-17A in human primary keratinocyte culture.
Human primary keratinocytes were stimulated with 10ng/ml of IL-17A in the presence or absence of
increasing concentrations of aptamer (5 nM-80 nM) and 80 nM of Apt21-2 alone. Cell supernatants were
then removed after 24 hours and protein levels analysed by ELISA. a – Human primary keratinocytes
were stimulated with 10 ng/ml of IL-17A in the presence or absence of Apt 21-2. Cell supernatants were
collected after 24 hours and IL-6 levels analysed using ELISA. n = 3. b - Human primary keratinocytes
were stimulated with 10 ng/ml of IL-17A in the presence or absence of Apt 21-2. Cell supernatants were
collected after 24 hours and IL-8 levels analysed using ELISA. Mean +/- SEM is depicted on all graphs.
NS = Non-stimulated. [476]
4.5 Unexpected uptake of Apt21-2
Results depicted in 4.3 and 4.4 indicate a huge contrast in efficacy of Apt21-2 in the two
different skin resident cells. Therefore, this led to some exploratory experiments and due
to the availability of fluorescently labelled aptamers this allowed for tracking of the
aptamer following its addition to cells. It had previously been suggested that relatively
small DNA molecules were internalised by cells [373], therefore this led to investigate
the possibility of RNA molecules being taken up in skin resident cells. Human primary
keratinocytes were treated with 3’ Cy3 labelled Apt21-2 in serum containing conditions
and imaged using live cell imaging at 3 hours and 20 hours (Figure 4-5 a + b).
Interestingly, even after the relatively short time period of 3 hours the images suggested
that the aptamer was being internalised by the human primary keratinocytes and this
uptake was further clarified at 20 hours. This was also confirmed in fixed cells using
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fluorescent microscopy. Primary human keratinocytes were treated with 3’ and 5’ (Cy3
and Cy5 respectively) labelled Apt21-2, as well as a 3’ Cy3 labelled 47tr size matched
control aptamer. After 4 hours of treatment with the aptamer cells were fixed with 4%
paraformaldehyde and counterstained with DAPI to distinguish the nuclei, following
which cells were mounted and imaged. After 4 hours both control aptamer (Figure 4-5
c) and Apt21-2 (Figure 4-5 d-f) were convincingly internalised by the human primary
keratinocytes. It appears that the keratinocytes have the ability to internalise any small
RNA molecules due to the control aptamer being internalised to the same degree. Cy3
and Cy5 were co-localised in images where cells had been treated with the double-
labelled aptamer (Figure 4-5 d-f), suggestive of the fact that the RNA aptamer had been
internalised and remained intact within the cells.
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Figure 4 – 5. Small RNA molecules are rapidly internalised by human primary keratinocytes.
Human primary keratinocytes were treated with 80 nM of labelled Apt21-2 at various time points in order
to track uptake of the RNA. a, b - Primary human keratinocytes treated with Cy3-labelled Apt21-2 at 3
hours (a) and 20 hours (b), using live-cell imaging. c - Human primary keratinocytes were also treated
with a Cy3-labelled control aptamer (47tr) for 4 hours. DAPI (diamidino-2-phenylindole, top left), Cy3
(top right hand), and merged (lower left). d–f Human primary keratinocytes were also treated with a
3’Cy3 and 5’Cy5 double-labelled aptamer for 4 hours. Images were taken at increasing magnification
from d through to f. DAPI (top left), Cy3 (top right hand), Cy5 (lower left), and merged (lower right).
Following incubation cells were fixed with 4% paraformaldehyde and stained for DAPI. Slides were
imaged using an inverted LSM510 confocal microscope coupled to a LSM Image Browser. Bars = 50 µM.
[476]
Previous publications have suggested that aptamer uptake may be receptor mediated
[375], therefore uptake may only occur in the presence of the target. In order to assess
whether this was true for Apt21-2 the human primary keratinocytes were treated with 80
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nM 3’ Cy3 labelled Apt21-2 alone (Figure 4-6 a-c) or with 10 ng/ml of recombinant IL-
17A in the presence of 3’ Cy3 labelled Apt21-2 (Figure 4-6 d-f). No difference could be
seen in the uptake ability whether IL-17A was present or not which is not surprising
because Apt21-2 should prevent IL-17A binding to its receptor. However, it does
indicate that Apt21-2 bound to IL-17A does not prevent internalisation.
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Figure 4 – 6. Apt21-2 is not dependent on IL-17A in order for internalisation to occur.
Human primary keratinocytes were treated with 80 nM of 3’ cy3 labelled Apt21-2 for 4 hours in the
presence and absence of 10 ng/ml of recombinant IL-17A in order to track uptake of the RNA. a – c
Human primary keratinocytes were incubated for 4 hours with 80 nM of 3’Cy3 labelled aptamer. a –
Nuclei stained with DAPI. b – Cy3 fluorescence. c – Merge of Cy3 fluorescence and DAPI. d - f Human
primary keratinocytes were incubated for 4 hours with 80nM of 3’Cy3 labelled aptamer in the presence of
10 ng/ml of recombinant IL-17A. d – Nuclei stained with DAPI. e – Cy3 fluorescence. f – Merge of Cy3
fluorescence and DAPI. Following incubation cells were fixed with 4% paraformaldehyde and stained for
DAPI. Slides were imaged using an inverted LSM510 confocal microscope coupled to a LSM Image
Browser. Images representative of two experiments. Bars = 50 µM.
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Due to the unexpected finding in human primary keratinocytes human primary
fibroblasts were also analysed for double-labelled 3’ and 5’ (Cy3 and Cy5 respectively)
labelled Apt21-2 uptake. Dermal fibroblasts were treated with Apt21-2 and then
incubated for 6 hours before fixation with 4% paraformaldehyde and then
counterstained with DAPI to distinguish the nuclei (Figure 4-7). Slides were then
mounted and imaged using fluorescent microscopy. Dermal fibroblasts were treated for
6 hours due to the fact that human primary fibroblasts have not been described to have
the same uptake ability as keratinocytes. After the 6 hour incubation there is some
uptake of Apt21-2 in to the cells and co-localisation is present, suggestive of an intact
RNA molecule. However, due to the higher level of background seen in the fibroblasts
compared to the keratinocytes it is suggestive that not as much Apt21-2 is taken up or a
longer time period is required for uptake.
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Figure 4 – 7. Small RNA molecules are also taken up by human primary fibroblasts.
Human primary fibroblasts were treated with 80 nM of 3’Cy3 and 5’Cy5 labelled Apt21-2 for 6 hours. a –
Nuclei stained with DAPI. b – 3’Cy3 fluorescence. c – 5’Cy5 fluorescence. d – Merge of Cy3 and Cy5.
Following incubation cells were fixed with 4% paraformaldehyde and stained for DAPI. Slides were
imaged using an inverted LSM510 confocal microscope coupled to a LSM Image Browser. Bars = 50
µM.
4.6 Immune activation by Apt21-2
Results depicted in 4.4 and 4.5 indicate that human primary keratinocytes and
fibroblasts effectively internalise RNA molecules however this may cause a RIG-I
response by the cell, which is a cytosolic sensor of intracellular PAMPs, particularly
RNA [483]. Endosomal TLRs such as TLR3, TLR7, TLR8 and TLR9 are also important
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in sensing intracellular pathogen derived nucleic acids [484]. Activation of these
intracellular receptors leads to release of type-I IFNs and pro-inflammatory cytokines.
However, these receptors importantly sense double stranded RNA and a 5’ triphosphate
therefore Apt21-2 should not be detectable by these intracellular receptors. In order to
investigate whether uptake of Apt21-2 was in fact eliciting response from these
receptors, primary human keratinocytes and fibroblasts were treated with either 80nM
Apt21-2, 100ng/ml poly (deoxyadenylic-deoxythymidylic) acid (Poly dA:dT) or 1µg/ml
Poly I:C. Poly dA:dT is a synthetic double stranded DNA and Poly I:C is a synthetic
double stranded RNA and both were used as positive controls that would activate the
intracellular pathogen sensors. Cells were treated for 24 hours before RNA was isolated
and qRT-PCR was performed to analyse known downstream genes of the intracellular
TLRs and RIG-I-like receptors as well as IFN induced genes such as IFNλ (Figure 4-8). 
MX1 and Gbp-1 were analysed and these are normally up-regulated following activation
of the cell by IFNs. IFNβ was analysed due to the fact that it is a known downstream 
mediator of TLR3. Both the human primary keratinocytes and human primary
fibroblasts did not show any increased expression of the panel of IFN and intracellular
receptor response genes, in comparison to the positive controls which did induce these
IFN response genes in different patterns depending on cell type. These results are
suggestive of the fact that internalisation of Apt21-2 is not eliciting an immune response
by either human primary keratinocytes or fibroblasts.
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Figure 4 – 8. Human primary cells were treated with small RNA molecules and no up-regulation of
interferon response genes could be detected.
Human primary cells were stimulated with either 1µg/ml Poly I:C, 100ng/ml Poly dA:dT or 80nM of
Apt21-2 for 24 hours before mRNA was isolated and qRT-PCR performed. a – Human primary
keratinocytes were stimulated with Poly I:C, Poly dA:dT and 80nM of Apt21-2 for 24 hours. qRT-PCR
was performed to assess levels of MX1, IFNβ, IL-29 and Gbp-1. b - Human primary fibroblasts were
stimulated with Poly I:C, Poly dA:dT and 80nM of Apt21-2 for 24 hours. qRT-PCR was performed to
assess levels of MX1, IFNβ, IL-29 and Gbp-1. All qRT-PCR data was normalised to the housekeeping 
gene U6. Mean +/- SEM is depicted on all graphs. NS = Non-stimulated.
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4.7 Discussion and future work
The role of IL-17 in chronic inflammatory skin diseases such as psoriasis is well
described. IL-17 has been identified as a key mediator involved in driving of the
inflammatory cascade seen in psoriatic lesions [424]. For this reason it has been
highlighted as a possible therapeutic target in the treatment of psoriasis. Humanised
monoclonal antibodies are currently in the latter stages of clinical trials or already
licensed for treatment and efficacy is promising in psoriasis showing potent and rapid
reduction of disease symptoms [474]. However this is a systemic therapy which if
effective in blocking the pathogenic IL-17 will also lead to side effects such as fungal
infections, due to the important role of IL-17 in anti-fungal immune responses [414].
There are also questions over the long term safety of these drugs and the extremely high
costs mean that alternatives are also necessary [485]. Therefore, it is crucial that for
chronic inflammatory skin diseases limited to the skin a topical therapy is developed to
avoid systemic side effects.
Developments have been made in moving the treatment of psoriasis to a more topical
rather than systemic approach. A recent study in mice has shown that the newly
developed skin penetrating methotrexate ameliorated imiquimod induced psoriasiform
inflammation using clinical criteria [486]. Methotrexate is used extensively in
dermatology as an inexpensive effective systemic therapy, however it is toxic to various
cell types including liver and bone marrow. These serious side effects limit the use of
this drug, however this recent study has established an effective novel way to use this
drug topically [486]. These up and coming topical therapies in psoriasis will be crucial
to increase effective treatments for patients where conventional therapy has failed. RNA
aptamers present as an ideal molecule to use for topical therapy. They are cost effective
due to the in vitro production and non-immunogenic. Due to the unique structure of
these molecules they can also bind epitopes that antibodies cannot so therefore maybe
an invaluable therapeutic tool when biologic therapy has failed. RNA aptamers are
currently being produced against a huge range of targets ranging from anti-cancer
therapies to anti-viral therapies [487]. One RNA aptamer is at present FDA approved
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and is used topically to treat age-related macular degeneration [379], therefore a topical
therapy for skin using this technology is within reach.
The experiments in this chapter aimed to establish whether Apt21-2 could be a potential
therapeutic for the topical treatment of IL-17 mediated skin diseases. Apt21-2 was
successful at neutralising the effects of recombinant IL-17A and endogenous IL-17 in
primary human fibroblasts however this same positive effect was not seen in the human
primary keratinocyte culture. This was likely due to the rapid uptake of Apt21-2 in to
the cells. The specific site by which Apt21-2 binds IL-17A was not established in this
study, however Ishiguro et al., [365] who designed the aptamer did establish binding
affinity (Kd - 48.5 pM) and specificity using surface plasmon resonance. This in
conjunction with our data showing reduction in IL-6 levels following addition of IL-17A
in combination with Apt21-2 indicates that Apt21-2 is preventing binding of IL-17A to
its receptor. Ishiguro et al., [365] identified that Apt21-2 showed neutralising effects for
both murine and human IL-17A, for which there is 63% homology suggesting binding is
occurring in this conserved region. However, in order to confirm the region of Apt21-2
binding that prevents IL-17A binding to its receptor co-crystallisation of IL-17A in
combination with the aptamer would be required. Alternatively, mutational analysis of
the aptamer or recombinant IL-17A could be performed to assess which regions are
required for binding.
Our previous work has shown that dermal fibroblasts are undoubtedly a significant
source of pro-inflammatory cytokines, so therefore reducing IL-17 mediated effects may
be beneficial for modulating disease. However, for a topical therapy to work
keratinocytes need to be taken into account because they form the barrier of the skin and
therefore are the first cells to come into contact with anything placed on the skin. If
Apt21-2 was to be used as a topical therapeutic in treating chronic inflammatory skin
diseases then keratinocytes would need to be bypassed. At present there are various
methods by which drugs can be administered directly into the dermis [488]. Results
depicted in this chapter indicate that despite internalisation of Apt21-2 in keratinocytes
and to a lesser degree fibroblasts there is not a type-1 IFN response. This is crucial when
designing therapeutics and despite the non-immunogenic features of small RNA
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aptamers, siRNA has been shown to activate a RIG-I response [489]. Therefore the lack
of a type-1 IFN response in human primary fibroblasts is an encouraging result for
developing Apt21-2 as a therapeutic.
There is an increasing demand for delivery of drugs or vaccines directly into the dermis
bypassing the difficult to penetrate stratum corneum, therefore technologies are being
developed. These include jet injectors, which involve a high powered stream of liquid
that pierces the skin and delivers the drug into the dermis [488]. Hollow microneedles
containing aqueous drugs [490] and biodegradable drug incorporated needles [491] have
both been developed as dermal delivery systems. A patch system has also been
developed where drug coated microneedles are attached to an adhesive patch and can be
placed on the skin piercing the epidermis and reaching the dermis [492]. These newly
developed technologies allow for therapeutic potential of Apt21-2 to prevent IL-17
mediated inflammation in the dermis. However, further studies are needed to establish
the penetrative capabilities of RNA aptamers once in the skin because at present this has
not been investigated. This needs to be established due to the abundant number of
RNases that are present in the skin. Ribonuclease (RNase) 7 and 5 are particularly well
described within the skin compartment due to their role in cutaneous defence [493]. The
effects of these RNAses on Apt21-2 integrity need to be established before the concept
of using RNA aptamers as a topical skin therapy can be taken further.
Data presented in this chapter indicates that Apt21-2 effectively neutralises both
recombinant and endogenous IL-17A in a human primary fibroblast culture. However,
the ineffective neutralising capacity in the human primary keratinocytes and the finding
that this small RNA aptamer was passively taken up into the cell was not an expected
finding. This may however explain the lack of neutralising ability because Apt21-2 was
not available in the extracellular space. Of note, the keratinocytes were inefficiently
stimulated by IL-17A and this may also account for lack of neutralisation, the low levels
of activation that were seen were however not altered. Data presented in this chapter
indicate that Apt21-2 neutralises endogenous IL-17 however it is worth noting that this
experiment was only performed once and the experimental setup has limitations. CD4+
CCR6+ enrichment of PBMCs can yield small numbers of cells which is likely to be the
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reason for the low levels of IL-6 seen following stimulation. This experiment need
repeating to confirm that this effect with the inclusion of an IL-17 neutralising antibody
control as well as FACS staining in conjunction to indicate efficient enrichment and
presence of IL-17, with these controls the neutralising effect of Apt21-2 could be
confirmed as IL-17 mediated.
The uptake of RNA molecules by keratinocytes is a novel finding as uptake of RNA
aptamers in to primary skin resident cells has not previously been described. However,
human primary keratinocytes do have tendencies to take up substances from the
environment and uptake of melanosomes is crucial for keratinocyte survival and
protection from UV. The mechanisms by which melanosome transfer into keratinocytes
occurs are not all together clear [494]. The rapid uptake of Apt21-2 may well explain the
lack of IL-17A neutralising capacity in human primary keratinocytes, however the
human primary fibroblasts also appeared to internalise the aptamer but still indicated
significant IL-17A neutralisation. The amount of background that is evident despite the
longer incubation compared to the keratinocytes is suggestive that the fibroblasts do not
internalise the RNA molecules as effectively. In order to establish this conclusively a
time resolve would be required comparing human primary keratinocytes and fibroblasts
which could be carried out using an in vitro assay on an IncuCyte™. Quantification of
uptake could also be analysed using FACS and again human primary keratinocytes and
fibroblasts could be compared. Uptake of oligonucleotides by human primary fibroblasts
has not been described in the literature, however uptake of the DNA aptamer AS1411
has been described in a human fibroblastic cell line, Hs27 [373]. This uptake was
described to be by a mechanism which led to endosomal entrapment or lysosomal
degradation in healthy cells [373]. Healthy human primary keratinocytes have been
described to passively take up plasmid DNA [374]. Interestingly in comparison to what
has been shown in Hs27 cells uptake of plasmid DNA led to a small amount of plasmid
transcription suggestive of the fact that not all DNA was degraded in lysosomes or
endosomes [374]. In fact in this study it was suggested that macropinocytosis was the
mechanism by which uptake of plasmid DNA occurred due to inhibition of the uptake
by phosphoinositide 3-kinase [495]. The DNA aptamer AS1411 was taken up by
macropinocytosis only in the cancer cells tested, however this did effectively deliver the
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aptamer to its intracellular target due to the leaky nature of macropinosomes. This is
consistent with the uptake of DNA plasmid where low levels of plasmid transcription
occurred. It is thought that unlike Gram-positive bacteria which express specific
receptors for uptake of DNA, mammalian cells are more likely to take up DNA by
utilising existing endocytic pathways [374]. It has been shown in muscle cells that
plasmid DNA is taken up by potocytosis, which is receptor mediated endocytosis [496].
AS1411 uptake has previously been described as being nucleolin dependent, however it
also appears to be taken up by alternative mechanisms which are not receptor dependent
[373]. RNA aptamer uptake has been described in a receptor mediated manner in a
haematopoietic cell line and in this study the RNA uptake was dependent on IL-6
receptor expression. Interestingly this RNA aptamer was used to carry cargo into the cell
and by this receptor mediated endocytosis cargo could be delivered into the cell 10 times
the size of the 19 nucleotide RNA aptamer [375].
Although in human primary keratinocytes Apt21-2 is not a viable option for
neutralisation of IL-17A, it does present as a possible novel way to target intracellular
mediators with the use of RNA aptamers without the need for chemical introduction.
There is undoubtedly a need for cell penetrating molecules that can deliver therapeutics
or act inside the cell [497]. The fact that Apt21-2 was effectively internalised in the
presence of its target suggests that there could be scope for the use of Apt21-2 as an
RNA aptamer to take cargo therapeutics into the cell. In order for new RNA aptamers to
be developed for use inside the cell the exact mechanisms by which uptake occurs need
to be established. It is likely due to published literature that this is an active mechanism,
however this needs to be confirmed in the human primary cells by assessing uptake
ability when the cells are at 4°C [374]. Lack of activity suggests an endocytic uptake
whereas internalisation at 4°C suggests a passive mechanism.
Following an initial temperature dependency experiment, more detailed experiments
would need to be performed in order to confirm what had been shown. As described in
Reyes-Reyes et al., [373] inhibition of various uptake mechanisms can be utilised to
establish the mechanism by which RNA aptamers are being taken up by the primary
skin resident cells. Macropinocytosis could be a mechanism by which uptake occurs as
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well as endocytosis, which is generally regarded as the mechanism by which siRNA is
internalised [376]. Endocytosis can be split into clathrin-mediated endocytosis,
caveolae-mediated endocytosis and clathrin and caveolae-independent endocytosis
[498]. Specific inhibitors would need to be used to establish if endocytosis was
responsible for uptake. Treatment of cells with cytocholasin D has been shown to inhibit
endocytosis therefore this could be used to assess this as an internalisation mechanism
[373]. Dynasore could be used to inhibit both clathrin and caveolae dependent
endocytosis due to the requirement for GTPase dynamin in these forms of endocytosis
[499]. Fluorescent staining of markers for endosomes such as EEA1, Rab5, and Rab11
would also be necessary to establish where the intact RNA aptamer was within the cell
[500]. If Apt21-2 was shown to be internalised by endocytosis, the development of the
formulation by which delivery was performed would have to carefully designed in order
to escape the endocytotic pathway by disrupting the endosomal membrane to deliver the
RNA aptamer into the cytosol [377]. However, this is a well-regarded essential
mechanism for siRNA delivery therefore many technologies are available to escape
endosomal degradation [377].
Macropinocytes is another possibility that may be responsible for internalisation of
Apt21-2 if endocytosis was ruled out. However it is worth noting that previous studies
have identified different internalisation pathways in different cell types, therefore a
number of relevant cell types would need to be tested. Following uptake of the aptamer
in to the cells co-staining with dextran would indicate whether macropinocytosis was
responsible for uptake, as well as chemical inhibition of this process using amiloride
[373]. Of note, hyperstimulation of macropinocytosis has been indicated to cause a
novel mechanism of cell death which was not seen in this study [501, 502].
Before Apt21-2 could be taken forward as a therapeutic more in depth studies would
need to be carried out regarding activation of the cells. In this chapter it was shown that
a RIG-I or TLR response was not evident in the panel of mediators analysed following
uptake of Apt21-2, which is to be expected due to the 5’ monophosphate group on RNA
aptamers. The intracellular pathogen sensors predominantly detect 5’ triphosphate
groups and double stranded RNA [477, 478] which are absent or limited in the RNA
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molecules used. Cell viability and cell death would also need to be assessed following
uptake of RNA aptamers using longer time points compared to what has been currently
carried out. Cell death is commonly regarded as a positive outcome in aptamer
development targeting cancer cells using specific cancer cell markers, therefore RNA
aptamers for intracellular targets would need to be carefully designed to avoid this.
In conclusion, this chapter has confirmed the neutralising efficacy of Apt21-2 on both
recombinant and endogenous IL-17 in human primary fibroblast culture. Unexpectedly,
it has also described a novel feature of human primary keratinocytes in their ability to
take up small RNA molecules. More work is required to fully elucidate the pathways
involved in this uptake. RNA aptamers have been shown to modulate protein-protein
interactions therefore aptamers could be designed to utilise this function inside the cell
both in an experimental and therapeutic setting [503]. This unique function of
keratinocytes could present with an invaluable tool to target pro-inflammatory signalling
pathways without the need for chemical introduction in to the cell. This could be utilised
in the topical treatment of chronic inflammatory skin diseases predominantly affecting
the epidermis which would not lead to the widespread side effects seen in systemic
therapies.
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Chapter 5 – Elucidating the role of IL-36 cleavage
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5.1 Introduction
IL-36 is a relatively newly described subfamily in the IL-1 family of cytokines. The
family includes four members; IL-36α, IL-36β, IL-36γ and IL-36 receptor antagonist 
(RA) that bind to the receptor IL-1Rrp2 (IL-36R). All apart from IL-36RA also bind
to the common accessory protein to all IL-1 members, IL-1RAcP [203, 204]. The IL-
36 members constitute an independent system from IL-1, however the IL-36R does
also signal via NF-κB [185]. In 2011 it was identified that, similar to other IL-1 
family members the IL-36 family members also require N-terminal cleavage to gain
biological activity [128]. In line with other IL-1 family members the IL-36RA plays
a crucial role in controlling the pro-inflammatory activity of IL-36α, IL-36β and IL-
36γ. As for other IL-1 members the balance between the agonists and antagonists is 
important in maintaining control over inflammatory responses. It has also been
proposed that another cytokine, IL-38 may also have antagonistic properties on IL-
36 by binding in a similar manner as IL-36RA to the IL-36R [126]. However, there
is at present limited literature on IL-38.
The predominant source of the IL-36 cytokines is keratinocytes. IL-36RA is
constitutively expressed, whereas IL-36γ is effectively induced following treatment 
with phorbol 12-myristate 13-acetate (PMA) and pro-inflammatory cytokines [60,
211]. IL-36 expression has also been identified in other epithelial tissues such as the
lung, however lack of available reagents has hampered the investigation at the
protein level [207, 208, 210]. Most recently it has been shown that IL-36 stimulates
maturation of DCs therefore driving T cell proliferation and actively playing a role in
skin inflammation [504]. Due to IL-36 being mainly expressed by epithelial cells the
majority of the research in this area is focused on the skin (and bronchial epithelial
cells). Therefore, emerging evidence in both human cells and in murine models
indicates that IL-36 may play a crucial role in skin inflammation.
IL-36 has particularly been implicated in the pathogenesis of psoriasis and different
studies have identified IL-36 mRNA and protein in psoriatic plaques [505]. IL-36γ is 
consistently one of the most up-regulated genes in these arrays and our unpublished
work suggests that it may be a biomarker to distinguish psoriasis from other
inflammatory skin conditions [97, 221, 222]. The link to psoriasis pathogenesis has
been further strengthened by the identification of a disease causing missense
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mutation in the IL-36RA gene that leads to dysfunctional IL-36RA. This mutation
has been identified in a subset of GPP patients in a number of populations [5, 111].
Biophysical analysis showing N-terminal cleavage results in >30000 fold increase in
receptor affinity [128]. However, the bioactive, cleaved form of IL-36 has not yet
been identified in physiological conditions therefore it is crucial to understand how
and when these pro-inflammatory cytokines are being activated. In addition to this
the protease responsible for IL-36 cleavage is still to be elucidated. As previously
discussed some IL-1 family members such as IL-1β and IL-18 are cleaved in to their 
active form inside the cell by inflammasome dependent caspase-1 [129]. It is
however unlikely that IL-36 is cleaved by caspase-1 due to its requirement for a
specific consensus sequence [205]. Both IL-1β and IL-18 if released from the cell in 
their inactive full length forms can be cleaved by a number of different proteases
[344] including the neutrophil serine protease, PR3 [342], however the activity of IL-
18 following cleavage by PR3 is yet to be fully elucidated [236]. Given the lack of
data on IL-36 bioactivity in vivo, a greater understanding of the biology of IL-36 and
the protease/s responsible for cleavage and the mechanisms by which IL-36 is
released is needed.
The aims of this work were to (1) elucidate the role of the predicted active forms of
IL-36 in vitro using primary skin resident cells derived from both healthy and
psoriatic donors, and (2) to elucidate which protease could be responsible for this
cleavage. Due to paucity of knowledge about the release of these cytokines from the
cell this will also be investigated using in vitro techniques. In order to establish
potential functional roles of IL-36 on skin phenotype 3-D skin equivalents as well as
single layer cultures will be treated with different forms of IL-36.
5.2 Response of primary skin resident cells to IL-36
Activated skin resident cells can produce significant levels of pro-inflammatory
cytokines, such as IL-8 which is a potent chemoattractant that will recruit neutrophils
in to the skin, this along with other cytokines aid in the mounting an inflammatory
response [506]. IL-36 has been shown to induce pro-inflammatory cytokines [218]
and due to the relevance of IL-36 in psoriasis and the importance of neutrophils in
this disease [3] IL-8 was used as a marker cytokine for IL-36 bioactivity.
Biophysical analysis suggested that cleavage of IL-36 at the N-terminus increased
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activity [128]. Cleaved IL-36 was commercially available therefore these were tested
using human skin resident cells.
5.2.1 IL-36α 
In order to study this, human primary keratinocytes and fibroblasts derived from
both healthy and psoriatic donors were stimulated with 100 ng/ml of both IL-36α in 
its full length form and its cleaved form (5 amino acids removed from the N-
terminus IL-36α K6), these were both commercially available (Figure 5-1). After 48 
hours of stimulation levels of IL-8 were analysed by ELISA. In the healthy human
primary fibroblasts a significant increase of IL-8 production was detected between
the non-stimulated control and the truncated IL-36α K6 that was not seen following 
treatment with the full length IL-36α (Figure 5-1 a). A significant increase of IL-8 
was also seen between the non-stimulated control and IL-36α K6 in the healthy 
human primary keratinocytes and no significant difference was seen following
treatment with the full length IL-36α (Figure 5-1 b). This suggests that in healthy 
human primary fibroblasts and keratinocytes IL-36α requires N-terminal cleavage to 
have a significant pro-inflammatory effect. However, although no statistically
significant differences were seen in the psoriatic human primary fibroblasts there
was a defined increase in IL-8 following treatment with IL-36α truncated (Figure 5-1 
a). The psoriatic human primary keratinocytes were un-responsive (Figure 5-1 b).
This was possibly due to high passage number and due to limited availability of
psoriatic keratinocytes no alternative donors were available for testing. No other IL-
36 members were tested using this donor due to the un-responsiveness.
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Figure 5 – 1. IL-36α requires cleavage for activity in human primary fibroblasts and 
keratinocytes.
Human primary cells were plated at 20,000 cells per well and stimulated for 48 hours following which
supernatants were removed and IL-8 levels analysed by ELISA. a – Human primary fibroblasts from
both healthy and psoriatic donors were stimulated with 100 ng/ml of both IL-36α full length and 
truncated forms. n = 3, independent experiments and different donors. b – Human primary
keratinocytes from both healthy and psoriatic donors were stimulated with 100 ng/ml of both IL-36α 
full length and truncated forms. Healthy donors n = 3, Psoriatic donors n = 1, independent
experiments and different donors. Mean +/- Standard error of the mean (SEM) is depicted on all
graphs. NS = Non-stimulated. Raw data was analysed using a Kruskal-Wallis test (GraphPad Prism
5.03, GraphPad Software, San Diego, CA). * = p ≤ 0.05 
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5.2.2 IL-36β 
Human primary skin resident cells were also treated with IL-36β in both its full 
length and truncated form. Human primary fibroblasts derived from both healthy and
psoriatic donors and healthy human primary keratinocytes were stimulated with 100
ng/ml of full length IL-36β and truncated IL-36β (4 amino acids removed from the 
N-terminus) (Figure 5-2). After 48 hours cell free supernatant was removed and IL-8
concentrations were analysed using ELISA. Although, with the limited available
sample number, no statistically significant differences were detected in either the
healthy or psoriatic human primary fibroblasts there is no doubt that following
treatment with IL-36β truncated compared to full length there is an increased 
production of IL-8 (Figure 5-2 a). This was also seen in the healthy human primary
keratinocytes (Figure 5-2 b). This data although lacking in statistical significance
does suggest that IL-36β in line with the other IL-36 family members requires N-
terminal cleavage to gain significant pro-inflammatory activity.
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Figure 5 – 2. IL-36β requires cleavage for activity in human primary fibroblasts and 
keratinocytes.
Human primary cells were plated at 20,000 cells per well and stimulated for 48 hours following which
supernatants were removed and an IL-8 ELISA performed. a – Human primary fibroblasts from both
healthy and psoriatic donors were stimulated with 100 ng/ml of both IL-36β full length and truncated 
forms. n = 3, independent experiments and different donors. b – Human primary keratinocytes from
healthy donors were stimulated with 100 ng/ml of both IL-36β full length and truncated forms. n = 3, 
independent experiments and different donors. Mean +/- SEM is depicted on all graphs. NS = Non-
stimulated. Raw data was analysed using a Kruskal-Wallis test (GraphPad Prism 5.03, GraphPad
Software, San Diego, CA).
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5.2.3 IL-36γ 
Human primary skin resident cells were also treated with IL-36γ in its full length 
form and also its truncated form. Human primary fibroblasts derived from both
healthy and psoriatic donors as well as healthy human primary fibroblasts were
stimulated with 100 ng/ml of full length and truncated IL-36γ (17 amino acids 
removed from the N-terminus – S18). After 48 hours of stimulation IL-8 protein
concentrations were analysed by ELISA (Figure 5-3). In human primary fibroblasts a
significant increase in IL-8 release was detected following treatment with truncated
IL-36γ (S18) compared to full length IL-36γ and this was seen in both fibroblasts 
derived from healthy and psoriatic donors (Figure 5-3 a). Interestingly, a significant
increase in IL-8 production was also detected between the healthy and psoriatic
human primary fibroblasts treated with 100 ng/ml IL-36γ truncated (S18) (Figure 5-3 
a). Preliminary data suggests that this difference in response is not related to
differential expression of the IL-36 receptor on the cells, as confirmed by FACS.
Although no statistical difference was detected in IL-8 production following
treatment with truncated IL-36γ (S18) in healthy human primary keratinocytes there 
was a defined increase in IL-8 production that was not seen upon treatment with full
length IL-36γ (Figure 5-3 b). This again is suggestive that IL-36γ requires N-
terminal cleavage in order to gain significant pro-inflammatory activity.
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Figure 5 – 3. IL-36γ requires cleavage for activity in human primary fibroblasts and 
keratinocytes.
Human primary cells were plated at 20,000 cells per well and stimulated for 48 hours before analysis
by IL-8 ELISA was performed. a – Human primary fibroblasts from both healthy and psoriatic donors
were stimulated with 100 ng/ml of both IL-36γ full length and truncated forms (S18). Healthy donors 
n = 6, psoriatic donors n = 4, independent experiments and different donors. b – Human primary
keratinocytes from healthy donors were stimulated with 100 ng/ml of both IL-36γ full length and 
truncated forms. Healthy donors n = 3, independent experiments and different donors. Mean +/- SEM
is depicted on all graphs. NS = Non-stimulated. Raw data was analysed using a Kruskal-Wallis test
(GraphPad Prism 5.03, GraphPad Software, San Diego, CA). * = p ≤ 0.05 ** = p ≤ 0.01 *** = p ≤ 
0.001.
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5.3.4 Effects of IL-36 on PMN and T cell activation
The truncated cleaved forms of IL-36 were also tested to assess their direct activity
on PMNs and PBMCs. Standard transwell chemotaxis assays were performed to
assess the effect of IL-36 on the migratory capacity of the PMNs. However, no
chemokinetic or chemotactic effects were observed. No increase in PMN activation
following IL-36 treatment was identified, as assessed by CD11b expression,
generation of reactive oxygen species from the PMNs or CD62L shedding. PBMCs
were also treated with both the full length and active cleaved forms of IL-36. Levels
of activation were established by looking at CD69 levels, however no T cell
activation was identified.
5.3 Cleavage of full length IL-36
As shown in the previous figures (5.1 to 5.3), IL-36 family members require N-
terminal cleavage to increase their pro-inflammatory functions. As previously
mentioned a distinctive feature of psoriasis is the accumulation of neutrophils in
epidermal-dermal junctions, known as Munro’s abscesses [3]. Therefore it was
logical to assume that with an increased level of neutrophils in a disease where
increased levels of IL-36 were also present that these highly protease rich cells may
be involved in the cleavage of IL-36. In order to study this hypothesis PMNs were
isolated from whole blood of healthy donors and immediately after isolation PMNs
were stimulated with 100 ng/ml of PMA for 1 hour at 37°C. After stimulation cells
were removed and supernatant was incubated with full length IL-36γ. IL-36γ was 
used for these experiments as it was found to be the most up-regulated IL-36
member in psoriasis. As well as the fact that the truncated form has 17 amino acids
removed from the N-terminus which means difference in mobility of the protein on
an SDS PAGE gel was detectable. This is not the case for other IL-36 members. IL-
36γ was incubated with the PMN supernatant for 10 minutes and 30 minutes at 37°C 
(Figure 5-4).
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Figure 5 – 4. Supernatant from stimulated polymorphonuclear (PMNs) cells can cleave IL-36γ. 
PMNs were isolated from peripheral blood of healthy donors and stimulated with 100 ng/ml of
phorbol 12-myristate 13-acetate (PMA) for 1 hour at 37°C. Following this incubation cells were
removed and supernatant either used immediately or frozen at -80°C. Supernatant was then incubated
with full length IL-36γ for 10 minutes and 30 minutes. Western blot analysis including a full length 
and cleaved control is shown. Western blot is representative of 3 independent experiments.
Following incubation samples were analysed by Western blotting. It was shown that
after even after 10 minutes of incubation with PMN supernatant cleavage of protein
could be detected which was more prominent after 30 minutes. The lower molecular
weight bands on the gel were suggestive of the full length protein being cleaved by a
protease derived from activated PMNs.
5.4 Production of recombinant tagged IL-36
Due to the exciting results depicted in Figure 5-4 numerous attempts were performed
to pull down the cleaved products seen in the lower bands on the Western blot using
immunoprecipitation. However, it was concluded that the commercially available
antibodies did not bind with great enough affinity for immunoprecipitation to
retrieve enough protein to analyse. Also, the experiments depicted in 5.3 could only
be performed on IL-36γ due to the small number of amino acids removed from the 
N-terminus of the other proteins. Therefore, in order to elucidate the accurate
products following protease cleavage without suitable reagents recombinant proteins
were produced containing an N-terminal SUMO tag. This allowed for identification
of N-terminal cleavage due to the size difference being evident on an SDS PAGE
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gel. Recombinant IL-36 proteins were also produced with an N-terminal SUMO tag
and a C-terminal His tag using a pET 28 (+) vector (see Appendix figure 2 for vector
map). This would allow for nickel affinity chromatography following digestion if
further analysis was required and needed to be isolated from the proteases that had
cleaved IL-36.
All figures depicted in this section are representative images of the production and
purification of N-terminally SUMO tagged IL-36γ, however the same method was 
utilised for all of the IL-36 proteins and for both the N-terminally tagged and N and
C-terminally tagged proteins. A diagrammatic representation of the constructs
produced is depicted in figure 5-5 a. The IL-36 members were all cloned into a
Champion pET SUMO expression system (see Appendix figure 1 for vector map)
and then transformed into DH5α cells to check accuracy of cloned sequence (See 
Appendix figure 4 - 23 for primers and sequences of all IL-36 members). The IL-36
members were expressed in BL21-CodonPlus (DE3)-RIPL strain of E. coli and the
overnight growth temperature following induction with IPTG was optimised (Figure
5-5 b). Following overnight culture samples were taken and run on an SDS PAGE
gel and stained with Coomassie. Compared to the pre-induction samples a band
relating to IL-36 can clearly be seen (indicated by the red arrow) at all temperatures,
however the strongest band is present at 25°C.
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Figure 5 – 5. Optimisation of IL-36 expression in E. coli
IL-36 members (IL-36α, IL-36γ, IL-36RA) were cloned using a pET expression system including a 
SUMO-his tag in order to purify the protein and aid solubility. a - Diagrammatic representation of the
N-terminal SUMO-His tag as well as constructs produced including a C-terminal His tag. b – IL-36s
were cloned and then transformed into expression strains of E. coli. A sample was taken prior to
induction and then compared to overnight growth following induction at 18°C, 25°C and 37°C.
Coomassie stained gel shows samples at different temperatures following overnight incubation. c –
Coomassie stained gel of nickel affinity chromatography soluble fractions. These figures are
representative experiments for one construct however this was carried out for all constructs.
All further larger scale expression cultures were induced using 0.8mM IPTG and
then grown overnight at 25°C due to optimisation results depicted in Figure 5-5 b.
Following overnight growth and cell lysis (see 2.3.8) the protein present in the
soluble fraction of the cells was then purified using nickel affinity chromatography.
Protein was eluted from the nickel column using increasing concentrations of
imidazole, 1ml fractions were taken and a sample of each run on an SDS PAGE gel
and stained using Coomassie. In Figure 5-5 c the prominent band is the purified IL-
36 protein. This method was used for all IL-36 recombinant proteins produced.
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Following nickel affinity chromatography IL-36 proteins were further purified using
a size exclusion column which then allowed for differentiation between monomers,
dimers and aggregates therefore allowing monomers to be purified and used for
further experiments (Figure 5-6 a). The fractions that represent the monomer peak
were run on an SDS PAGE gel and stained with Coomassie to assess purity. As
shown in Figure 5-6 b following this purification method the sample is extremely
pure.
Figure 5 – 6. Further purification of IL-36 proteins using size exclusion.
IL-36 members were purified using nickel column chromatography following which they were further
purified using size exclusion. a – A representative 280nm UV graph taken from the software used to
analyse the fractions removed from the size exclusion column. Fractions from the peak that
represented the monomer fraction was collected and concentrated. b – Coomassie stained gel of size
exclusion fractions. The depicted experiments are representative of the experiments carried out for all
constructs.
Following numerous attempts to express IL-36β it was concluded that expression 
was not viable. Various optimisation methods were performed including using
different strains of expression E. coli – Shuffle® competent cells, Rosetta™ 2 (DE3)
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competent cells and ArticExpress competent cells. The induction stage of the E. coli
was also optimised with the use of auto-induction and alterations of glucose and
lactose concentrations. However, none of these techniques led to any IL-36β 
expression so therefore from here on IL-36β was not used in any of the experiments 
(See Appendix figure 10 – 13 for primers used and sequences). The lack of
expression could be due to its reduced phylogenetic relationship and therefore less
structural similarity to the other IL-36 members [507].
5.5 Identifying putative proteases responsible for IL-36 cleavage
In order to identify specific proteases that cleave IL-36 all IL-36 proteins were
produced as described in 5.4 with an N-terminal SUMO tag. The tag allowed for
visualisation of N-terminal cleavage via SDS PAGE analysis. Therefore different
cellular supernatants could be tested in order to assess their cleavage activity. In
order to study this, PMN supernatant was obtained as described in 5.3 and human
primary fibroblasts and keratinocytes were also stimulated with 100ng/ml of PMA
for 24 hours at 37°C before supernatant was removed. Supernatant from the three
different cell types was then incubated with IL-36α (Figure 5-7 a), IL-36γ (Figure 5-
7 b) and IL-36RA (Figure 5-7 c) for 1 hour at 37°C. Following incubation samples
were then analysed by Western blot. N-terminal cleavage of the IL-36 members was
only present when incubated with supernatant from activated PMN. This is in line
with what was shown using the commercially available IL-36γ in 5.3 and it is 
interesting to note that all of the IL-36 members are cleaved.
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Figure 5-7. IL-36 proteins with a SUMO tag incubated with activated cellular supernatants are
cleaved by supernatant from PMNs.
SUMO tagged IL-36s were incubated with a range of supernatants from activated cells. PMNs were
isolated from whole blood of healthy donors and then stimulated with 100 ng/ml of PMA for 1 hour at
37°C. Human primary keratinocytes and fibroblasts were stimulated with 100 ng/ml of PMA for 24
hours at 37°C. Supernatant was then removed from the cells and incubated with IL-36α (a), IL-36γ 
(b) or IL-36RA (c) for 1 hour at 37°C, along with a PBS control which was also incubated for 1 hour
at 37°C. Samples were then analysed by Western blotting.
In order to further elucidate the protease that appears to be responsible for the
cleavage of IL-36 all proteins were cleaved using supernatant from activated PMNs
in the presence and absence of various protease inhibitors. IL-36α (Figure 5-8 a), IL-
36γ (Figure 5-8 b) and IL-36RA (Figure 5-8 c) were incubated with activated PMN 
supernatant for 1 hour at 37°C. This was carried out in the presence of pan serine,
cysteine and aspartic protease inhibitors (PI, PI Roche), MMP inhibitors (EDTA),
pan cysteine protease inhibitors (IAA) or pan serine proteases inhibitors (PMSF, α1 
anti-trypsin). Following incubation, samples were analysed via Western blot analysis
and run alongside a positive control and a sample that was incubated with activated
PMN supernatant and did not contain any protease inhibitors. As expected both pan
protease inhibitors prevented cleavage in all IL-36 members tested. EDTA and IAA
did not prevent cleavage which suggests that an MMP or cysteine protease was not
responsible for IL-36 cleavage. However, both serine protease inhibitors (PMSF, α1 
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anti-trypsin) prevented cleavage which is suggestive of a PMN derived serine
protease that is responsible for IL-36 cleavage.
Figure 5 – 8. IL-36 cleavage by activated PMN supernatant can be prevented by serine protease
inhibitors.
Sumo tagged IL-36s were incubated with supernatant from PMNs stimulated with PMA for 1 hour at
37°C. Incubation was performed in the presence or absence of a range of protease inhibitors. PI =
complete protease inhibitor cocktail (Roche), EDTA = Ethylenediaminetetraacetic acid, inhibitor of
proteases where a metal ion is required for cleavage, PI Roche = complete ultra-protease inhibitor
cocktail which includes aspartic proteases (Roche), IAA = iodoacetic acid a pan cysteine protease
inhibitor, PMSF = phenylmethylsulfonyl fluoride a pan serine protease inhibitor, α1 anti-trypsin is 
another pan serine protease inhibitor. a – IL-36α was incubated with activated PMN supernatant in 
the presence and absence of the panel of protease inhibitors. b - IL-36γ was incubated with activated 
PMN supernatant in the presence and absence of the panel of protease inhibitors. c - IL-36RA was
incubated with activated PMN supernatant in the presence and absence of the panel of protease
inhibitors. Samples were then analysed using Western blotting.
Although Figures 5-7 and 5-8 were suggestive of PMN serine proteases being
responsible for cleavage other proteases were analysed for completeness. Due to the
expression of the IL-36 members being largely limited to human epithelium and the
143
known relevance of IL-36 in inflammatory skin diseases we focused on cleavage in
the skin compartment. Therefore in collaboration with Dr Ulf Meyer-Hoffert at the
University of Kiel, Germany the SUMO tagged IL-36 members were also subjected
to cleavage by recombinant kallikreins. These are serine proteases that are produced
predominantly by keratinocytes [300]. In order to study this, IL-36α was incubated 
with kallikrein 5 (Figure 5-9 a) and kallikrein 7 (Figure 5-9 b) for increasing periods
of time. There was no cleavage of IL-36α following even prolonged incubation with 
kallikrein 7, however after 3 hours of incubation with kallikrein 5 N-terminal
cleavage could be detected. IL-36γ was also incubated with kallikrein 5 (Figure 5-9 
c) and kallikrein 7 (Figure 5-9 d) for increasing periods of time. Minimal cleavage of
IL-36γ was detected following 24 hours of incubation with kallikrein 5, however 
substantial cleavage of IL-36γ was detected after only 5 minutes of incubation with 
kallikrein 7 and after 24 hours nearly all protein was cleaved. IL-36RA was also
incubated with kallikrein 5 (Figure 5-9 e) and kallikrein 7 (Figure 5-9 f) for
increasing periods of time. No remarkable cleavage could be detected when IL-
36RA was incubated with kallikrein 5 or 7 at even 24 hours of incubation.
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Figure 5-9. IL-36 proteins with a SUMO tag can be cleaved by recombinant kallikreins.
SUMO tagged IL-36 proteins were incubated with recombinant kallikreins for a range of time
periods. a – IL-36α was incubated with recombinant kallikrein 5 (KLK5). b - IL-36α was incubated 
with recombinant kallikrein 7 (KLK7). c – IL-36γ was incubated with recombinant kallikrein 5. d -
IL-36γ was incubated with recombinant kallikrein 7 (KLK7). e - IL-36RA was incubated with
recombinant kallikrein 5 (KLK5). f - IL-36RA was incubated with recombinant kallikrein 7 (KLK7).
Silver stained gels show protein bands following incubation with the kallikreins. Cleaved samples
were then analysed by mass spectrometry. The data displayed in this figure was carried out by Dr Ulf
Meyer-Hoffert and Jan Fischer, Department of Dermatology, University Hospital Schleswig-Holstein,
Kiel, Germany.
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The cleavage products of IL-36γ identified in Figure 5-9 d were analysed by mass 
spectrometry and the results will be discussed along with all other mass spectrometry
data in 5.6 (see Table 5-1).
5.6 IL-36 cleavage products identified
Figure 5-8 suggested that a serine proteases derived from PMNs were responsible for
IL-36 cleavage. In order to identify the precise cleavage products by mass
spectrometry recombinant proteases were used in order to maintain a relatively pure
sample suitable for mass spectrometry. The three most prominent neutrophil serine
proteases, cathepsin G (CG), elastase (E) and proteinase 3 (PR3) were tested. In
order to study this, recombinant CG, E and PR3 were incubated with SUMO tagged
IL-36α (Figure 5-10 a), IL-36γ (Figure 5-10 b) and IL-36RA (Figure 5-10 c) for 10 
minutes at 37°C. Following incubation samples were run on an SDS PAGE gel and
protein bands determined by Coomassie stain. Incubation with all of the recombinant
PMN serine proteases results in complete cleavage of IL-36α and IL-36γ, however 
cleavage of IL-36RA was detectable but not all IL-36RA was cleaved. The red
arrows indicate the N-terminally cleaved IL-36 and the SUMO tag, which is depicted
as the higher band on the Coomassie stained gels.
Figure 5 – 10. IL-36 proteins can be efficiently cleaved using recombinant neutrophil serine
proteases.
Sumo tagged IL-36 proteins were incubated with the three most common neutrophil serine proteases,
cathepsin G (CG), elastase (E) and proteinase 3 (PR3) at 1:20th of IL-36 added for 10 minutes at
37°C. a - IL-36α. b – IL-36γ. c – IL-36RA. Coomassie stained gel shows samples following
incubation.
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This incubation was exclusively carried out with recombinant proteins therefore the
samples were relatively pure, as depicted on the Coomassie stained gels on Figure 5-
10 a-c. This allowed for further analysis by mass spectrometry and N-terminal
sequencing. The N-terminal cleavage products identified are diagrammatically
depicted in Figure 5-11 a-c. From here on the N-terminal cleavage products are
referred to as the N-terminal amino acid and the number of amino acids from the N-
terminus.
Figure 5-11. Diagrammatic representation of cleavage products identified following incubation
with recombinant neutrophil serine proteases.
Following incubation with recombinant serine proteases samples were analysed by mass spectrometry
and N-terminal sequencing. Diagrammatic representation of the N-terminal cleavage products
detected for IL-36α (a), IL-36γ (b) and IL-36RA (c), depicted by the red arrows.
The cleavage product of IL-36α identified was I7 following incubation with 
recombinant neutrophil serine proteases. Two IL-36γ cleavage products were 
identified following incubation with recombinant serine proteases, these were Y16
and Q17. Two cleavage products were also identified for IL-36RA, S4 and V2. The
biophysical prediction of cleavage products identified IL-36RA V2 as the most
active form of the receptor antagonist [128]. As depicted in Figure 5-8 IL-36γ 
following cleavage with kallikrein 7 was also analysed by mass spectrometry and the
same products were identified as with the recombinant serine proteases, which were
Y16 and Q17.
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IL-36α Elastase Proteinase 3 Cathepsin G PMN SN PMN SN
+ AMN
K6
I7 x
L5 x
N-terminal sequencing of product cleaved with all 3 proteases confirm I7
IL-36γ Elastase Proteinase 3 Cathepsin G KLK7 PMN
SN
PMN
SN +
AMN
Y16 x x x x
Q17 x x x x
S18
N-terminal sequencing of product cleaved with all 3 proteases confirm Y16 and Q17
IL-36RA Elastase Proteinase 3 Cathepsin G PMN SN PMN SN
+ AMN
V2 x
L3 x
S4 x x x x x
Table 5-1. Summary table of cleavage products identified by mass spectrometry and N-terminal
sequencing.
Depicted are all the cleavage products identified by mass spectrometry and N-terminal sequencing
following incubation with recombinant serine proteases (elastase, proteinase 3 and cathepsin G) as
well as with activated PMN supernatant (PMN SN). IL-36 proteins were also incubated with activated
PMN supernatant following which aminopeptidase N (AMN) was added and incubated further. As
described in Figure 5-9 KLK7 cleavage of IL-36γ was also analysed using mass spectrometry. The 
IL-36 cleavage products are depicted as the amino acid and the number from the N-terminus
indicating the amount of amino acids removed from the N-terminus.
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The cleavage products identified for IL-36α and IL-36γ were not products that had 
been predicted as active forms by Towne et al., [128] (see Table 5-1). In order to
assess whether these active products could be identified other proteases were
incubated with IL-36. Owing to the fact that the products identified for IL-36α and 
IL-36γ only had one extra amino acid compared to the active form, aminopeptidases 
were a logical target due to their known cleavage functions. Aminopeptidase N
(AMN), also known as CD13, is a type II metalloprotease that cleaves single amino
acids from the N-terminus of proteins [508]. In order to assess the role of AMN it
was incubated at 1:20th and 1:100th of the IL-36 protein, this was added to the IL-36
proteins following cleavage by recombinant serine proteases or in combination with
recombinant serine proteases. However, following cleavage with AMN the same
products were identified by mass spectrometry to those following incubation with
recombinant serine proteases alone. However, this may have been due to the AMN
not working. In order to test whether the N-terminal SUMO could possibly affect
cleavage the SUMO tag was removed prior to cleavage. This did not affect the
cleavage products detected. All cleavage products are summarised in table 5-1.
In order to compare the cleavage products following incubation with recombinant
neutrophil serine proteases and the proteases responsible for the cleavage in the
activated PMN supernatant, the IL-36 proteins that had N- and C-terminal tags to
allow for purification following cleavage were used. Using these tagged IL-36
proteins cleavage was carried out with supernatants and cells relevant to
inflammatory skin diseases, including activated PMN supernatant, activated PMNs,
detached and attached activated keratinocytes and a punch skin biopsy from healthy
and psoriatic donors. This was carried out with a range of stimulations to activate the
cells known to be relevant in psoriatic inflammation (IL-17 and TNFα; also added as 
stimulus: PMA). However, following purification and analysis by mass spectrometry
the biophysical predictions of the active IL-36 forms were not identified and results
were inconclusive due to apparent complete digestion of the protein, therefore
experiments need to be performed using a more diverse range of time points.
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5.7 Production of identified cleaved products
In order to test the activity of the identified IL-36 cleavage products in mammalian
cell culture all the identified cleavage products shown in 5.6 were produced as
recombinant proteins. These proteins were generated in the same manner as
described in 5.4 with the specific cleaved sequence cloned into the Champion pET
SUMO expression system. However once the SUMO tagged proteins were purified
the SUMO tag was removed using a specific protease (His-ULP-1) that cleaves only
the SUMO tag (leaving the exact N-terminus). Both His-ULP-1 protease and the
SUMO tag following cleavage contain His tags, allowing for purification of the IL-
36 proteins away from the protease and SUMO tag (Figure 5-12 a). Following
purification, the IL-36 proteins were verified using mass spectrometry. The predicted
active products [128] for IL-36α (K6) and IL-36γ (S18) were also produced to act as 
positive controls. A summary gel of all constructs produced with SUMO tags
removed is depicted in Figure 5-12 b.
Figure 5 - 12. Cleavage products identified following serine protease cleavage are produced in
E. coli.
The cleavage products identified following recombinant neutrophil serine protease cleavage depicted
in Figure 5 – 10 were produced in E. coli. a – The IL-36 cleavage products were produced in the same
manner as the full length IL-36 proteins using a Champion pET SUMO expression system and then
purifying the protein using nickel affinity chromatography followed by size exclusion
chromatography. After purification the SUMO tag was removed using a highly specific protease, His-
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ULP-1 which also contains a His tag following which the His-ULP-1 and the SUMO tag were
purified by nickel affinity chromatography. Mass spectrometry analysis was performed to ascertain
that the exact protein sequence had been produced. b – Coomassie stained gel of all IL-36 cleaved
proteins produced including positive controls, 36γ S18 and 36α K6 that were not identified following 
serine protease cleavage.
5.8 Response of human primary fibroblasts to the cleaved IL-36
proteins
In order to determine the activity of the truncated IL-36 proteins produced as
described in 5.7 primary human skin resident cells were treated with these proteins.
Human primary fibroblasts were stimulated with increasing concentrations of IL-36
proteins and after 48 hours concentrations of IL-8 were analysed using ELISA.
Healthy human primary fibroblasts were treated with 100 ng/ml of commercially
available IL-36β truncated (T), which was used as a positive control to confirm cell 
responsiveness. Increasing concentrations (1 nM – 100 nM) of IL-36α full length, 
K6 and I7 were used to stimulate the fibroblasts (Figure 5-13 a). A statistically
significant increase in release of IL-8 was detected following treatment with 100 nM
IL-36α K6 compared to non-stimulated control. A steady increase in IL-8 was 
evident with increasing concentrations of IL-36α K6, however the full length and I7 
IL-36α did not induce any substantial release of IL-8. In order to control for LPS 
contamination a control IL-36 sample which was boiled for 20 minutes prior to
addition to cells confirms that the increase in IL-8 is not related to LPS
contamination. A limulus amebocyte lysate (LAL) test was also performed following
manufacturer’s instructions in order to assess endotoxin levels, levels were deemed
at a low enough level for tissue culture experiments (<1 EU/µg).
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Figure 5 – 13. IL-36 proteins require specific N-terminal cleavage in order to increase activity in
healthy human primary fibroblasts.
Healthy human primary fibroblasts were plated at 20,000 cells per well and stimulated with the IL-36
cleavage products identified previously for 48 hours before levels of IL-8 were analysed by ELISA. a
– Human primary fibroblasts were stimulated with IL-36α cleavage products (K6 and I7) as well as 
the full length control. n = 3, independent experiments and different donors. b - Human primary
fibroblasts were stimulated with IL-36γ cleavage products (Y16, Q17 and S18) as well as the full 
length control. n = 3, independent experiments and different donors. IL-36β truncated (T) at 100 
ng/ml (5.4nM) was used as positive control in both experiments, which is a commercially available
IL-36 which has previously been shown to be active. Mean +/- SEM is depicted on all graphs. NS =
Non-stimulated. Raw data was analysed using a Kruskal-Wallis test (GraphPad Prism 5.03, GraphPad
Software, San Diego, CA). * = p ≤ 0.05 
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Healthy human primary fibroblasts were also treated with increasing concentrations
(1 nM – 100 nM) of IL-36γ in its full length and cleaved forms, Y16, Q17 and S18 
(Figure 5-13 b). Although no statistical significance was shown in the IL-36γ S18 
treated samples, it is evident that a dose dependent increase of IL-8 release can be
seen following increasing concentrations of IL-36γ S18. A boiled control for IL-36γ 
S18 was also performed and this confirms the increase in IL-8 is not related to LPS
contamination. There was no substantial IL-8 release following treatment with full
length or Y16 IL-36γ however a small induction of IL-8 could be detected following 
treatment with 100 nM of IL-36γ Q17. 
In order to establish differences in response to IL-36 in cells derived from psoriatic
patients compared to healthy cells psoriatic human primary fibroblasts were also
stimulated with IL-36. This was performed in the same manner as previously
described with the cleavage products of IL-36α and IL-36γ and then after 48 hours 
IL-8 concentrations analysed by ELISA. Psoriatic human primary fibroblasts were
treated with increasing concentrations (1 nM- 100 nM) of full length and cleavage
products (K6 and I7) of IL-36α as well as commercially available IL-36β truncated 
(T) as a positive control (Figure 5-14 a). Statistically significant increases of IL-8
release were detected following treatment with 50 nM and 100 nM of IL-36α K6. No 
significant increases in IL-8 were detected following treatment with the full length
protein or IL-36α I7. Interestingly, IL-8 expression in response to 50 nM and 100 
nM of IL-36α K6 is significantly higher in psoriatic fibroblasts (~3000 pg/ml to 
~7000 pg/ml) compared to healthy fibroblasts (Figure 5-14 c). Psoriatic human
primary fibroblasts were also treated with full length and cleavage products (Y16,
Q17 and S18) of IL-36γ alongside IL-36β truncated (T) as a positive control (Figure 
5-14 b). A statistically significant increase in IL-8 release was detected following
treatment with both 50 nM and 100 nM of IL-36γ S18. As in the healthy human 
primary fibroblasts there was little IL-8 release following treatment with IL-36γ full 
length or Y16. However IL-36γ Q17 did induce some IL-8 which was significantly 
increased (~200 pg/ml to ~600 pg/ml) compared to the concentration that was
detected in healthy human primary fibroblasts. This may be physiologically
significant however it is much lower than the IL-8 levels seen with IL-36γ S18. In 
the same manner as to with the IL-36α K6 the levels of IL-8 released in the psoriatic 
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compared to healthy human primary fibroblasts was significantly higher (~2000
pg/ml to ~6000 pg/ml) (Figure 5-14 d).
Figure 5 – 14. IL-36 proteins require specific N-terminal cleavage in order to increase activity in
psoriatic human primary fibroblasts.
Psoriatic human primary fibroblasts were plated at 20,000 cells per well and stimulated with the IL-36
cleavage products identified previously for 48 hours and levels of IL-8 analysed by ELISA. a –
Human primary fibroblasts were treated with IL-36α cleavage products (K6 and I7) as well as the full 
length control. n = 4, independent experiments and different donors. b - Human primary fibroblasts
were stimulated with IL-36γ cleavage products (Y16, Q17 and S18) as well as the full length control. 
n = 3, independent experiments and different donors. c – Comparison of human primary fibroblasts
from both healthy (Figure 5-13 a) and psoriatic donors stimulated with IL-36α K6 (Figure 5-14 a). d –
Comparison of human primary fibroblasts from both healthy (Figure 5-13 b) and psoriatic (Figure 5-
14 b) donors stimulated with IL-36γ S18. IL-36γ truncated (T) at 100 ng/ml (5.4nM) was used as 
positive control in both experiments (commercially available IL-36). Mean +/- SEM is depicted on all
graphs. NS = Non-stimulated. Raw data was analysed using a Kruskal-Wallis test (a+b) and multiple
student’s T test with Holm-Sidak post-test (GraphPad Prism 5.03, GraphPad Software, San Diego,
CA). * = p ≤ 0.05 ** = p ≤ 0.01 
The activity of the IL-36 proteins appeared to be determined by the removal of a
precise number of amino acids from the N-terminus (see Figure 5-14). In order to
study this further mutational analysis was performed for both IL-36α K6 and IL-36γ 
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S18 to assess whether the specific amino acid or the length of the N-terminus was
crucial for activity. The N-terminal amino acid was therefore substituted for an
alanine. Following amino acid substitution from a lysine (IL-36α K6) or a serine (IL-
36γ S18) to an alanine IL-36γ showed no reduction in activity (Figure 5-15) 
suggestive of the importance of the N-terminal length rather than a specific amino
acid. Preliminary data suggests that the same is true for IL-36α (data not shown). 
Figure 5-15. IL-36γ requires a specific N-terminal length in order to maintain activity. 
Healthy human primary fibroblasts were treated with both IL-36γ S18 and IL-36γ S18A, where the N-
terminal serine has been substituted for an alanine. Following 48 hours of stimulation IL-8 levels
were detected using ELISA. n = 3, independent experiments and different donors. Mean +/- SEM is
depicted on all graphs. NS = Non-stimulated. Preliminary results suggest that these results also reflect
what is seen for IL-36α K6. 
As mentioned previously RAs are crucial in order to control inflammation.
Following cleavage of IL-36RA by the recombinant neutrophil serine protease,
elastase, a cleavage product was detected where the methionine was removed from
the N-terminus. Also following cleavage by recombinant neutrophil serine proteases
and activated PMNs another product was detected with three amino acids removed
from the N-terminus (IL-36RA S4). In order to test the efficacy of these
differentially cleaved receptor antagonists both healthy and psoriatic human primary
fibroblasts were treated of IL-36RA V2 in the presence and absence of commercially
available IL-36γ truncated (T) at 100 ng/ml (5.4nM) or the active IL-36γ S18 at 10 
nM. In both the healthy and psoriatic human primary fibroblasts the IL-36RA
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effectively reduced the IL-36γ T or IL-36γ S18 induced IL-8 release on increasing 
concentrations of IL-36 V2 (Figure 5-16 a + b). In the healthy human primary
fibroblasts complete reduction of IL-36γ T induced IL-8 to non-stimulated levels 
was seen at 50 nM of IL-36RA V2 (Figure 5-16 a). However, in the psoriatic human
primary fibroblasts higher concentrations (100 nM) of IL-36RA V2 were required to
reduce IL-8 levels to non-stimulated control, this is likely to be due to the increased
responsiveness of these cells (Figure 5-16 b). In contrast to IL-36RA V2 which alone
showed no activation of the cells and in combination with IL-36γ truncated (S18) 
showed antagonistic properties IL-36RA S4 indicated no antagonistic properties
(Figure 5-16 c).
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Figure 5 – 16. IL-36 receptor antagonist requires removal of the N-terminal methionine to
enable antagonistic properties.
Healthy and psoriatic human primary fibroblasts were plated at 20,000 cells per well and treated with
IL-36RA cleavage products (V2 and S4) in the presence and absence of commercially available IL-
36γ truncated (T) or IL-36γ S18 at 100ng/ml (5.4nM) or 10nM, which has previously shown to be 
active. After 48 hours of treatment IL-8 concentrations analysed by ELISA. a – Healthy human
primary fibroblasts were stimulated with IL-36RA V2 in the presence and absence of commercially
available IL-36γ T. n = 3, independent experiments and different donors. b - Psoriatic human primary
fibroblasts were stimulated with IL-36RA V2 in the presence and absence of active IL-36γ S18. n = 3, 
independent experiments and different donors. Boiled controls were performed for IL-36RA V2 to
rule out LPS contamination (data not shown) c – Healthy human primary fibroblasts were treated with
100nM of IL-36RA S4 in the presence and absence of IL-36γ S18. n = 1. Mean +/- SEM is depicted 
on all graphs. NS = Non-stimulated.
5.9 Response of skin equivalent models to stimulation by IL-36
In 5.8 it was shown that the cleaved IL-36α K6 and IL-36γ S18 induce release of 
high levels of IL-8 in human primary fibroblasts. However, due to the significance of
the IL-36 members in chronic inflammatory skin diseases such as psoriasis it was
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presumed that IL-36 may play a more complex role than simply increasing IL-8
release. Therefore in order to study the potential interplay between fibroblasts and
keratinocytes in a more physiological setting, 3-D skin equivalents were produced
using human primary keratinocytes and fibroblasts derived from both healthy and
psoriatic donors.
3-D skin equivalent models were produced using healthy human primary
keratinocytes and fibroblasts. These models were cultured for 10 days at the air-
liquid interface before addition of 20 ng/ml of IL-22, 100 nM IL-36α full length and 
IL-36γ full length or 100 nM IL-36α K6 and IL-36γ S18 for a further 96 hours. 
Following 14 days of culture at the air-liquid interface skin equivalents were fixed
with 4% formaldehyde, sectioned and mounted onto microscope slides. Sections
were then stained using H&E and stained for the presence of cytokeratin 10 (CK10).
Figure 5-17 identifies active IL-36 compared to untreated control and IL-22, which
is regarded as an inducer of psoriatic phenotype in skin equivalents [509], IL-36α K6 
and IL-36γ S18 indicate a marked change in phenotype (Figure 5-17 a-c). An 
enlarged epidermis is clearly present however, the CK10 which is a differentiation
marker, staining does not suggest that this is related to aberrant differentiation
because the CK10 levels look relatively consistent in untreated, IL-22 and IL-36
treated skin equivalent sections.
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Figure 5 – 17. Treatment of skin equivalents constructed with healthy fibroblasts and
keratinocytes with IL-36 shows a defined phenotype.
Skin equivalents produced from healthy human primary keratinocytes and fibroblasts were treated for
96 hours with either IL-22 or IL-36α K6 and IL-36γ S18. Following which skin equivalents were 
fixed in 4% paraformaldehyde, sectioned and stained with H&E or cytokeratin 10 (CK10) using a
DAB detection system and counterstained with haematoxylin then imaged using a Leiss light
microscope at a 16x objective. Multiple images were taken and a representative image is displayed.
Untreated skin equivalent sections were stained using H&E (a) and CK10 (d). n = 1 experiment. IL-
22 (20 ng/ml) treated skin equivalent sections were stained using H&E (b) and CK10 (e). n = 1
experiment. IL-36α K6 and IL-36γ S18 (100 nM) treated skin equivalent sections were stained using 
H&E (c) and CK10 (f) n = 1 experiment.
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The images taken of the CK10 stained sections were counterstained with
haematoxylin enabling nuclei counting to be performed for each image frame and an
average nuclei count to be analysed (Figure 5-18). A statistically significant increase
in the number of nuclei was detected following treatment with 100 nM of IL-36α K6 
and IL-36γ S18, however an increase in the number of nuclei was also seen in the 
skin equivalents treated with 100nM of full length IL-36α and IL-36γ.   
Figure 5 – 18. IL-36 treatment of skin equivalents derived from healthy keratinocytes and
fibroblasts induces proliferation in the epidermal layer.
Skin equivalents produced from healthy fibroblasts and keratinocytes were stained with CK10 and
counterstained with haematoxylin which allowed quantification of nuclei. Nuclei were counted in
each x16 image frame using Image J software. 4 representative images of each skin equivalent were
counted and the IL-36α K6 and IL-36γ S18 represented 2 experiments. NT = non-treated. Mean +/- 
SEM is depicted on the graph. Raw data was analysed using a Kruskal-Wallis test (GraphPad Prism
5.03, GraphPad Software, San Diego, CA). * = p ≤ 0.05  
3-D skin equivalent models were also produced using keratinocytes and fibroblasts
from healthy and psoriatic patients to attempt to elucidate the intrinsic roles of skin
cells derived from psoriatic patients. However, the results were not conclusive
therefore data is not shown.
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5.10 IL-38 as a possible IL-36 antagonist in human fibroblasts
IL-38 has been described to have antagonistic properties on IL-36 acting in a similar
manner as the IL-36RA [126]. IL-38 proteins were produced in the Champion pET
SUMO expression system in the same manner as the IL-36 proteins described in 5.4
and 5.7. Four different forms of IL-38 were produced, one full length and 3 others
with amino acids removed from the N-terminus (IL-38 C2, IL-36 S3, IL-38 L4).
These forms were produced due to the alignment with other IL-1 members in the
same manner as was used for prediction of IL-36 cleavage (see Appendix figure 24
for alignment). The SUMO tag was removed using His-ULP-1 protease before the
IL-38 proteins were used to treat human primary cells. In order to test this in a
culture system in which the IL-36RA V2 had been shown to be an effective
antagonist on IL-36 members (see 5.8), healthy human primary fibroblasts were
stimulated with increasing concentrations (1 nM – 100 nM) of full length and
cleaved IL-38. This was performed in the presence and absence of 100ng/ml of the
commercially available IL-36γ truncated (T) (Figure 5-19). After 48 hours of 
stimulation IL-8 concentrations analysed by ELISA.
Following treatment with increasing concentrations of full length IL-38 in the
absence of IL-36γ T increasing levels of IL-8 were detected and a further increase of 
IL-8 was seen when IL-38 in combination with IL-36γ T was used (Figure 5-19 a). 
This suggests that full length IL-38 binds to a receptor on the cells causing
downstream signalling and therefore displays an agonist and not antagonistic role.
Full length IL-38 was also boiled for 20 minutes before being added to the cells and
this confirmed that LPS was not responsible for the increase in IL-8 release (data not
shown). When human primary fibroblasts were treated with increasing
concentrations of IL-38 C2 in the absence of IL-36γ an increase in IL-8 release was 
also seen and this was increased further when IL-38 C2 was used in combination
with IL-36γ T (Figure 5-19 b). This shows that removing one amino acid from the N-
terminus does not enable the antagonistic properties in this experimental set-up. In
contrast both IL-38 S3 and IL-38 L4 even at 100 nM in the absence of IL-36γ T did 
not induce IL-8 (Figure 5-19 c + d). In combination with IL-36γ T IL-38 S3 does 
still not display any antagonistic properties, however IL-38 L4 in combination with
IL-36γ T showed a slight tendency to reduce IL-36γ T induced IL-8 release in some 
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donors. However, the overall trend is that neither the full length IL-38 nor the
cleavage products produced here have an antagonistic role on IL-36.
Figure 5 – 19. Both full length IL-38 and cleavage products fail to antagonise IL-36.
Human primary fibroblasts were plated at 20,000 cells per well treated with cleavage products (C2,
S3 and L4) of IL-38 in the presence or absence of a commercially available IL-36γ truncated (T) that 
is known to be active. 48 hours after stimulation supernatants were removed and IL-8 protein
concentrations were assessed by ELISA. a – Human primary fibroblasts were stimulated with full
length (FL) IL-38 in the presence and absence of IL-36γ T. n = 4, independent experiments and 
different donors. b - Human primary fibroblasts were stimulated with IL-38 C2 in the presence and
absence of IL-36γ T. n = 4, independent experiments and different donors. c - Human primary
fibroblasts were stimulated with IL-38 S3 in the presence and absence of IL-36γ T. n = 4, independent 
experiments and different donors. d - Human primary fibroblasts were stimulated IL-38 L4 in the
presence and absence of IL-36γ T. n = 4, independent experiments and different donors. NS = non-
stimulated. Mean +/- SEM is depicted on all graphs.
5.11 Mammalian expression of IL-36
As mentioned previously, the majority of the IL-1 family proteins do not contain a
leader sequence, therefore release from the cell has to be via a non-conventional
pathway. Caspase-1 is thought to play a role in the release of some IL-1 members
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(shown for IL-1α and IL-1β, discussed in 1.4.1) from the cell. Therefore, the 
cleavage and consequent increased activity of the IL-36 members may occur inside
the cell prior to release or it may be released and cleaved into activation outside the
cell. In order to study this, a vector, pcDNA 3.1+ (see Appendix figure 3 for vector
map), over-expressing the IL-36 members with and without N- (myc) and C-(His)
terminal tags was transfected in to a range of mammalian cells (depicted in Figure 5-
20 a). The figures depicted in 5-20 are representative but have been performed in all
conditions and different cell types. The transfection efficiency was confirmed using a
green fluorescent protein (GFP) vector, which identified a good percentage of cells
were successfully transfected (Figure 5-20 b). After 24 hours of transfection mRNA
was isolated and levels of IL-36 mRNA established using qRT-PCR which
confirmed that the plasmid was being successfully transcribed (Figure 5-20 c).
However, no IL-36 protein could be detected using the plasmid containing IL-36
alone or in combination with the myc and His tags. This was attempted in various
cell lines including 293T, 293TT, 293FT, Cos7 cells as well as primary cells.
Optimisation was extensively carried out altering transfection time, transfection
reagents and cell confluency. The transfection was also carried out 12 hours prior to
the addition of the proteasome (MG132) or lysosome (chloroquine) inhibitors to
prevent protein degradation before cells were harvested for protein analysis.
Unfortunately, due to the lack of protein seemingly being produced the trafficking
and cleavage of IL-36 could not be monitored in a cellular system. Of note, available
commercial antibodies also fail to detect intracellular IL-36.
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Figure 5 – 20. IL-36 is potentially post-translationally regulated.
Various cell lines (293T, 293TT, 293FT and Cos7) and human primary cells were transfected with
pcDNA 3.1+ containing IL-36 constructs and mRNA levels and transfection efficiency analysed. a –
Diagrammatic representation of the pcDNA 3.1+ plasmid constructs used. IL-36α, IL-36β and IL-
36RA were cloned into the plasmid without N- and C-terminal tags. All IL-36 products were also
cloned into the pcDNA 3.1+ plasmid containing a C-terminal His tag and N-terminal myc tag. b – A
GFP control plasmid was also transfected in conjunction with the experimental plasmids to assess
transfection efficiency. These images represent the transfection efficiency in all cell lines transfected.
c – 24 hours after transfection mRNA was isolated from the cells and qRT-PCR performed for IL-36α 
and IL-36RA, Ct values are shown following ΔΔCT-analysis and fold increase is depicted compared 
to GFP transfection control. U6 – housekeeping gene, GOI = gene of interest. This table represents
results for 293T and Cos7 cells, however similar results were identified for all other cell types used.
5.12 Discussion and future work
The IL-36 family of cytokines have only been described relatively recently and there
is currently a significant lack of suitable reagents e.g. for protein detection. As a
consequence the full IL-36 functional activity, intra- and extracellular trafficking and
regulation still needs to be elucidated. This is of clinical relevance due to clear link
between subtypes of GPP and an uncontrolled IL-36 activity due to a loss-of-
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function mutation in the RA [5]. Numerous studies have also identified that IL-36 is
highly up-regulated in lesional psoriatic skin compared to the non-lesional skin in
the same patients [222]. Keratinocytes derived from psoriatic patients intrinsically
produce more IL-36 in response to IL-17 and TNFα [60]. These clear links with 
psoriasis suggests that the IL-36 family may be of interest as a therapeutic target. It
is consequently crucial to gain insight in mechanisms and pathways leading to IL-36
activation and inactivation.
In this chapter the previously predicted cleavage products that were thought to be the
most active using biophysical analysis [128] were tested in human primary skin
resident cells. It was confirmed that compared to the full length proteins the cleaved
IL-36α, IL-36β and IL-36γ were all significantly more active in their ability to 
increase IL-8 release (>10 fold increase, see Figure 5-1 - 3) in both keratinocytes and
fibroblasts, which is in line with the biophysical predictions. IL-8 is a chemokine
that attracts neutrophils, and the significant levels released from skin resident cells
may drive the neutrophilic inflammation seen in psoriasis. This effect has also been
shown in lung fibroblasts, where treatment of IL-36 induces significant levels of IL-
8 [213]. However it was shown that IL-36 had to be used at high concentrations to
see an effect, suggestive of the fact that full length proteins were used in these
experiments [213]. Results depicted in this chapter demonstrate that the truncated IL-
36α caused significantly more IL-8 release compared to truncated IL-36γ. This is in 
line with finding from Towne et al., [128] who analysed the binding affinity of the
cleaved products. All IL-36 cleavage products displayed a higher binding affinity
compared to the full length protein, however the cleaved IL-36α had a significantly 
higher binding affinity compared to the cleaved IL-36β and IL-36γ [128]. In this 
chapter, data was presented in support of human primary fibroblasts being more
efficient responders to IL-36 in their production of IL-8 compared to human primary
keratinocytes. This is in line with the suggestion that human primary fibroblasts are
the predominant responders to IL-36 in the skin whereas the human primary
keratinocytes are the significant producers of IL-36 [60].
Of note, in response to the cleaved IL-36 proteins human primary fibroblasts derived
from psoriatic patients produced significantly higher levels of IL-8. This is
suggestive of the fact that psoriatic cells are intrinsically more responsive to IL-36.
This may well be due to increased IL-36R levels on these cells, however preliminary
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experiments carried out alongside the work shown in this chapter did not indicate
any changes in receptor levels compared to healthy human primary fibroblasts. Due
to these findings it is unlikely that differential expression of IL-36 receptor is the
cause for increased responsiveness. As previously discussed the IL-36 receptor
signals via NF-κB [185]. It is well regarded that in some psoriatic patients the NF-κB 
pathway is dysregulated due to common genetic mutations (see Table 1-1). These
mutations effect negative regulators in this pathway causing potential over activity
and consequent increase in pro-inflammatory mediator release [99]. It would be an
interesting avenue for further work to assess responsiveness of psoriatic fibroblasts
to IL-36 according to the patient’s genotype.
The results depicted in this chapter suggest that all the IL-36 members require
cleavage to increase binding affinity to the IL-36 receptor in order to see an increase
in pro-inflammatory cytokine release downstream of the NF-κB pathway. This work 
has been focused on elucidating the cleavage of IL-36 proteins into their most
bioactive forms. Of note, a newly described neutrophil serine protease, NSP4, was
not tested in the panel of recombinant neutrophil serine proteases. This was due to its
known low abundance in neutrophil azurophils, NSP4 is released at levels
representing only 5% of the cathepsin G released [510]. However, if this neutrophil
protease was responsible for cleavage then the active IL-36 products would have
been identified following incubation with activated PMN supernatant.
IL-36RA is cleaved in to its active and highly antagonistic form by the recombinant
serine protease, elastase. This is an important finding due to the crucial role of
receptor antagonists in controlling inflammation and preventing the possibility of
chronic inflammation. In contrast the proteases released from activated PMNs and
recombinant neutrophil serine proteases cleave the IL-36 agonists (IL-36α and IL-
36γ) into a form in which they are inactive. However, the cleavage site identified in 
this work is in close proximity to the site in which cleavage would lead to the highly
active form [128]. This is not consistent with the N-terminal cleavage of IL-1β 
which can be cleaved at different points within a small range on the N-terminus with
no effect to activity [511]. This specific cleavage site required for IL-36 is likely to
be related to activation of the active site within the receptor. In this chapter the
length of the N-terminus rather than the specific amino acid has been shown to play
a crucial in biological activity. In order to establish the specific receptor binding sites
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for IL-36 the crystal structure should be solved in complex with its receptors, this
would be an important area for further work. A recent publication has reported the
crystal structure of IL-36γ [512] and previously the structure of murine IL-36RA had 
been reported [513]. This crystal structure despite not being co-crystallised with the
receptors does allow modelling of IL-36γ with the previously published IL-1 
receptor complexes [512]. This is in line with what was shown in Figure 5-15 that
the length and not the amino acid on the N-terminus is important for receptor
binding. When IL-36γ is modelled in the IL-1 receptors the backbone of the serine at 
the N-terminus forms a hydrogen bond with an aspartate in the receptor. Therefore,
confirming the length of the amino acid is important to form the hydrogen bond and
the backbone of any amino acid could form this bond. Any extra amino acids would
cause steric hindrance for receptor binding. The structural analysis of IL-36γ and 
consequent in vitro techniques indicated a mutation at amino acid 162 from an
alanine to aspartic acid increased binding affinity [512]. This is of interest due to the
possibility of a gain-of-function mutation in a subset of psoriatic patients.
The identified IL-36γ cleavage product Q17 did initiate some IL-8 release which was 
more pronounced in the psoriatic fibroblasts, at a local concentration this could be
physiologically relevant. It is known that neutrophils, the large proportion of cells in
PMNs, are present at a high density in psoriatic lesions [3]. The data presented in
this chapter favours a regulatory role of PMNs in a psoriatic lesion regarding IL-36-
mediated inflammation. This is not all together surprising considering the substantial
role neutrophils play in the resolution of inflammation (see 1.2.3). The IL-36α and 
IL-36γ cleavage products, I7 and Y16, Q17 respectively, detected were highly 
reproducible with the neutrophil proteases and kallikreins tested. This could suggest
that these cleavage products are highly physiologically relevant and there is a
possibility that another cleavage step is required to cleave IL-36α and IL-36γ into 
their active form, however this remains to be elucidated. This could however be due
to a susceptible free region at the N-terminus present in all IL-36 members as shown
by previously published crystal structures [512] [513]. This structural analysis
suggests that the N-termini of the IL-36 proteins contain exposed flexible regions
that are discrete from the IL-1 domain that could simply make the N-terminus more
susceptible to proteolytic processing.
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The results depicted in this chapter do however leave the protease responsible for
cleavage of the agonist IL-36 members in to their active forms undetermined. The
data suggest that proteases released from skin resident cells or from activated PMNs
are not, on their own, responsible for processing IL-36 into the fully active form. The
lack of detection of the active forms could also potentially indicate that the IL-36
members are in fact not released from the cell in their full length form, which would
be in line with other IL-1 family members such as IL-1β and IL-18 (see 1.4.1 for in 
depth discussion on other IL-1 members) [140]. IL-36 may either be released from
the cell in its active form, a cleaved inactive form or its full length form. If it was
released in an inactive but cleaved form then cleavage by proteases present in the
skin compartment need to act on IL-36 proteins to process it in to its active form
outside the cell. However, it may the case, as with IL-1β that following necrotic cell 
death full length inactive IL-1β is present in the extracellular space and neutrophil 
serine proteases then cleave it into its active form (see 1.6.3) [342].
There is evidence in murine models to suggest that the full length IL-36 is cleaved
outside of the cell rather than prior to release from the cell. Intratracheal
administration of full length IL-36α [514] or IL-36γ [210] in to mice induces a 
significant influx of neutrophils in an IL-1α/IL-1β independent manner and also 
increases expression of other pro-inflammatory cytokines. In this in vivo model it is
likely that IL-36 is cleaved by an extracellular protease in order to exert its pro-
inflammatory effects. This theory could be tested by producing mutants that are un-
cleavable and injecting this protein to compare the pro-inflammatory effects exerted
by the mutant and physiologic full length IL-36. Therefore, despite having tested
inflammatory cells and skin resident cells for their ability to cleave IL-36 the
conditions or microenvironment to enable IL-36 processing may have been
overlooked. Psoriasis shows altered protease activity and serine proteases mutations
have been identified which are linked with disease susceptibility (see Table 1-1) [99,
515]. Therefore increased protease activity in psoriasis may actually lead to more
active IL-36 and play a significant role in disease pathogenesis.
There are many proteases in the skin including MMPs, cysteine and serine proteases
(discussed in more detail in 1.6.1) as well as proteases derived from the skin
microflora. Experiments presented in this chapter included skin biopsies from both
healthy and psoriatic patients that were incubated with IL-36 before the protein was
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purified and analysed. However, results from these experiments failed to
demonstrate biological active IL-36 forms. This may be due to the incubation period
being too long, if the tissue was available then numerous shorter time points could be
performed to rule this out and this is a crucial area for further work. One healthy skin
biopsy was stimulated with cytokines thought to be important in psoriasis, IL-17 and
TNFα, and the other biopsies left untreated including one from a psoriatic donor. 
Although cleavage was detected following incubation with both treated and
untreated skin biopsies, the correct cytokine micro milieu may not have been present
in order to produce proteases that could cleave IL-36 into its active form. This
reiterates the need for sensitive reagents to detect IL-36 and its active cleaved forms
in vivo to fully understand the role it plays in disease.
Another possibility for the lack of active form identified is that the cleavage could be
occurring by a protease derived from an exogenous source. Skin biopsies were
removed from healthy and psoriatic donors and washed extensively with antibiotics
to prevent bacterial contamination in culture. However, this means that the potential
influence of skin microbiota derived proteases may have been missed. The skin has a
diverse microbial flora and in its healthy state contains 1012 resident bacteria/m2,
therefore the proteases produced by bacteria must be taken into consideration. Skin
relevant bacteria such as Staphylococci aureus and S. epidermidis, Streptococcus
pyogenes and Pseudomonas aeruginosa produce extracellular proteases [300]. These
include serine-, cysteine- and metallo-proteases. Fungi also present a source for
proteases in the skin, Candida albicans and Malazessia are commensal yeasts
present on healthy skin without any symptoms. When fungal colonisation becomes
pathogenic, proteases are produced as a virulence factor to aid the infective process.
For Candida albicans these proteases include secreted aspartic proteases (Saps) and
may disturb the endogenous balance of protease and protease inhibitor [516]. House
dust mite (HDM) presents as a common allergen in many allergic disease, it has been
shown that the main allergen from HDM displays protease activity. There are 4
known proteases; Dermatophagoides pteronyssinus (Der p), Der p1, Der p3, Der p6,
Der p9 and they all require cleavage to facilitate activity. These proteases have been
shown to play a role in cleavage of PAR-2 and other membrane associated receptors
[517]. Der p1 does have a preference for a serine at its P1’ site (MEROPS database),
therefore this may well be a target for cleavage of IL-36γ in to its active form. Of 
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note, it has also been shown in murine models that IL-36γ is up-regulated in 
response to HDM challenge [518]. All of these possible exogenous proteases may
well shift the balance of the endogenous protease – protease inhibitor system and
may be related to pathogenesis of inflammatory skin diseases, this could potentially
also involve increasing activity of possible mediators of disease such as IL-36. It has
been shown that IL-36 is up-regulated in response to live scabies mites in a skin
equivalent model [519] and also in various bacterial [520, 521] and fungal infection
[126, 522]. It is well known that scabies mites produce significant levels of proteases
in order to aid their life cycle [523] and the fungal and bacterial proteases have been
discussed previously. Therefore it is possible that these exogenous proteases may
play a role in IL-36 cleavage following up-regulation of IL-36 upon infection. Of
note, there is rarely infection seen in psoriatic skin lesions and there is reduced
microbiome diversity [524]. However in comparison to other chronic inflammatory
skin disease there is a unique microbiome which may be relevant to disease
pathogenesis [524]. As previously discussed there are many emerging roles of IL-36
in the inflammatory response. From data depicted in this chapter there is no doubt
that it plays a role in neutrophil infiltration in to the skin and there is certainly much
more to elucidate about this group of cytokines.
A type of tissue immune cells not discussed with regard to IL-36 cleavage are mast
cells which are abundant in tissues such as the skin [525]. These cells would have
undoubtedly been present in a skin biopsy however they may not have been activated
sufficiently in order to degranulate and release their plethora of proteases. It has been
shown that in response to LPS mast cells will only release cytokines and no obvious
degranulation was detected [526]. Therefore this may be an area for further
investigation in the pursuit of the protease responsible for IL-36 cleavage.
IL-36 release from the cell remains to be fully elucidated due to the lack of a leader
peptide which is a common feature of all IL-1 family members [527]. There are
many studies identifying increases in IL-36 mRNA in various epithelial cell types
however there is a significant lack of data with regard to IL-36 protein and in
particular IL-36 in the extracellular space. At present the literature suggests that IL-
36 is released from the cell following loss of membrane integrity such as pyroptosis
[206, 211]. A double activation signal of cells has also been suggested as a
mechanism for release of IL-36 in a similar manner to IL-1β [405]. It seems that IL-
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36 protein is often detected in the extracellular space following treatment of cells
with dsRNA [213] which as observed by Lian et al., [211] causing loss of cellular
membrane integrity.
In this chapter it was demonstrated that attempts were made to over express IL-36
members in mammalian cell culture in order to try and elucidate the point at which
IL-36 cleavage is likely to occur. In order to assess whether the active form was
released from the cell an in vitro set up with N- and C-terminal tags was required, as
described in 5.11. N- and C-terminal tags were required due to the minimal
difference in molecular weight it would be difficult to assess the difference between
active and inactive forms simply by the mobility on an SDS PAGE gel. The
problems encountered whilst attempting to over express IL-36 may be due to the
presence of mRNA instability elements. This has been described for other IL-1
family members, IL-18 and IL-37, in which the rapid degradation of mRNA is
thought to be a tightly maintained control mechanism utilised to control release of
pro-inflammatory cytokines [172]. Another option for detection of cleaved and full
length forms would be to produce antibodies specifically against the active cleaved
IL-36 forms. This may be difficult to achieve however it would an invaluable tool to
identify the different forms of IL-36 found in vivo. There is minimal data identifying
IL-36 in vivo, however IL-36α has been identified in the synovium of patients 
suffering from rheumatoid arthritis and PsA [225]. At present the commercially
available antibodies appear to lack sensitivity and this may therefore be the reason
for the paucity in IL-36 protein data. A crucial area for further work will be to
identify the cleaved active forms in vivo and produce more sensitive reagents to
study IL-36.
IL-36 has been shown to be up-regulated in psoriasis as described previously (see
1.4.3.2). However, at present, IL-36 has not been implicated in causing
morphological changes in psoriatic plaque. In this chapter a novel function of the
active form of IL-36 has been described regarding the hyperproliferation of the
epidermal compartment in a 3-D skin equivalent model following 96 hours of
cleaved active IL-36 treatment. The induction of a psoriatic like phenotype using
pro-inflammatory cytokines has been previously demonstrated in a skin equivalent
model using a de-epidermised dermis to seed keratinocytes [509]. IL-22 treatment
was used as a control due to its known role in epidermal thickening and psoriatic
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pathogenesis [528]. However IL-36 was a much more potent inducer of epidermal
enlargement and keratinocyte proliferation. In comparison to the full length IL-36
active cleaved IL-36 induced significantly more epidermal proliferation. However
this has also been alluded to in murine models. In a fibroblast growth factor receptor
(FGFR) deficient murine model severe barrier defects are seen as well as activation
of keratinocytes and T cells, with an increased expression of IL-36β in the epidermis 
[529]. The relevance of IL-36 in the barrier defects seen was confirmed by injecting
recombinant IL-36β intradermally, this showed increased keratinocyte proliferation 
after 24 hours [529]. Another study has shown that ADAM17, which is downstream
of FGFR2, deficient mice show a similar phenotype and at 10 days old mRNA levels
of IL-36α and IL-36β are significantly increased [530]. Data shown in this chapter as 
well as previously published murine models indicates a potential role for IL-36 in the
epidermal changes that are characteristically identified in psoriasis. An interesting
avenue for further work would be to include IL-36RA along with the active cleaved
IL-36 to assess how much of the hyperproliferation could be ameliorated in the skin
equivalent cultures. This would then establish whether the hyperproliferation seen
was purely IL-36 mediated. It may well be that IL-36 is inducing other mediators,
therefore it would be interesting to analyse the supernatants from these skin
equivalents and assess levels of pro-inflammatory mediators using a multiple analyte
detection method, such as FlowCytomix™. The IL-36 effect may well have been
overridden by mediators released from the psoriatic skin resident cells that were not
present in the healthy cells, which may be the reason for the limited changes in
morphology seen when psoriatic cells were used.
This experimental set-up used both healthy keratinocytes and fibroblasts, however
interestingly when psoriatic keratinocytes were used in combination with healthy
fibroblasts an increased epidermal compartment was observed. This was regardless
of the treatment conditions suggestive of an intrinsic proliferative role of psoriatic
keratinocytes. However, it is worth noting these experiments are preliminary and
need to be repeated with different donors due to the donor variability that is often
seen in primary cultures. In addition the fact that the psoriatic keratinocytes used
were of high passage number and therefore in an altered ‘differentiation’ state needs
to be taken into consideration. Proliferation was determined in this chapter using
nuclei counting, however further work is required to stain for proliferation markers
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such as Ki67. Further work is also required to expand the panel of markers used to
stain the skin equivalent sections such as cytokeratin 16 which is known to be
dysregulated in psoriasis [531], this is required to substantiate the preliminary
findings shown in this chapter. However the treatment of the healthy skin equivalent
models with active IL-36 was reproduced using cells from two different donors
suggestive of this being a reproducible finding. In order to fully replicate psoriatic
skin the skin equivalent model would ideally be populated with autologous immune
cells that are known to be relevant in psoriasis in a similar manner as described by
van den Bogaard et al., [532]. It would be of great interest to assess the role of IL-36
in an immune cell populated 3-D skin equivalent model.
IL-38 was also investigated in this chapter due to its potential role as an antagonist of
the IL-36 family [126]. The aforementioned study was performed using full length
IL-38 and PBMCs, this suggested antagonistic properties on IL-36 however this was
shown to be much weaker than IL-36RA. Preliminary work is depicted in this
chapter which indicates that IL-38 is not an antagonist for the IL-36 family in human
primary fibroblasts. Cleavage products were produced for IL-38 using the same basis
that appears to hugely increase the activity of IL-36 (alignment shown in Appendix
figure 24). Using the method of counting from the conserved IL-1 domain at the N-
terminus correctly identified the active IL-36 products, this method would suggest
that IL-38 S3 should be active. However, this could not be verified in the preliminary
work depicted here. This may be because IL-8 is not the ideal downstream marker to
analyse, therefore a range of pro-inflammatory mediators should be assessed. It is
also possible that IL-38 is binding to a different receptor that is not necessarily
expressed on human primary fibroblasts but exerts inhibitory effects on the IL-36
downstream signalling in other cells such as SIGIRR, which functions at present are
poorly understood.
In conclusion, the truncated active form of IL-36 stimulates significant IL-8 release
from skin resident cells which consequently attracts neutrophils into the skin and this
IL-8 release is increased further in fibroblasts derived from psoriatic patients. This
points to an intrinsic difference of these cells regarding responsiveness to IL-36 and
indicates a role for IL-36 in the neutrophilic inflammation seen in psoriasis. The
activated neutrophils present in psoriatic skin fail to fully activate the pro-
inflammatory IL-36 members and activate the IL-36RA which suggests that
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neutrophils could play a regulatory role in the IL-36-mediated inflammation. IL-36
also potentially plays a role in the psoriatic phenotype in which the epidermis is
enlarged and keratinocyte proliferation is evident. Therefore, IL-36 may be a pivotal
cytokine in psoriatic inflammation and may be an invaluable target for psoriatic
therapeutics as well as other chronic inflammatory disorders. However, more work is
required to fully elucidate the release, activation and control of this newly described
family of cytokines.
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Chapter 6 – Discussion
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A key problem for treating diseases such as psoriasis and eczema is their tendency to
become chronic and the complex disease pathogenesis including different subtypes
of disease. It is crucially important to understand processes leading to chronic
inflammation and subtypes of disease in order to develop therapeutics that
effectively reduce inflammation without severe side effects. There are many
suggestions of how chronic inflammation occurs and a complex network of immune
cells, surrounding stromal cells as well as the cytokine micro milieu all contribute to
the process.
6.1 The balance between pro- and anti-inflammatory mediators
As discussed throughout this work pro-inflammatory cytokine release is always
accompanied by expression of regulatory molecules that inhibits the pro-
inflammatory function. These control mechanisms are present at various levels
including the receptor level. Agonists are prevented from binding to their receptor by
receptor antagonists, decoy receptors, binding proteins [187] as well as altering
binding capacity of the mediators by proteolytic cleavage. Control mechanisms are
also present downstream from the receptor at transcription and translational levels.
There are numerous examples of the importance of regulators within the IL-1 family
and much has been learned from monogenetic diseases affecting the inflammasome
in which excessive activation of IL-1β leads to episodic fever syndromes such as 
Muckle Wells [533]. These syndromes are often successfully treated with
Anakinra® which is a recombinant IL-1RA which neutralises IL-1 activity. This
illustrates the consequences and severe symptoms that ensue when the imbalance
between pro- and anti-inflammatory mediators are disturbed. The up-regulation of
IL-1RA by a component of Aspergillus fumigatus cell wall (galactosaminogalactan)
has also been shown to be a virulence factor in Aspergillus fumigatus infection
[534]. This illustrates the powerful immune modulatory effects these ‘controllers’ of
the immune system play.
The newly described subset of IL-1 family members, IL-36, are also crucially
controlled by the IL-36RA and loss-of-function mutations in this protein lead to a
severe, life-threatening subset of psoriasis, GPP [5, 111]. This, as well as data
depicted in chapter 5 indicating the importance of IL-36RA in controlling the pro-
inflammatory IL-36 members suggests that a recombinant IL-36RA therapeutic may
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be a valid option for treatment of psoriasis. As has been already described, IL-36γ 
specifically is highly up-regulated in psoriasis therefore controlling these IL-36
members, could be of potential therapeutic benefit.
The IL-1 family consists of one binding protein, IL-18BP. This BP importantly
controls the highly pro-inflammatory IL-18. Previously IFNγ was the only known 
inducer of IL-18BP [450]. In chapter 3 a novel mechanism by which IL-18BP can be
up-regulated was described. IL-27 was described to efficiently up-regulate IL-18BP
in human primary skin resident cells. Interestingly, levels of IL-18BP were
significantly higher in human primary fibroblasts which indicates a potentially more
regulatory role of the dermal layer of the skin compared to the highly reactive and
pro-inflammatory keratinocytes. One could speculate that some tissue cells are
programmed to be more regulatory than pro-inflammatory and work on
mesenchymal stromal cells which used dermal fibroblasts as control cells has already
delivered hints for the generally more regulatory properties of fibroblasts [535]. The
importance of the IL-18/IL-18BP balance is currently of great interest in disease
states where IL-18 has been long regarded as highly up-regulated. Recent literature
is focused on the importance of this IL-18/IL-18BP balance in cardiac dysfunction
[465, 536]. Inefficient up-regulation of IL-18BP to control the increase of IL-18 in
diseases such as systemic lupus erythematosus is also thought to be crucial to the
chronicity of this disease [537]. IL-18 currently also re-gains increased interest as a
key factor in ILC1 polarisation [121, 243]. In chapter 3, IL-27 in addition to
hydrocortisone was shown to up-regulate IL-18BP without the induction of the pro-
inflammatory chemokine CXCL10. Therefore endogenous induction of IL-18BP
using IL-27 in combination with hydrocortisone could be a therapeutic tool to re-
address this balance.
6.2 Control of pro-inflammatory mediators by proteases
Pro-inflammatory mediators are also controlled at the transcriptional level and
changes in mRNA stability is a well described mechanism by which this occurs. This
has been described for both IL-37 and IL-18 within the IL-1 family [172]. Another
mechanism by which pro-inflammatory mediators are regulated is by their
proteolytic activation. As extensively discussed in this thesis, proteolytic cleavage is
important in the control of IL-1 family members. In chapter 5 the importance of
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proteolytic cleavage of IL-36 is demonstrated. The results demonstrate that the
activity of IL-36 changes dramatically between removal of only one extra amino acid
from the N-terminus. This is however different for the related family member IL-1β 
which can be cleaved into activation at different sites in close proximity on the N-
terminus [511].
As previously mentioned, over-activation of caspase-1 seen in cryopyrin-associated
periodic fever syndromes leads to excessive IL-1 release and consequently
autoinflammation [68, 538]. This may be of relevance in psoriasis in which IL-36
may be the driver of disease for a subset of patients and over-activation of the
protease cleaving IL-36 or diminished IL-36RA activity may cause the chronic skin
inflammation seen. Given the recent description of DITRA as an autoinflammatory
psoriasis subtype and our current knowledge on the IL-36 system, it can be
postulated that psoriatic inflammation (even in the absence of the IL-36RA loss-of-
function mutation) shows features of autoinflammation and that IL-36 may promote
this [538]. Probably due to the limited expression of IL-36 mostly in epithelial
tissues and its specific activation requirements it may be unlikely to cause systemic
inflammation. Results presented in chapter 5 highlight release of IL-8 from skin
resident cells as a functional property of active IL-36. The chemokine IL-8 leads to
neutrophilic infiltration into the skin and this is a defined feature of psoriatic
histology. Over-activation of a protease and consequent over-activation of IL-36
could be a driver of psoriatic disease however, it is clear that T cell activation and
recruitment into the skin is also key to the psoriatic phenotype.
In health there is a balance not only between pro- and anti-inflammatory mediators
but also between proteases and protease inhibitors. A reduced activity of protease
inhibitors can lead to uncontrolled protease activity, as is seen in Netherton
syndrome. A genetic mutation in the serine protease inhibitor Kazal-type 5
(SPINK5) which encodes lympho-epithelial Kazal type inhibitor (LEKTI) 5 leads to
chronic skin inflammation and loss of epidermal integrity due to uncontrolled serine
protease activity [539]. In vitro using SPINK5 knockdown skin equivalents the
epidermal thickness and increased tendency for the epidermis to detach from the
dermis was reduced when KLK5 and KLK7 were also knocked down. This indicates
that kallikrein inhibitors may of therapeutic benefit in this disease [539].
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6.3 Possible novel therapeutics in psoriasis
Due to the importance of proteases in the activation of IL-36, protease inhibitors
could be of therapeutic value in psoriasis, the benefits of these being that they are
more cost effective than biological therapy. Phase I trials have indeed been carried
out for cathepsin S inhibitors for treatment of psoriasis. This was performed due to
the up-regulation of cathepsin S by psoriatic keratinocytes [540]. At present,
protease inhibitors are used extensively in anti-viral therapies. However, in diseases
such as asthma where altered levels of MMPs have been reported [541] broad range
MMP inhibitors such as tetracycline and doxycycline have been investigated as
potential treatment strategies [542]. Once the protease/s that cleaves IL-36 is
determined therapeutic approaches could be developed aiming to inhibit IL-36
activation. Doxycycline has also been shown to indirectly inhibit the proteolytic
activity of kallikrein-related peptidases [543] as well as other more specific trypsin-
like serine protease inhibitors (ε-aminocaproic acid) [544]. These have been 
suggested for use in rosacea where increased activity of KLK5 has been shown
[544]. α1 Antitrypsin deficiency leads to a lack of serine protease inhibition and 
predisposes to chronic obstructive pulmonary disease and liver disease, treatment of
this disease is achieved by readdressing the balance of proteases/protease inhibitors
[545]. This could be of relevance if a dysregulation of proteases is identified in
relation to IL-36 activity in psoriasis.
Psoriasis is undoubtedly related to uncontrolled pro-inflammatory mediators.
Genetic mutations in the NF-κB pathway, namely A20 and CARD14 have been
linked to the most common form of psoriasis [99], psoriasis vulgaris. This points to a
loss of control at the signalling level which leads to high levels of pro-inflammatory
mediator expression. Chronic inflammation as seen in rheumatoid arthritis and lupus
erythematosus but also skin psoriasis has been shown to have a negative impact on
life expectancy, thought to be related to the increased risk of cardiovascular disease.
As with rheumatoid arthritis severe psoriasis also presents with co-morbidities [86].
Cardiovascular disease is also thought to be a life limiting factor in severe psoriasis,
this is likely due to the uncontrolled systemic inflammation [546]. Importantly, on
reducing inflammation this risk is also reduced [547, 548] strongly supporting the
view that any state of chronic inflammation should be treated early and efficiently.
Rheumatoid arthritis, as other chronic inflammatory diseases such as inflammatory
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bowel diseases and psoriasis can often be successfully treated and even cleared with
biological therapies. Currently the most widely used biologics block the action of
TNFα thereby reducing the uncontrolled inflammation [549]. In most health systems 
only a minority of severely affected patients will receive biologics due to the
enormous costs of this therapy. However, given the emerging view that chronic
inflammation may drastically increase the risk of cardiovascular events, health
economists may have to re-calculate the long term benefit of efficient and early
treatment.
There are many options for treatment of psoriasis ranging from topical anti-
inflammatories to systemic biological therapy for more severe disease. However,
traditional systemic therapy such as ciclosporin A, methotrexate, acitretin and
fumaric acid can cause significant side effects, slow onset or suboptimal efficacy. On
the other hand, topical therapy which is often used for localised disease is often not
sufficient to clear the skin of psoriatic plaques and has low patient compliance [550].
Therefore, more targeted therapies are required and over the past decade biologic
therapy targeting specific cytokine pathways have been developed. Small molecule
inhibitors have more recently been developed which target pro-inflammatory
signalling pathways and neutralise action of transcription factors such as JAKs [550].
At present, there is an increasing array of FDA approved anti-TNFα humanised 
monoclonal antibodies (etanercept, adalimumab, infliximab, golimumab) used to
successfully treat psoriasis in some patients [551]. The IL-17 pathway is also being
targeted for biologic therapies and various neutralising antibodies have been
produced against one IL-17 family member, IL-17A (secukinumab, ixekizumab),
[552]. However, despite the promising results achieved for patients following
treatment with these biologic therapies there have also been severe side effects in
some patients. The most prominent issue with blocking cytokine function is the
increased risk of serious infection. IL-17A and IL-17F are both crucial for
mucocutaneous fungal defence and genetic mutations in the IL-17RA subunit have
been shown to lead to recurrent Candida albicans infection [553]. There are other
risks including immunogenicity of the antibodies and also infusion reactions can
occur which has recently been extensively reviewed by Carrascosa et al., [554].
There is no doubt that for severely affected patients these biologic therapies have
revolutionised psoriasis treatment and there is an ongoing discussion if they should
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be utilised early to prevent the ‘psoriatic march’ of co-morbidities [1]. However, for
some patients these therapies are not an option due to unavailability (e.g. when
disease activity is scored mild or moderate by PASI), side effects or lack of efficacy
and therefore other avenues must be developed. It is also well recognised that there
is paucity in topical treatment for limited and/or localised disease that would prevent
unnecessary side effects in these patients.
In chapter 4 the use of RNA aptamers for topical therapy of inflammatory skin
diseases was explored using an RNA aptamer to neutralise IL-17A. Topical therapy
is advantageous because it is not associated with the infection risks and other side
effects seen in systemic therapy. RNA aptamers are still at the early stages of clinical
use, however one RNA aptamer is FDA approved (Macugen®) and many are in
clinical trials. In chapter 4 the concept of RNA aptamers as a topical skin therapy
was described due to the novel discovery that small RNA molecules can be taken up
by keratinocytes without the need for chemical permeabilisation of the cell. This
would allow for a new generation of topical therapy that could target specific pro-
inflammatory signalling pathways in a similar way to the small molecule inhibitors
but without the widespread immune system suppression. However, more work is
needed to show whether this approach to target intracellular molecules with RNA
apatmers is indeed feasible.
6.4 Conclusion
In conclusion, understanding the mechanisms by which regulatory mechanisms are
controlled is crucial in order to fully elucidate chronic inflammation and produce
effective specific therapeutics. The focus of this thesis has been on psoriasis which
was originally portrayed as simply a skin disease, however recently the disease has
been further investigated and in its severe form is now regarded as a systemic disease
which may have symptoms in the joints and cardiovascular system as well as some
psychological associations. It is therefore important that therapies to treat this life-
altering and probably life-expectancy reducing disease are constantly evolving
mirroring the progressive treatment options available in rheumatology clinics. In the
future, the aim for treatment of psoriatic disease would be to screen for genetic
mutations in order to subcategorise patients and assess the best pathway to target.
Such stratified medicine approaches are currently being explored in large national
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and international initiatives. However, novel ways to target these pathways need to
established and this work is continuing, as described in chapter 4. This would
prevent the ‘trial and error’ method of treatment and hopefully reduce side effects
and increase treatment efficacy for patients.
There also needs to be further work into the concept of biomarkers to specifically
distinguish subtypes of psoriasis further than what is currently performed by simply
categorising based on clinical phenotype. Currently progress is being made in
distinguishing psoriasis from other chronic inflammatory skin diseases using
molecular signatures, of which IL-36 has been identified as a marker for psoriasis
[555]. However biomarkers for subtypes of psoriasis are still be identified. This
would hopefully identify those that require early biologic intervention to prevent
psoriatic arthritic joint damage as well as distinguish between other similar chronic
inflammatory skin diseases and treat more specifically. As described in this thesis,
targeting IL-36, IL-18 or IL-17 pathways topically or systemically may all be of
significant clinical benefit if the most suitable patient subgroup for these approaches
can be identified.
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Appendix
Appendix Figure 1 - Champion pET SUMO bacterial expression (Invitrogen).
Schematic representation of the vector used for the bacterial expression of IL-36.
220
Appendix Figure 2 - pET-28a(+) used for bacterial expression (Novagen).
Schematic diagram of the vector used for bacterial expression of IL-36 with N-terminal SUMO (from
another vector) and C terminal His.
221
Appendix Figure 3 - pcDNA3.1+ used for mammalian expression (Invitrogen).
Schematic diagram of vector used for mammalian expression of IL-36 for both untagged and tagged
proteins, with tags being incorporated with the primers.
222
MEKALK IDTPQQGSIQDINHRVWVLQDQTLIAVPRKDRMSPVTIALISCRHVETLEKDRG
NPIYLGLNGLNLCLMCAKVGDQPTLQLKEKDIMDLYNQPEPVKSFLFYHSQSGRNSTFES
VAFPGWFIAVSSEGGCPLILTQELGKANTTDFGLTMLF
Appendix Figure 4 – IL-36α sequence. 
IL-36α sequence depicting predicted IL-1 domain (Blue), active form [128] (Red), PMN cleavage 
products (space).
223
IL-36a F
1 ATGGAAAAAGCATTGAAAATTGACACACCTCAGCAGGGGAGCATTCAGGATATCAATCAT
1 -M--E--K--A--L--K--I--D--T--P--Q--Q--G--S--I--Q--D--I--N--H-
61 CGGGTGTGGGTTCTTCAGGACCAGACGCTCATAGCAGTCCCGAGGAAGGACCGTATGTCT
21 -R--V--W--V--L--Q--D--Q--T--L--I--A--V--P--R--K--D--R--M--S-
121 CCAGTCACTATTGCCTTAATCTCATGCCGACATGTGGAGACCCTTGAGAAAGACAGAGGG
41 -P--V--T--I--A--L--I--S--C--R--H--V--E--T--L--E--K--D--R--G-
181 AACCCCATCTACCTGGGCCTGAATGGACTCAATCTCTGCCTGATGTGTGCTAAAGTCGGG
61 -N--P--I--Y--L--G--L--N--G--L--N--L--C--L--M--C--A--K--V--G-
241 GACCAGCCCACACTGCAGCTGAAGGAAAAGGATATAATGGATTTGTACAACCAACCCGAG
81 -D--Q--P--T--L--Q--L--K--E--K--D--I--M--D--L--Y--N--Q--P--E-
301 CCTGTGAAGTCCTTTCTCTTCTACCACAGCCAGAGTGGCAGGAACTCCACCTTCGAGTCT
101 -P--V--K--S--F--L--F--Y--H--S--Q--S--G--R--N--S--T--F--E--S-
361 GTGGCTTTCCCTGGCTGGTTCATCGCTGTCAGCTCTGAAGGAGGCTGTCCTCTCATCCTT
121 -V--A--F--P--G--W--F--I--A--V--S--S--E--G--G--C--P--L--I--L-
IL-36a R
421 ACCCAAGAACTGGGGAAAGCCAACACTACTGACTTTGGGTTAACTATGCTGTTTTAA
141 -T--Q--E--L--G--K--A--N--T--T--D--F--G--L--T--M--L--F--*-
Appendix Figure 5 - IL-36α – primers for Champion pET SUMO vector. 
IL-36α sequence containing primers depicted by arrows – F = forward primer, R = reverse primer. 
Following successful cloning and transformation into DH5α cells sequences were confirmed by Sanger 
sequencing.
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36a F no tag
HindIII
TAGAGAAAGCTTCCACCATGGAAAAAGCATTGAAAATTGACAC
36a R no tag
Not1
TAGAGGCGGCCGCTTAAAACAGCATAGTTAACCCAAAG
aagcttccacccatggaaaaagcattgaaaattgacacacctcagcag
M E K A L K I D T P Q Q
gggagcattcaggatatcaatcatcgggtgtgggttcttcaggaccagacgctcatagca
G S I Q D I N H R V W V L Q D Q T L I A
gtcccgaggaaggaccgtatgtctccagtcactattgccttaatctcatgccgacatgtg
V P R K D R M S P V T I A L I S C R H V
gagacccttgagaaagacagagggaaccccatctacctgggcctgaatggactcaatctc
E T L E K D R G N P I Y L G L N G L N L
tgcctgatgtgtgctaaagtcggggaccagcccacactgcagctgaaggaaaaggatata
C L M C A K V G D Q P T L Q L K E K D I
atggatttgtacaaccaacccgagcctgtgaagtcctttctcttctaccacagccagagt
M D L Y N Q P E P V K S F L F Y H S Q S
ggcaggaactccaccttcgagtctgtggctttccctggctggttcatcgctgtcagctct
G R N S T F E S V A F P G W F I A V S S
gaaggaggctgtcctctcatccttacccaagaactggggaaagccaacactactgacttt
E G G C P L I L T Q E L G K A N T T D F
gggttaactatgctgttttaagcggccgctcgagtctagagggcccgtttaaacccgctg
G L T M L F - A A A R V
Appendix Figure 6 – IL-36α primers for mammalian expression with no tags. 
A - Primers for pcDNA3.1 (+) vector – no tags. Highlighted red sequence depicts restriction sites used. F
= forward and contains a HindIII restriction site and R = reverse and contains a Not1 restriction site. B –
Following cloning and transformation into DH5α cells the sequence was verified by Sanger sequencing, 
sequence depicted. Red highlighted section depicts Kozak sequence and the restriction sites are also
highlighted (green – HindIII, blue – Not1).
A
B
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36a F N and C tag
HindIII Myc Kpn1
TAGAGAAGCTTCCACCATGGAGCAGAAACTCATCTCTGAAGAGGATCTGGGTACCATGGAAAAAGCATTGA
AAATTGACAC
36a R N and C tag
Not1 His EcoR1
CTCTAGCGGCCGCTCAGTGATGGTGATGGTGATGGAATTCAAACAGCATAGTTAACCCAAA
1 - ACGTGCTGGTTTACTTTAGCTTCACCATGGAGCAGAAACTCATCTCTGAAGAGGATCTGG - 60
1 - V L V Y F S F T M E Q K L I S E E D L G - 20
61 - GTACCATGGAAAAAGCATTGAAAATTGACACACCTCAGCAGGGGAGCATTCAGGATATCA - 120
21 - T M E K A L K I D T P Q Q G S I Q D I N - 40
121 - ATCATCGGGTGTGGGTTCTTCAGGACCAGACGCTCATAGCAGTCCCGAGGAAGGACCGTA - 180
41 - H R V W V L Q D Q T L I A V P R K D R M - 60
181 - TGTCTCCAGTCACTATTGCCTTAATCTCATGCCGACATGTGGAGACCCTTGAGAAAGACA - 240
61 - S P V T I A L I S C R H V E T L E K D R - 80
241 - GAGGGAACCCCATCTACCTGGGCCTGAATGGACTCAATCTCTGCCTGATGTGTGCTAAAG - 300
81 - G N P I Y L G L N G L N L C L M C A K V - 100
301 - TCGGGGACCAGCCCACACTGCAGCTGAAGGAAAAGGATATAATGGATTTGTACAACCAAC - 360
101 - G D Q P T L Q L K E K D I M D L Y N Q P - 120
361 - CCGAGCCTGTGAAGTCCTTTCTCTTCTACCACAGCCAGAGTGGCAGGAACTCCACCTTCG - 420
121 - E P V K S F L F Y H S Q S G R N S T F E - 140
421 - AGTCTGTGGCTTTCCCTGGCTGGTTCATCGCTGTCAGCTCTGAAGGAGGCTGTCCTCTCA - 480
141 - S V A F P G W F I A V S S E G G C P L I - 160
481 - TCCTTACCCAAGAACTGGGGAAAGCCAACACTACTGACTTTGGGTTAACTATGCTGTTTG - 540
161 - L T Q E L G K A N T T D F G L T M L F E - 180
541 - AATTCCATCACCATCACCATCACTGAGCGGCCGCTCGAGTCTAGAGGGCCCGTTTAAACC - 600
181 - F H H H H H H *
A
B
226
Appendix Figure 7 – IL-36α primers for mammalian expression with N and C-terminal tags. 
A - Primers for pcDNA3.1 (+) vector – N and C-terminal tags. Highlighted red sequence depicts
restriction sites used. F = forward and contains a HindIII and Kpn1 restriction site as well as a myc tag
(blue). R = reverse and contains a Not1 and EcoR1 restriction site (red) and a His tag (purple). B –
Following cloning and transformation into DH5α cells the sequence was verified by Sanger sequencing, 
sequence depicted. Red highlighted section depicts the restriction sites (Kpn1 and EcoR1) and tags are
also highlighted (blue – myc, purple – His).
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F no his SUMO Nco1
Nco1 SUMO
TAGTAGCCATGGATGTCGGACTCAGAAGTCAATCAAG
ATGTCGGACTCAGAAGTCAATCAAGAAGCTAAGCCAGAGGTCAAGCCAGAAGTCAAGCCT - 60
1 - M S D S E V N Q E A K P E V K P E V K P - 20
61 - GAGACTCACATCAATTTAAAGGTGTCCGATGGATCTTCAGAGATCTTCTTCAAGATCAAA - 120
21 - E T H I N L K V S D G S S E I F F K I K - 40
121 - AAGACCACTCCTTTAAGAAGGCTGATGGAAGCGTTCGCTAAAAGACAGGGTAAGGAAATG - 180
41 - K T T P L R R L M E A F A K R Q G K E M - 60
181 - GACTCCTTAAGATTCTTGTACGACGGTATTAGAATTCAAGCTGATCAGACCCCTGAAGAT - 240
61 - D S L R F L Y D G I R I Q A D Q T P E D - 80
241 – TTGGACATGGAGGATAACGAT
81 - L D M E D N D
ATTATTGAGGCTCACAGAGAACAGATTGGTGGTATGGAAAAAGCATTGAAAATTGACAC - 300
81 - I I E A H R E Q I G G M E K A L K I D T - 100
301 - ACCTCAGCAGGGGAGCATTCAGGATATCAATCATCGGGTGTGGGTTCTTCAGGACCAGAC - 360
101 - P Q Q G S I Q D I N H R V W V L Q D Q T - 120
361 - GCTCATAGCAGTCCCGAGGAAGGACCGTATGTCTCCAGTCACTATTGCCTTAATCTCATG - 420
121 - L I A V P R K D R M S P V T I A L I S C - 140
421 - CCGACATGTGGAGACCCTTGAGAAAGACAGAGGGAACCCCATCTACCTGGGCCTGAATGG - 480
141 - R H V E T L E K D R G N P I Y L G L N G - 160
481 - ACTCAATCTCTGCCTGATGTGTGCTAAAGTCGGGGACCAGCCCACACTGCAGCTGAAGGA - 540
161 - L N L C L M C A K V G D Q P T L Q L K E - 180
541 - AAAGGATATAATGGATTTGTACAACCAACCCGAGCCTGTGAAGTCCTTTCTCTTCTACCA - 600
181 - K D I M D L Y N Q P E P V K S F L F Y H - 200
A
B
228
601 - CAGCCAGAGTGGCAGGAACTCCACCTTCGAGTCTGTGGCTTTCCCTGGCTGGTTCATCGC - 660
201 - S Q S G R N S T F E S V A F P G W F I A - 220
661 - TGTCAGCTCTGAAGGAGGCTGTCCTCTCATCCTTACCCAAGAACTGGGGAAAGCCAACAC - 720
221 - V S S E G G C P L I L T Q E L G K A N T - 240
721 - TACTGACTTTGGGTTAACTATGCTGTTTGAATTCCATCACCATCACCATCACTGAGCGGC - 780
241 - T D F G L T M L F E F H H H H H H * A A - 260
781 - CGCACTCGAGCACCACCACCACCACCACTGA
Appendix Figure 8 – IL-36α primers for N and C-terminal tagged protein bacterial expression. 
A - Primers for pET 28 (+) vector using IL-36α in pET expression system as template. Highlighted red 
sequence depicts restriction sites (Nco1) used. Reverse primers as depicted in Appendix Figure 7. B –
Following cloning and transformation into DH5α cells the sequence was verified by Sanger sequencing, 
sequence depicted. N-terminal Sumo tag is depicted in blue, EcoR1 restriction site (red) and His tag is
depicted in purple.
229
MNPQR EAAPKSYAIRDSRQMVWVLSGNSLIAAPLSRSIKPVTLHLIACRDTEFSDKEKGN
MVYLGIKGKDLCLFCAEIQGKPTLQLKLQGSQDNIGKDTCWKLVGIHTCINLDVRESCFM
GTLDQWGIGVGRKKWKSSFQHHHLRKKDKDFSSMRTNIGMPGRM
Appendix Figure 9 – IL-36β sequence. 
IL-36β sequence depicting predicted IL-1 domain (Blue), active form [128] (Red), PMN cleavage 
products (space).
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IL-36b F
1 ATGAACCCACAACGGGAGGCAGCACCCAAATCCTATGCTATTCGTGATTCTCGACAGATG
1 -M--N--P--Q--R--E--A--A--P--K--S--Y--A--I--R--D--S--R--Q--M-
61 GTGTGGGTCCTGAGTGGAAATTCTTTAATAGCAGCTCCTCTTAGCCGCAGCATTAAGCCT
21 -V--W--V--L--S--G--N--S--L--I--A--A--P--L--S--R--S--I--K--P-
121 GTCACTCTTCATTTAATAGCCTGTAGAGACACAGAATTCAGTGACAAGGAAAAGGGTAAT
41 -V--T--L--H--L--I--A--C--R--D--T--E--F--S--D--K--E--K--G--N-
181 ATGGTTTACCTGGGAATCAAGGGAAAAGATCTCTGTCTCTTCTGTGCAGAAATTCAGGGC
61 -M--V--Y--L--G--I--K--G--K--D--L--C--L--F--C--A--E--I--Q--G-
241 AAGCCTACTTTGCAGCTTAAGCTTCAGGGCTCCCAAGATAACATAGGGAAGGACACTTGC
81 -K--P--T--L--Q--L--K--L--Q--G--S--Q--D--N--I--G--K--D--T--C-
301 TGGAAACTAGTTGGAATTCACACATGCATAAACCTGGATGTGAGAGAGAGCTGCTTCATG
101 -W--K--L--V--G--I--H--T--C--I--N--L--D--V--R--E--S--C--F--M-
361 GGAACCCTTGACCAATGGGGAATAGGAGTGGGTAGAAAGAAGTGGAAGAGTTCCTTTCAA
121 -G--T--L--D--Q--W--G--I--G--V--G--R--K--K--W--K--S--S--F--Q-
421 CATCACCATCTCAGGAAGAAGGACAAAGATTTCTCATCCATGCGGACCAACATAGGAATG
141 -H--H--H--L--R--K--K--D--K--D--F--S--S--M--R--T--N--I--G--M-
IL-36b R
481 CCAGGAAGGATGTAG
161 -P--G--R--M--*-
Appendix Figure 10 - IL-36β – primers for Champion pET SUMO vector. 
IL-36β sequence containing primers depicted by arrows – F = forward primer, R = reverse primer. 
Following successful cloning and transformation into DH5α cells sequences were confirmed by Sanger 
sequencing.
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36b F no tags
BamH1
TAGAGAGGATCCCCACCATGAACCCACAACGGGAGGCAGCACCC
36b R no tags
Not1
TCTCTAGCGGCCGCCTACATCCTTCCTGGCATTCCTATGTTG
ggatccccaccatgaacccacaacgg
M N P Q R
gaggcagcacccaaatcctatgctattcgtgattctcgacagatggtgtgggtcctgagt
E A A P K S Y A I R D S R Q M V W V L S
ggaaattctttaatagcagctcctcttagccgcagcattaagcctgtcactcttcattta
G N S L I A A P L S R S I K P V T L H L
atagcctgtagagacacagaattcagtgacaaggaaaagggtaatatggtttacctggga
I A C R D T E F S D K E K G N M V Y L G
atcaagggaaaagatctctgtctcttctgtgcagaaattcagggcaagcctactttgcag
I K G K D L C L F C A E I Q G K P T L Q
cttaagcttcagggctcccaagataacatagggaaggacacttgctggaaactagttgga
L K L Q G S Q D N I G K D T C W K L V G
attcacacatgcataaacctggatgtgagagagagctgcttcatgggaacccttgaccaa
I H T C I N L D V R E S C F M G T L D Q
tggggaataggagtgggtagaaagaagtggaagagttcctttcaacatcaccatctcagg
W G I G V G R K K W K S S F Q H H H L R
aagaaggacaaagatttctcatccatgcggaccaacataggaatgccaggaaggatgtag
K K D K D F S S M R T N I G M P G R M -
gcggccgctcgagtctagagggcccgtttaaacccgctgatcagcctcgactgtgccttc
A A A R V
Appendix Figure 11 – IL-36β primers for mammalian expression with no tags. 
A - Primers for pcDNA3.1 (+) vector – no tags. Highlighted red sequence depicts restriction sites used. F
= forward and contains a BamH1 restriction site and R = reverse and contains a Not1 restriction site. B –
Following cloning and transformation into DH5α cells the sequence was verified by Sanger sequencing, 
sequence depicted. Red highlighted section depicts Kozak sequence and the restriction sites are also
highlighted (green – BamH1, blue – Not1).
A
B
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36b F N + C
BamH1 Myc Kpn1
TAGAGGGATCCCCACCATGGAGCAGAAACTCATCTCTGAAGAGGATCTGGGTACCATGAACCCACAACGGG
AGGCA
36b R N + C
Not1 His EcoRV
CTCTAGCGGCCGCTCAGTGATGGTGATGGTGATGGATATCCATCCTTCCTGGCATTCC
1 - CCATGTACGTTTACTTAGCTTGGTACCGAGCTCGGATCCCCACCATGGAGCAGAAACTCA - 60
1 - M Y V Y L A W Y R A R I P T M E Q K L I - 20
61 - TCTCTGAAGAGGATCTGGGTACCATGAACCCACAACGGGAGGCAGCACCCAAATCCTATG - 120
21 - S E E D L G T M N P Q R E A A P K S Y A - 40
121 - CTATTCGTGATTCTCGACAGATGGTGTGGGTCCTGAGTGGAAATTCTTTAATAGCAGCTC - 180
41 - I R D S R Q M V W V L S G N S L I A A P - 60
181 - CTCTTAGCCGCAGCATTAAGCCTGTCACTCTTCATTTAATAGCCTGTAGAGACACAGAAT - 240
61 - L S R S I K P V T L H L I A C R D T E F - 80
241 - TCAGTGACAAGGAAAAGGGTAATATGGTTTACCTGGGAATCAAGGGAAAAGATCTCTGTC - 300
81 - S D K E K G N M V Y L G I K G K D L C L - 100
301 - TCTTCTGTGCAGAAATTCAGGGCAAGCCTACTTTGCAGCTTAAGCTTCAGGGCTCCCAAG - 360
101 - F C A E I Q G K P T L Q L K L Q G S Q D - 120
361 - ATAACATAGGGAAGGACACTTGCTGGAAACTAGTTGGAATTCACACATGCATAAACCTGG - 420
121 - N I G K D T C W K L V G I H T C I N L D - 140
421 - ATGTGAGAGAGAGCTGCTTCATGGGAACCCTTGACCAATGGGGAATAGGAGTGGGTAGAA - 480
141 - V R E S C F M G T L D Q W G I G V G R K - 160
481 - AGAAGTGGAAGAGTTCCTTTCAACATCACCATCTCAGGAAGAAGGACAAAGATTTCTCAT - 540
161 - K W K S S F Q H H H L R K K D K D F S S - 180
541 - CCATGCGGACCAACATAGGAATGCCAAGGATGGATATCCATCACCATCACCATCACTGAG - 600
181 - M R T N I G M P R M D I H H H H H H * A - 200
A
B
233
Appendix Figure 12 – IL-36β primers for mammalian expression with N and C-terminal tags. 
A - Primers for pcDNA3.1 (+) vector – N and C-terminal tags. Highlighted red sequence depicts
restriction sites used. F = forward and contains a BamH1 and Kpn1 restriction site as well as a myc tag
(blue). R = reverse and contains a Not1 and EcoRV restriction site (red) and a His tag (purple). B –
Following cloning and transformation into DH5α cells the sequence was verified by Sanger sequencing, 
sequence depicted. Red highlighted section depicts restriction sites (Kpn1 and EcoRV) tags are also
highlighted (blue - myc, purple – His).
234
F no his SUMO Nco1
Nco1 SUMO
TAGTAGCCATGGATGTCGGACTCAGAAGTCAATCAAG
1 - ATGTCGGACTCAGAAGTCAATCAAGAAGCTAAGCCAGAGGTCAAGCCAGAAGTCAAGCCT - 60
1 - M S D S E V N Q E A K P E V K P E V K P - 20
61 - GAGACTCACATCAATTTAAAGGTGTCCGATGGATCTTCAGAGATCTTCTTCAAGATCAAA - 120
21 - E T H I N L K V S D G S S E I F F K I K - 40
121 - AAGACCACTCCTTTAAGAAGGCTGATGGAAGCGTTCGCTAAAAGACAGGGTAAGGAAATG - 180
41 - K T T P L R R L M E A F A K R Q G K E M - 60
181 - GACTCCTTAAGATTCTTGTACGACGGTATTAGAATTCAAGCTGATCAGACCCCTGAAGAT - 240
61 - D S L R F L Y D G I R I Q A D Q T P E D - 80
241 - TTGGACATGGAGGATAACGATATTATTGAGGCTCACAGAGAACAGATTGGTGGTATGAAC - 300
81 - L D M E D N D I I E A H R E Q I G G M N - 100
301 - CCACAACGGGAGGCAGCACCCAAATCCTATGCTATTCGTGATTCTCGACAGATGGTGTGG - 360
101 - P Q R E A A P K S Y A I R D S R Q M V W - 120
361 - GTCCTGAGTGGAAATTCTTTAATAGCAGCTCCTCTTAGCCGCAGCATTAAGCCTGTCACT - 420
121 - V L S G N S L I A A P L S R S I K P V T - 140
421 - CTTCATTTAATAGCCTGTAGAGACACAGAATTCAGTGACAAGGAAAAGGGTAATATGGTT - 480
141 - L H L I A C R D T E F S D K E K G N M V - 160
481 - TACCTGGGAATCAAGGGAAAAGATCTCTGTCTCTTCTGTGCAGAAATTCAGGGCAAGCCT - 540
161 - Y L G I K G K D L C L F C A E I Q G K P - 180
541 - ACTTTGCAGCTTAAGCTTCAGGGCTCCCAAGATAACATAGGGAAGGACACTTGCTGGAAA - 600
181 - T L Q L K L Q G S Q D N I G K D T C W K - 200
601 - CTAGTTGGAATTCACACATGCATAAACCTGGATGTGAGAGAGAGCTGCTTCATGGGAACC - 660
201 - L V G I H T C I N L D V R E S C F M G T - 220
661 - CTTGACCAATGGGGAATAGGAGTGGGTAGAAAGAAGTGGAAGAGTTCCTTTCAACATCAC - 720
A
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221 - L D Q W G I G V G R K K W K S S F Q H H - 240
721 - CATCTCAGGAAGAAGGACAAAGATTTCTCATCCATGCGGACCAACATAGGAATGCCAGGA - 780
241 - H L R K K D K D F S S M R T N I G M P G - 260
781 - AGGATGGATATCCATCACCATCACCATCACTGAGCGGCCGCACTCGAGCACCACCACCAC - 840
261 - R M D I H H H H H H * A A A
Appendix Figure 13 – IL-36β primers for N and C-terminal tagged protein bacterial expression. 
A - Primers for pET 28 (+) vector using IL-36α in pET expression system as template. Highlighted red 
sequence depicts restriction sites (Nco1) used. Reverse primers as depicted in Appendix Figure 7. B –
Following cloning and transformation into DH5α cells the sequence was verified by Sanger sequencing, 
sequence depicted. N-terminal Sumo tag is depicted in blue, EcoR1 restriction site (red) and His tag is
depicted in purple.
236
MRGTPGDADGGGRAV Y QSMCKPITGTINDLNQQVWTLQGQNLVAVPRSDSVTPVTVAVIT
CKYPEALEQGRGDPIYLGIQNPEMCLYCEKVGEQPTLQLKEQKIMDLYGQPEPVKPFLFY
RAKTGRTSTLESVAFPDWFIASSKRDQPIILTSELGKSYNTAFELNIND
Appendix Figure 14 – IL-36γ sequence. 
IL-36γ sequence depicting predicted IL-1 domain (Blue), active form [128] (Red), PMN cleavage 
products (space).
237
IL-36g F
1 ATGAGAGGCACTCCAGGAGACGCTGATGGTGGAGGAAGGGCCGTCTATCAATCAATGTGT
1 -M--R--G--T--P--G--D--A--D--G--G--G--R--A--V--Y--Q--S--M--C-
61 AAACCTATTACTGGGACTATTAATGATTTGAATCAGCAAGTGTGGACCCTTCAGGGTCAG
21 -K--P--I--T--G--T--I--N--D--L--N--Q--Q--V--W--T--L--Q--G--Q-
121 AACCTTGTGGCAGTTCCACGAAGTGACAGTGTGACCCCAGTCACTGTTGCTGTTATCACA
41 -N--L--V--A--V--P--R--S--D--S--V--T--P--V--T--V--A--V--I--T-
181 TGCAAGTATCCAGAGGCTCTTGAGCAAGGCAGAGGGGATCCCATTTATTTGGGAATCCAG
61 -C--K--Y--P--E--A--L--E--Q--G--R--G--D--P--I--Y--L--G--I--Q-
241 AATCCAGAAATGTGTTTGTATTGTGAGAAGGTTGGAGAACAGCCCACATTGCAGCTAAAA
81 -N--P--E--M--C--L--Y--C--E--K--V--G--E--Q--P--T--L--Q--L--K-
301 GAGCAGAAGATCATGGATCTGTATGGCCAACCCGAGCCCGTGAAACCCTTCCTTTTCTAC
101 -E--Q--K--I--M--D--L--Y--G--Q--P--E--P--V--K--P--F--L--F--Y-
361 CGTGCCAAGACTGGTAGGACCTCCACCCTTGAGTCTGTGGCCTTCCCGGACTGGTTCATT
121 -R--A--K--T--G--R--T--S--T--L--E--S--V--A--F--P--D--W--F--I-
421 GCCTCCTCCAAGAGAGACCAGCCCATCATTCTGACTTCAGAACTTGGGAAGTCATACAAC
141 -A--S--S--K--R--D--Q--P--I--I--L--T--S--E--L--G--K--S--Y--N-
IL-36g R
481 ACTGCCTTTGAATTAAATATAAATGACTGA
161 -T--A--F--E--L--N--I--N--D--*-
Appendix Figure 15 - IL-36γ – primers for Champion pET SUMO vector. 
IL-36γ sequence containing primers depicted by arrows – F = forward primer, R = reverse primer. 
Following successful cloning and transformation into DH5α cells sequences were confirmed by Sanger 
sequencing.
238
36g F no tag
HindIII
TAGAGAAAGCTTCCACCATGAGAGGCACTCCAGGAGACGCTGATG
36g R no tag
Not1
CTCTCAGCGGCCGCTCAGTCATTTATATTTAATTCAAAGGCAGTGTTGTATG
aagcttccaccatgagaggcactccaggagacgctgatggtggaggaagggccgtctatcaatcaatgtgt
M R G T P G D A D G G G R A V Y Q S M C
aaacctattactgggactattaatgatttgaatcagcaagtgtggacccttcagggtcag
K P I T G T I N D L N Q Q V W T L Q G Q
aaccttgtggcagttccacgaagtgacagtgtgaccccagtcactgttgctgttatcaca
N L V A V P R S D S V T P V T V A V I T
tgcaagtatccagaggctcttgagcaaggcagaggggatcccatttatttgggaatccag
C K Y P E A L E Q G R G D P I Y L G I Q
aatccagaaatgtgtttgtattgtgagaaggttggagaacagcccacattgcagctaaaa
N P E M C L Y C E K V G E Q P T L Q L K
gagcagaagatcatggatctgtatggccaacccgagcccgtgaaacccttccttttctac
E Q K I M D L Y G Q P E P V K P F L F Y
cgtgccaagactggtaggacctccacccttgagtctgtggccttcccggactggttcatt
R A K T G R T S T L E S V A F P D W F I
gcctcctccaagagagaccagcccatcattctgacttcagaacttgggaagtcatacaac
A S S K R D Q P I I L T S E L G K S Y N
actgcctttgaattaaatataaatgactgagcggccgc
T A F E L N I N D -
A
B
239
Appendix Figure 16 – IL-36γ primers for mammalian expression with no tags. 
A - Primers for pcDNA3.1 (+) vector – no tags. Highlighted red sequence depicts restriction sites used. F
= forward and contains a HindIII restriction site and R = reverse and contains a Not1 restriction site. B –
Following cloning and transformation into DH5α cells the sequence was verified by Sanger sequencing, 
sequence depicted. Red highlighted section depicts Kozak sequence and the restriction sites are also
highlighted (green – HindIII, blue – Not1).
240
36g F N + C tag
HindIII Myc Kpn1
TAGAGAAGCTTCCACCATGGAGCAGAAACTCATCTCTGAAGAGGATCTGGGTACCATGAGAGGCACTCCAG
GAGAC
36g R N + C tag
Not1 His EcoR1
TCTCAGCGGCCGCTCAGTGATGGTGATGGTGATGGAATTCGTCATTTATATTTAATTCAAA
1 - CCCGGGGTGCGTTTACTTAGCTTCACCATGGAGCAGAAACTCATCTCTGAAGAGGATCTG - 60
1 - P G V R L L S F T M E Q K L I S E E D L - 20
61 - GGTACCATGAGAGGCACTCCAGGAGACGCTGATGGTGGAGGAAGGGCCGTCTATCAATCA - 120
21 - G T M R G T P G D A D G G G R A V Y Q S - 40
121 - ATGTGTAAACCTATTACTGGGACTATTAATGATTTGAATCAGCAAGTGTGGACCCTTCAG - 180
41 - M C K P I T G T I N D L N Q Q V W T L Q - 60
181 - GGTCAGAACCTTGTGGCAGTTCCACGAAGTGACAGTGTGACCCCAGTCACTGTTGCTGTT - 240
61 - G Q N L V A V P R S D S V T P V T V A V - 80
241 - ATCACATGCAAGTATCCAGAGGCTCTTGAGCAAGGCAGAGGGGATCCCATTTATTTGGGA - 300
81 - I T C K Y P E A L E Q G R G D P I Y L G - 100
301 - ATCCAGAATCCAGAAATGTGTTTGTATTGTGAGAAGGTTGGAGAACAGCCCACATTGCAG - 360
101 - I Q N P E M C L Y C E K V G E Q P T L Q - 120
361 - CTAAAAGAGCAGAAGATCATGGATCTGTATGGCCAACCCGAGCCCGTGAAACCCTTCCTT - 420
121 - L K E Q K I M D L Y G Q P E P V K P F L - 140
421 - TTCTACCGTGCCAAGACTGGTAGGACCTCCACCCTTGAGTCTGTGGCCTTCCCGGACTGG - 480
141 - F Y R A K T G R T S T L E S V A F P D W - 160
481 - TTCATTGCCTCCTCCAAGAGAGACCAGCCCATCATTCTGACTTCAGAACTTGGGAAGTCA - 540
161 - F I A S S K R D Q P I I L T S E L G K S - 180
541 - TACAACACTGCCTTTGAATTAAATATAAATGACGAATTCCATCATCATCATCATCATTGA - 600
181 - Y N T A F E L N I N D E F H H H H H H * - 200
A
B
241
Appendix Figure 17 – IL-36γ primers for mammalian expression with N and C-terminal tags. 
A - Primers for pcDNA3.1 (+) vector – N and C-terminal tags. Highlighted red sequence depicts
restriction sites used. F = forward and contains a HindIII and Kpn1 restriction site as well as a myc tag
(blue). R = reverse and contains a Not1 and EcoR1 restriction site (red) and a His tag (purple). B –
Following cloning and transformation into DH5α cells the sequence was verified by Sanger sequencing, 
sequence depicted. Red highlighted section depicts restriction sites (Kpn1 and EcoR1) tags are also
highlighted (blue - myc, purple – His).
242
F no his SUMO Nco1
Nco1 SUMO
TAGTAGCCATGGATGTCGGACTCAGAAGTCAATCAAG
1 - GGTGACGAATTCCCTCTAAATAATTTTGTTTACTTTAAGAAGGAGATATACCATGGATGT - 60
1 - * R I P S K * F C L L * E G D I P W M S - 20
61 - CGGACTCAGAAGTCAATCAAGAAGCTAAGCCAGAGGTCAAGCCAGAAGTCAAGCCTGAGA - 120
21 - D S E V N Q E A K P E V K P E V K P E T - 40
121 - CTCACATCAATTTAAAGGTGTCCGATGGATCTTCAGAGATCTTCTTCAAGATCAAAAAGA - 180
41 - H I N L K V S D G S S E I F F K I K K T - 60
181 - CCACTCCTTTAAGAAGGCTGATGGAAGCGTTCGCTAAAAGACAGGGTAAGGAAATGGACT - 240
61 - T P L R R L M E A F A K R Q G K E M D S - 80
241 - CCTTAAGATTCTTGTACGACGGTATTAGAATTCAAGCTGATCAGACCCCTGAAGATTTGG - 300
81 - L R F L Y D G I R I Q A D Q T P E D L D - 100
301 - ACATGGAGGATAACGATATTATTGAGGCTCACAGAGAACAGATTGGTGGTATGAGAGGCA - 360
101 - M E D N D I I E A H R E Q I G G M R G T - 120
361 - CTCCAGGAGACGCTGATGGTGGAGGAAGGGCCGTCTATCAATCAATGTGTAAACCTATTA - 420
121 - P G D A D G G G R A V Y Q S M C K P I T - 140
421 - CTGGGACTATTAATGATTTGAATCAGCAAGTGTGGACCCTTCAGGGTCAGAACCTTGTGG - 480
141 - G T I N D L N Q Q V W T L Q G Q N L V A - 160
481 - CAGTTCCACGAAGTGACAGTGTGACCCCAGTCACTGTTGCTGTTATCACATGCAAGTATC - 540
161 - V P R S D S V T P V T V A V I T C K Y P - 180
541 - CAGAGGCTCTTGAGCAAGGCAGAGGGGATCCCATTTATTTGGGAATCCAGAATCCAGAAA - 600
181 - E A L E Q G R G D P I Y L G I Q N P E M - 200
601 - TGTGTTTGTATTGTGAGAAGGTTGGAGAACAGCCCACATTGCAGCTAAAAGAGCAGAAGA - 660
201 - C L Y C E K V G E Q P T L Q L K E Q K I - 220
661 - TCATGGATCTGTATGGCCAACCCGAGCCCGTGAAACCCTTCCTTTTCTACCGTGCCAAGA - 720
A
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221 - M D L Y G Q P E P V K P F L F Y R A K T - 240
721 - CTGGTAGGACCTCCACCCTTGAGTCTGTGGCCTTCCCGGACTGGTTCATTGCCTCCTCCA - 780
241 - G R T S T L E S V A F P D W F I A S S K - 260
781 - AGAGAGACCAGCCCATCATTCTGACTTCAGAACTTGGGAAGTCATACAACACTGCCTTTG - 840
261 - R D Q P I I L T S E L G K S Y N T A F E - 280
841 - AATTAAATATAAATGACGAATTCCATCATCATCATCATCATTGAGCGGCCGCACTCGAGC - 900
281 - L N I N D E F H H H H H H * A A A L E H - 300
Appendix Figure 18 – IL-36γ primers for N and C-terminal tagged protein bacterial expression. 
A - Primers for pET 28 (+) vector using IL-36α in pET expression system as template. Highlighted red 
sequence depicts restriction sites (Nco1) used. Reverse primers as depicted in Appendix Figure 7. B –
Following cloning and transformation into DH5α cells the sequence was verified by Sanger sequencing, 
sequence depicted. N-terminal Sumo tag is depicted in blue, EcoR1 restriction site (red) and His tag is
depicted in purple.
244
M VL SGALCFRMKDSALKVLYLHNNQLLAGGLHAGKVIKGEEISVVPNRWLDASLSPVILG
VQGGSQCLSCGVGQEPTLTLEPVNIMELYLGAKESKSFTFYRRDMGLTSSFESAAYPGWF
LCTVPEADQPVRLTQLPENGGWNAPITDFYFQQCD
Appendix Figure 19 – IL-36RA sequence.
IL-36RA sequence depicting predicted IL-1 domain (Blue), active form [128] (Red), PMN cleavage
products (space).
245
IL-36RA F
1 ATGGTCCTGAGTGGGGCGCTGTGCTTCCGAATGAAGGACTCGGCATTGAAGGTGCTTTAT
1 -M--V--L--S--G--A--L--C--F--R--M--K--D--S--A--L--K--V--L--Y-
61 CTGCATAATAACCAGCTTCTAGCTGGAGGGCTGCATGCAGGGAAGGTCATTAAAGGTGAA
21 -L--H--N--N--Q--L--L--A--G--G--L--H--A--G--K--V--I--K--G--E-
121 GAGATCAGCGTGGTCCCCAATCGGTGGCTGGATGCCAGCCTGTCCCCCGTCATCCTGGGT
41 -E--I--S--V--V--P--N--R--W--L--D--A--S--L--S--P--V--I--L--G-
181 GTCCAGGGTGGAAGCCAGTGCCTGTCATGTGGGGTGGGGCAGGAGCCGACTCTAACACTA
61 -V--Q--G--G--S--Q--C--L--S--C--G--V--G--Q--E--P--T--L--T--L-
241 GAGCCAGTGAACATCATGGAGCTCTATCTTGGTGCCAAGGAATCCAAGAGCTTCACCTTC
81 -E--P--V--N--I--M--E--L--Y--L--G--A--K--E--S--K--S--F--T--F-
301 TACCGGCGGGACATGGGGCTCACCTCCAGCTTCGAGTCGGCTGCCTACCCGGGCTGGTTC
101 -Y--R--R--D--M--G--L--T--S--S--F--E--S--A--A--Y--P--G--W--F-
361 CTGTGCACGGTGCCTGAAGCCGATCAGCCTGTCAGACTCACCCAGCTTCCCGAGAATGGT
121 -L--C--T--V--P--E--A--D--Q--P--V--R--L--T--Q--L--P--E--N--G-
IL-36RA R
421 GGCTGGAATGCCCCCATCACAGACTTCTACTTCCAGCAGTGTGACTAG
141 -G--W--N--A--P--I--T--D--F--Y--F--Q--Q--C--D--*-
Appendix Figure 20 - IL-36RA – primers for Champion pET SUMO vector.
IL-36RA sequence containing primers depicted by arrows – F = forward primer, R = reverse primer.
Following successful cloning and transformation into DH5α cells sequences were confirmed by Sanger 
sequencing.
246
36RA F no tags
HindIII
TAGAGAAAGCTTCCACCATGGTCCTGAGTGGGGCGCTGTGC
36RA R no tags
Not1
TCTCTAGCGGCCGCCTAGTCACACTGCTGGAAGTAGAAGTC
aagcttcaccatggtcctgagtggggcgctgtgcttccgaatgaag
M V L S G A L C F R M K
gactcggcattgaaggtgctttatctgcataataaccagcttctagctggagggctgcat
D S A L K V L Y L H N N Q L L A G G L H
gcagggaaggtcattaaaggtgaagagatcagcgtggtccccaatcggtggctggatgcc
A G K V I K G E E I S V V P N R W L D A
agcctgtcccccgtcatcctgggtgtccagggtggaagccagtgcctgtcatgtggggtg
S L S P V I L G V Q G G S Q C L S C G V
gggcaggagccgactctaacactagagccagtgaacatcatggagctctatcttggtgcc
G Q E P T L T L E P V N I M E L Y L G A
aaggaatccaagagcttcaccttctaccggcgggacatggggctcacctccagcttcgag
K E S K S F T F Y R R D M G L T S S F E
tcggctgcctacccgggctggttcctgtgcacggtgcctgaagccgatcagcctgtcaga
S A A Y P G W F L C T V P E A D Q P V R
ctcacccagcttcccgagaatggtggctggaatgcccccatcacagacttctacttccag
L T Q L P E N G G W N A P I T D F Y F Q
cagtgtgactaggcggccgctcgagtctagagggcccgtttaaacccgctgatcagcctc
Q C D - A A A R V
Appendix Figure 21 – IL-36RA primers for mammalian expression with no tags.
A - Primers for pcDNA3.1 (+) vector – no tags. Highlighted red sequence depicts restriction sites used. F
= forward and contains a BamH1 restriction site and R = reverse and contains a Not1 restriction site. B –
Following cloning and transformation into DH5α cells the sequence was verified by Sanger sequencing, 
sequence depicted. Red highlighted section depicts Kozak sequence and the restriction sites are also
highlighted (green – HindIII, blue – Not1).
A
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36RA F N and C tags
HindIII Myc Kpn1
TAGAGAAGCTTCCACCATGGAGCAGAAACTCATCTCTGAAGAGGATCTGGGTACCATGGTCCTGAGTGGGG
CGCTG
36RA R N and C tags
Not1 His EcoR1
TCTCAGCGGCCGCTCAGTGATGGTGATGGTGATGGAATTCGTCACACTGCTGGAAGTAGAA
1 - CCGTGTAGGTTTACTTAGCTTCCACCATGGAGCAGAAACTCATCTCTGAAGAGGATCTGG - 60
1 - V * V Y L A S T M E Q K L I S E E D L G - 20
61 - GTACCATGGTCCTGAGTGGGGCGCTGTGCTTCCGAATGAAGGACTCGGCATTGAAGGTGC - 120
21 - T M V L S G A L C F R M K D S A L K V L - 40
121 - TTTATCTGCATAATAACCAGCTTCTAGCTGGAGGGCTGCATGCAGGGAAGGTCATTAAAG - 180
41 - Y L H N N Q L L A G G L H A G K V I K G - 60
181 - GTGAAGAGATCAGCGTGGTCCCCAATCGGTGGCTGGATGCCAGCCTGTCCCCCGTCATCC - 240
61 - E E I S V V P N R W L D A S L S P V I L - 80
241 - TGGGTGTCCAGGGTGGAAGCCAGTGCCTGTCATGTGGGGTGGGGCAGGAGCCGACTCTAA - 300
81 - G V Q G G S Q C L S C G V G Q E P T L T - 100
301 - CACTAGAGCCAGTGAACATCATGGAGCTCTATCTTGGTGCCAAGGAATCCAAGAGCTTCA - 360
101 - L E P V N I M E L Y L G A K E S K S F T - 120
361 - CCTTCTACCGGCGGGACATGGGGCTCACCTCCAGCTTCGAGTCGGCTGCCTACCCGGGCT - 420
121 - F Y R R D M G L T S S F E S A A Y P G W - 140
421 - GGTTCCTGTGCACGGTGCCTGAAGCCGATCAGCCTGTCAGACTCACCCAGCTTCCCGAGA - 480
141 - F L C T V P E A D Q P V R L T Q L P E N - 160
481 - ATGGTGGCTGGAATGCCCCCATCACAGACTTCTACTTCCAGCAGTGTGACGAATTCCATC - 540
161 - G G W N A P I T D F Y F Q Q C D E F H H - 180
541 - ACCATCACCATCACTGAGCGGCCGCTCGAGTCTAGAGGGCCCGTTTAAACCCGCTGATCA - 600
181 - H H H H *
A
B
248
Appendix Figure 22 – IL-36RA primers for mammalian expression with N and C-terminal tags.
A - Primers for pcDNA3.1 (+) vector – N and C-terminal tags. Highlighted red sequence depicts
restriction sites used. F = forward and contains a HindIII and Kpn1 restriction site as well as a myc tag
(blue). R = reverse and contains a Not1 and EcoR1 restriction site (red) and a His tag (purple). B –
Following cloning and transformation into DH5α cells the sequence was verified by Sanger sequencing, 
sequence depicted. Red highlighted section depicts restriction sites (Kpn1 and EcoR1) tags are also
highlighted (blue - myc, purple – His).
249
F no his SUMO Nco1
Nco1 SUMO
TAGTAGCCATGGATGTCGGACTCAGAAGTCAATCAAG
1 - CCTGGACGGGTAAATTCCCTCTAGAAATATTTTGTTTAACTTTAAGAAGGAGATATACCA - 60
1 - P G R V N S L * K Y F V * L * E G D I P - 20
61 - TGGATGTCGGACTCAGAAGTCAATCAAGAAGCTAAGCCAGAGGTCAAGCCAGAAGTCAAG - 120
21 - W M S D S E V N Q E A K P E V K P E V K - 40
121 - CCTGAGACTCACATCAATTTAAAGGTGTCCGATGGATCTTCAGAGATCTTCTTCAAGATC - 180
41 - P E T H I N L K V S D G S S E I F F K I - 60
181 - AAAAAGACCACTCCTTTAAGAAGGCTGATGGAAGCGTTCGCTAAAAGACAGGGTAAGGAA - 240
61 - K K T T P L R R L M E A F A K R Q G K E - 80
241 - ATGGACTCCTTAAGATTCTTGTACGACGGTATTAGAATTCAAGCTGATCAGACCCCTGAA - 300
81 - M D S L R F L Y D G I R I Q A D Q T P E - 100
301 - GATTTGGACATGGAGGATAACGATATTATTGAGGCTCACAGAGAACAGATTGGTGGTATG - 360
101 - D L D M E D N D I I E A H R E Q I G G M - 120
361 - GTCCTGAGTGGGGCGCTGTGCTTCCGAATGAAGGACTCGGCATTGAAGGTGCTTTATCTG - 420
121 - V L S G A L C F R M K D S A L K V L Y L - 140
421 - CATAATAACCAGCTTCTAGCTGGAGGGCTGCATGCAGGGAAGGTCATTAAAGGTGAAGAG - 480
141 - H N N Q L L A G G L H A G K V I K G E E - 160
481 - ATCAGCGTGGTCCCCAATCGGTGGCTGGATGCCAGCCTGTCCCCCGTCATCCTGGGTGTC - 540
161 - I S V V P N R W L D A S L S P V I L G V - 180
541 - CAGGGTGGAAGCCAGTGCCTGTCATGTGGGGTGGGGCAGGAGCCGACTCTAACACTAGAG - 600
181 - Q G G S Q C L S C G V G Q E P T L T L E - 200
601 - CCAGTGAACATCATGGAGCTCTATCTTGGTGCCAAGGAATCCAAGAGCTTCACCTTCTAC - 660
201 - P V N I M E L Y L G A K E S K S F T F Y - 220
A
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661 - CGGCGGGACATGGGGCTCACCTCCAGCTTCGAGTCGGCTGCCTACCCGGGCTGGTTCCTG - 720
221 - R R D M G L T S S F E S A A Y P G W F L - 240
721 - TGCACGGTGCCTGAAGCCGATCAGCCTGTCAGACTCACCCAGCTTCCCGAGAATGGTGGC - 780
241 - C T V P E A D Q P V R L T Q L P E N G G - 260
781 - TGGAATGCCCCCATCACAGACTTCTACTTCCAGCAGTGTGACGAATTCCATCACCATCAC - 840
261 - W N A P I T D F Y F Q Q C D E F H H H H - 280
841 - CATCACTGAGCGGCCGCACTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAAC - 900
281 - H H * A A A L E H H H H H H * D P A A N - 300
Appendix Figure 23 – IL-36RA primers for N and C-terminal tagged protein bacterial expression.
A - Primers for pET 28 (+) vector using IL-36α in pET expression system as template. Highlighted red 
sequence depicts restriction sites (Nco1) used. Reverse primers as depicted in Appendix Figure 7. B –
Following cloning and transformation into DH5α cells the sequence was verified by Sanger sequencing, 
sequence depicted. N-terminal Sumo tag is depicted in blue, EcoR1 restriction site (red) and His tag is
depicted in purple.
251
36a ------------------------------------------------------------
gama ------------------------------------------------------------
RA ------------------------------------------------------------
IL38 ------------------------------------------------------------
il37 ------------------------------------------------------------
il1b MAEVPELASEMMAYYSGNEDDLFFEADGPKQMKCSFQDLDLCPLDGGIQLRISDHHYSKG
beta ------------------------------------------------------------
36a ---------------------------------------------------MEKALKIDT
36-g ---------------------------------------MRGTPGDADGGGRAVYQSMCK
RA -------------------------------------------------------MVLSG
IL38 ------------------------------------------------------MCSLPM
il37 ----MSFVGENSGVKMGSEDWEKDEPQCCLEDPAGSPLEPGPSLPTMNFVHTSPKVKNLN
il1b FRQAASVVVAMDKLRKMLVPCPQTFQENDLSTFFPFIFEEEPIFFDTWDNEAYVHDAPVR
b ----------------------------------------------------MNPQREAA
36a PQQGSIQDINHRVWVLQDQTLIA--VPRKDRMSPVTIALISCRHVETLEKDRGNPIYLGL
36-g PITGTINDLNQQVWTLQGQNLVA--VPRSDSVTPVTVAVITCKYPEALEQGRGDPIYLGI
RA ALCFRMKDSALKVLYLHNNQLLAGGLHAGKVIKGEEISVVPNRWLDASL----SPVILGV
IL38 ARYYIIKYADQKALYTRDGQLLVGDPVADNCC-AEKICILPNRGLDRTK----VPIFLGI
il37 PKKFSIHDQDHKVLVLDSGNLIA--VPDKNYIRPEIFFALASSLSSASAE-KGSPILLGV
il1b SLNCTLRDSQQKSLVMSGPYELKALHLQGQDMEQQVVFSMSFVQGEESND--KIPVALGL
b PKSYAIRDSRQMVWVLSGNSLIA--APLSRSIKPVTLHLIACRDTEFSDKEKGNMVYLGI
. :. . : . :. . : **:
36a NGLNLCLMCA--KVGDQPTLQLKEKDIMDLYNQPEPVKS-FLFYHSQSGRNSTFESVAFP
36g QNPEMCLYCE--KVGEQPTLQLKEQKIMDLYGQPEPVKP-FLFYRAKTGRTSTLESVAFP
RA QGGSQCLSCG--VGQE-PTLTLEPVNIMELYLGAKESKS-FTFYRRDMGLTSSFESAAYP
IL38 QGGSRCLACV--ETEEGPSLQLEDVNIEELYKGGEEATR-FTFFQSSSGSAFRLEAAAWP
il37 SKGEFCLYCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLESAAHP
il1b KEKNLYLSCV--LKDDKPTLQLESVDPKNYP--KKKMEKRFVFNKIEINNKLEFESAQFP
b KGKDLCLFCA--EIQGKPTLQLKLQGSQDNIGKDTCWKLVGIHTCINLDVRESCFMGTLD
. . * * *:* *: . . . .
36a GWFIAVSSEGGCPLILTQELGKANT----TDFGLTMLF-----------
gama DWFIASS-KRDQPIILTSELGKSYN----TAFELNIND-----------
RA GWFLCTVPEADQPVRLTQLPENGGWNAPITDFYFQQCD-----------
IL38 GWFLCGPAEPQQPVQLTKESEPSAR----TKFYFEQSW-----------
il37 GWFICTSCNCNEPVGVTDKFENRKH----IEFSFQPVCKAEMSPSEVSD
il1 NWYISTSQAENMPVFLGGTKGGQDI----TDFTMQFVSS----------
b QWGIGVGRKKWKSSFQHHHLRKKDKDFSSMRTNIGMPGRM---------
Appendix Figure 24 – Alignment of IL-36s, IL-38, IL-37 and IL-1β. 
Alignment of all of these IL-1 members allows for comparison of the site of cleavage in order to increase
activity. The red highlighted amino acid indicates the point of cleavage for IL-36 and IL-1β to increase 
activity, however of note IL-1β can also be cleaved into activity around this point. IL-37 and IL-38 are 
speculated to have increased activity if cleaved at this point. The green highlighted amino acids are the
conserved aspartic acids 9 amino acids away from the cleavage point that have been used in order to
predict active forms of IL-36.
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Appendix figure 25 – Ethical approval letter
Letter confirming ethical approval had been granted in order to take biopsies or collect excess skin from
NHS patients.
